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“Lo que sabemos es una 
gota de agua, lo que 
ignoramos es el océano” 
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1.1. Context of the thesis 
In the last two decades, the organoborane chemistry has evolved from proof of 
concept to several advanced applications. The practical use of new synthetic 
methods requires to be inexpensive, atom-economical and environmentally 
friendly. Related to that, borylative cyclization reactions with the concomitant 
incorporation of a reactive functional group such a boronate moiety, fulfill all the 
requirements previously mentioned. The presence of a boron unit guarantees 
further functionalizations and derivatizations such as, oxidation and cross-coupling 
reactions among others. For that reason, organoborane compounds have been 
considered powerful synthetic tools for many different applications. Moreover, 
compounds containing boryl groups have special benefits due to their low toxicity 
and high functional group tolerance.[1]  
Currently, organoboron reagents offer prominent transformations in both metal 
catalyzed[1c] and transition metal-free[2] methodologies for the synthesis of selective 
C-B bonds. 
 
In this context, the present thesis is focused in the formation of cyclic systems, 
through C-C and C-B bonds formation, considered to be very interesting building 
blocks for many applications. Taking advantage of the Lewis acidity of the boron 
unit, these cyclic systems have been derivatized into a series of O-GlcNAcase 
inhibitors with potential application in the treatment of Alzheimer’s disease. For the 
synthesis of those molecules, different diboron reagents as well as gem-
diborylalkane substituted and non-substituted reagents have been used. 
1.2. Organoborane reagents 
Organodiboron reagents can be divided principally in two groups: diboron and gem-
diborylalkane reagents. Among the most interesting diboron reagents containing a 
B-B σ-bond are the boronic esters bis(pinacolato)diboron [B2pin2] (1), 
bis(neopentylglycolato)diboron [B2neop2] (2) and bis(hexylenglycolato)diboron 
[B2hex2] (3). Among them, B2pin2 (1) is the most frequently used since it is 
commercially available, easy to handle and to store. Alternatively, gem-
diborylalkanes represent a new and diverse class of boron compounds with similar 
properties than the diboron species. These gem-diborylalkanes are deemed as 
attractive reagents for constructing new complex molecules and expand the 
chemical library.[3] The most widely used gem-diborylalkane is the commercially 
available 1,1-diborylmethane [CH2(Bpin)2] (4). The landmark transformation of gem-
diborylalkane reagents is the one-pot carbon-homologation through a CH2Bpin 
fragment. Substituted gem-diborylalkanes can contain other versatile functional 
group such as trimethylsilyl group as substituent in (bis(4,4,5,5-tetramethyl-1,3,2-
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dioxaborolan-2-yl)methyl)trimethylsilane [CH(Bpin)2(SiMe3)] (5). Interelement 
boron reagents of formula pinB-SR (R= Ph, Tol) (6) have been prepared in the group 
of Prof. Westcott[4] to be used in this thesis towards the preparation of 
multifunctional systems CH(Bpin)(SiMe3)(SR) (Figure 1.1). 
 
Figure 1.1 Commercially and non-commercially available 
diboron and boron interelement reagents used in this thesis. 
1.3. Intramolecular borylative cyclization involving 
bis(pinacolato)diboron 
One of the greatest challenge of modern chemistry is the increasing need for 
developing sustainable synthetic methods. Among these, borylative ring-closing 
reactions with in situ incorporation of a boryl unit along with the formation of a 
cyclic compound, provide efficient routes while satisfying these requirements. The 
following sections of this introduction describe the transition metal catalyzed 
borylative ring-closing reactions using B2pin2 as the boron source developed over 
the last decades. 
1.3.1 Borylative cyclization of alkynes 
Copper (I) is the most widely used transition metal for the activation of diboron 
reagents and addition to alkynes in order to promote an intramolecular cyclization 
(Scheme 1.1).[5] The principal reason for this is the high compatibility of copper (I) 
with many functional groups as well as its low price. Ito and co-workers[6] reported 
the formation of cyclic products (Scheme 1.1a) by initial borylcupration of silylated 
alkynes.  
Later, the same group[7] combined the previous methodology with the introduction 
of different heteroatoms in the substrates, leading to the formation of borylated 
cyclic systems including ether or amine groups (Scheme 1.1b).  
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Scheme 1.1 Cu (I) catalyzed borylative ring-closing of propargylic systems  
containing silyl, ether or amine groups. 
Moreover, the use of 2-(cyano)phenyl propargyl carbamates, reported by Liu and 
co-workers,[8] promoted the formation of borylated aromatic compounds (Scheme 
1.2a) through copper catalyzed borylative cyclization. However, this transformation 
required and excess of the diboron reagent. Carretero´s group[9] reported an 
interesting cyclization using epoxides as electrophilic group. The cyclization step 
occurs once the Cu-B addition to the alkyne has been completed, followed by 
subsequent intramolecular kinetic attack to the epoxide that promotes the 
formation of the desired cyclic system (Scheme 1.2b). 
 
Scheme 1.2 Cu (I) catalyzed borylative ring-closing of a) propargylic carbamates and  
b) alkynes bearing an epoxide ring. 
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Apart from copper catalysis, palladium complexes are also suitable catalysts 
towards borylative cyclization.[10] Harrity and co-workers[11] developed the 
aminative ring-closing borylation reaction of ortho-alkynylanilines catalyzed by 
Pd2(dba)3 in the presence of AsPh3 as ligand (Scheme 1.3). Is well known the ability 
of palladium (II) complexes to promote the indole forming cyclization and then 
subsequent addition of the Bpin unit. 
 
Scheme 1.3 Palladium catalyzed borylative cyclization of ortho-alkynylanilines. 
Murakami and co-workers[12] have reported the synthesis of interesting building 
blocks such as oxindoles by the combination of rhodium catalyst and ortho-
alkynylphenyl isocyanates (Scheme 1.4). 
 
Scheme 1.4 Rhodium catalyzed borylative cyclization of ortho-alkynylphenyl isocyanates. 
1.3.2 Borylative cyclization of allenes 
The use of allenes as substrates, has also been reported in the borylative cyclization 
context. Lin and co-workers,[13] reported the borylcupration of allenes with the 
concomitant intramolecular 1,3-addition process, generating cis-decalinol 
derivatives (Scheme 1.5a). The cyclization required high amounts of B2pin2 (1) and 
the borylated products showed low stability under purification in silica gel 
chromatography. For this reason, the borylated intermediates were oxidized in situ 
after consumption of the substrate. In addition, Liu´s group[14] also reported a similar 
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strategy with in situ generation of the allene, followed by borylcupration and 
subsequent intramolecular addition to a cyano group leading to the formation of 
cyclic imine intermediates, which underwent hydrolysis and aromatization to 
deliver highly substituted 3-boryl-naphthylamines (Scheme 1.5b). 
 
Scheme 1.5 Borylative cyclization of allenes catalyzed by Cu (I) complexes. 
1.3.3 Borylative cyclization of allenynes 
In contrast to the above mentioned Cu (I) catalyzed borylative cyclization protocols, 
the use of palladium catalysis in combination with allenyne substrates, is key in the 
efficient generation of the corresponding cyclized products containing the boron 
function. 
Cárdenas and co-workers[15] have contributed to the palladium-catalyzed cyclization 
of substituted allenynes towards cyclopentene derivatives in a highly selective 
manner (Scheme 1.6a). Following with this idea, Bäckvall and co-workers[16] made 
use of highly substituted allenynes, now containing an internal alkyne, accessing 
different alkenylboron cyclic products to the ones described by Cardenas under 
oxidative conditions (BQ) and also with excellent selectivities (Scheme 1.6b). 
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Scheme 1.6 Palladium catalyzed borylative cyclization of allenynes. 
1.3.4 Borylative cyclization of enallenes 
Palladium complexes are the catalyst of choice for the borylative cyclization of 
enallenes. Cárdenas and co-workers[15] described the borylative cyclization of 
enallenes in the presence of a catalytic amount of Pd(OAc)2 under non-oxidative 
conditions (Scheme 1.7a). Subsequently, Bäckvall´s group [17] developed the 
borylative ring-closing of enallenes under oxidative conditions, leading to 
unsaturated cyclic products (Scheme 1.7b). The same group reported on the 
enantioselective version of enallenes extending Cárdena’s methodology with the 
use of a chiral phosphoric acid.[18] This asymmetric version allows access to the 
formation of chiral cyclic carbocycles with a pendant boronate unit with excellent 
enantioselectivities (Scheme 1.7c). 
Scheme 1.7 Palladium catalyzed borylative cyclization of enallenes. 
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1.3.5 Borylative cyclization of enynes 
Enynes has shown high reactivity in borylative cyclization reactions towards the 
formation of carbocyclic and heterocyclic structures. Cárdenas and co-workers have 
extensively studied these transformations (Scheme 1.8). The first example reported 
by this group involved a variety of 1,6-enynes as substrates which lead to the 
formation of 5-memebered rings containing homoallylic boronates. This reaction 
was also extended to 1,7-enynes (Scheme 1.8a).[19] The same group reported as well 
the ring-closing of enynes containing an internal alkyne.[20] Encouraged by the rich 
reactivity showed by enynes, Cárdenas and co-workers[21] also demonstrated that 
dienynes are suitable substrates in the palladium-catalyzed borylative ring-closing 
reaction (Scheme 1.8b). Moreover, non-conjugated systems containing 
polyunsaturated multiple C-C bonds also participate of this transformation leading 
to double cyclization products in a one-pot reaction (Scheme 1.8c).[22] 
 
Scheme 1.8 Borylative ring-closing of enynes, dienynes or  
polyunsaturated substrates catalyzed by palladium. 
The use of copper for the enantioselective borylative cyclization of enynes was also 
demonstrated by Lin and co-workers.[23] This reaction proceeds with the use of CuCl 
and a chiral phosphoramidite ligand, which facilitatate the β-borylation of the 
internal alkyne by subsequent conjugated addition to the Michael acceptor. Hence, 
provided the formation of the targeted products with good yields and high levels of 
enantioselectivity (Scheme 1.9). 
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Scheme 1.9 Copper-catalyzed enantioselective borylative cyclization of cyclic 1,6-enynes. 
1.4. Intramolecular borylative cyclization of alkenes 
The transition metal catalyzed addition of diboron reagents to double bonds can 
generate hydroborated products[24] or lead to intramolecular cyclization products 
via 1,2-carboboration process when electrophilic sites are present in the same 
molecule. A variety of alkenes bearing different leaving groups, carbonyl groups, 
isocyanides or imines can be employed for the carboboration reaction. The 
preferred catalysts for all these transformations are copper (I) complexes modified 
with basic ligands, such as phosphines or N-heterocyclic carbene ligands. 
1.4.1 Borylative ring-closing of alkenes bearing good leaving groups 
The cooper (I) catalyzed ring-closing reaction of alkenes, in substrates containing 
good leaving groups, commonly proceeds via regioselective addition of the boryl 
copper (I) species, forming the endo- or exo-cyclic product under substrate control, 
followed by subsequent intramolecular nucleophilic substitution to the C-LG (LG= 
leaving group), with the concomitant formation of the cyclic borylated product. 
Ito and Sawamura´s group[25] reported the first copper catalyzed intramolecular 
carboboration process with the use of silylated allylic carbonates and B2pin2 as 
diboron reagent. The process leads to boryl cyclopropane derivatives with high 
efficiency. The stereochemistry of the alkene (Z/E) was found to have large influence 
on the reaction rate and chemoselectivity (Scheme 1.10). Notably, when the Z-
isomer was used, a faster formation of the trans-cyclopropane isomer was 
observed, with high chemoselectivity and diastereoselectivity, without competition 
for the formation of the corresponding allyl boron compound. These results have 
been attributed to the activating effect from the corresponding silyl group (Scheme 
1.10a). However, the reaction with the E-isomer required higher catalyst loading 
and longer reaction times compared to the Z-isomer and displayed lower reactivity, 
chemoseletivity and trans/cis-diastereoselectivity (Scheme 1.10b). Once the E-
isomer is submitted to borylative conditions, the intermediate B might be formed 
with retention of the configuration leading to the formation of the cis-isomer. 
However intermediate B is disfavored due to the steric hindrance between the silyl 
group and the boron unit, being this a minor reaction pathway (Scheme 1.10b).  
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Scheme 1.10 Study of substrate effect (Z/E-isomer) on  
the copper (I) catalyzed borylative cyclization. 
For that reason, intermediate B might undergo interconversion to intermediate C, 
which demands an inversion of the Cu-C bond configuration and a pseudo linear Cu-
C-C-O arrangement. Intermediate C would then be the major reaction pathway to 
provide the trans-isomer. Due to the slow formation of the cyclopropane ring with 
the E-isomer, it seems reasonable that the formation of the allyl boron compound 
competes. 
Additionally, the enantioselective version of this reaction was developed for the Z-
isomer as substrate and the use of (R,R)-QuinoxP* as chiral ligand. The reaction took 
place with high enantioselectivity, affording exclusively the formation of the (1S,2S)-
(trimethylsilyl)cyclopropan-2-ylboronate. 
The same group reported a new asymmetric synthesis of aryl and heteroaryl 
substituted cyclopropanes from the corresponding Z-allylic phosphate and (R,R)-iPr-
DuPhos as chiral ligand. Under these conditions a variety of trans-cyclopropane 
products substituted with different aryl and heteroaryl groups could be obtained 
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(Scheme 1.11).[26] The best enantioselectivities were observed when electron-
donating substituents were placed in the benzene ring. Different functional groups 
such as chloro, ether, ester, BocNR2, and acetal are tolerated in this transformation. 
 
Scheme 1.11 Borylative ring-closing of aryl  
substituted alkenes with phosphate as leaving group. 
Furthermore, when the corresponding E-allylic phosphates were submitted to the 
borylative conditions, a ligand dependence was observed. Switching from the (R,R)-
iPr-DuPhos to the (R,R)-QuinoxP*, cis-cyclopropane or the trans-cyclopropane were 
formed respectively in excellent yield (Scheme 1.12). 
 
Scheme 1.12 Ligand dependence on the formation of the cis/trans-cyclopropane isomer. 
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As depicted in Scheme 1.12, when the E-isomer was submitted to borylative 
conditions with (R,R)-iPr-DuPhos, the intermediate formed underwent 
intramolecular substitution with retention of the stereochemistry towards the 
formation of the cis-isomer. In contrast, when the ligand of choice was (R,R)-
QuinoxP*, it was suggested that an inversion of the stereochemistry should take 
place during the cyclization process, hence leading to the formation of the trans-
isomer. 
Similar reactivity was observed by Ito and Sawamura[27] in the borylative cyclization 
of the corresponding E- and Z-homoallylic substituted sulfonates. This reaction 
generated the corresponding 1,2-disubstituted cyclobutanes in a stereospecific cis- 
or trans-manner (Scheme 1.13). 
 
Scheme 1.13 Stereospecific formation of cycloalkylboronates. 
This reactivity is in contrast to the observed reactivity in previous studies with E- or 
Z-allylic carbonates,[25] where only the trans-cyclopropane isomer was obtained as 
the predominant product independently of the configuration of the starting alkene. 
Interestingly, the transformation was extended the formation of the five and six 
cyclic membered ring. However, in the second case only traces were observed.  
In this work, a mechanistic proposal for the borylative cyclization of alkenes wearing 
good leaving groups was reported for the first time (Scheme 1.14).[27] 
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Scheme 1.14 Suggested mechanism for the borylative  
ring-closing catalyzed by copper.[27] 
The catalytic cycle starts with the generation of the specie A, formed from the 
reaction of CuCl, KOtBu and dppp. Then, upon addition of 1 through σ-bond 
metathesis the reactive specie B is formed. At that point, the insertion of the Cu-B 
specie B into the double bond of the substrate leading to C occurs regioselectively 
and it is stabilized by the electronic effect of the adjacent silyl or aryl group (R1 or 
R2). Then, coordination of KOtBu (D) favors the intramolecular oxidative addition 
towards intermediate E. Finally, reductive elimination in E generated the cycloalkyl 
boronate product and recovers the active specie A (Scheme 1.14). 
The fact that the ring-closing step proceeds through the Cu (III) metallacycle 
intermediate E is in agreement with the traces of product observed for the 
formation of the six-membered ring. The formation of the four- and five-membered 
rings occurs with good yields, as it would go through a five- and six-metallacycle 
intermediate. However, the formation of the six-membered ring involves an 
unfavored seven-metallacycle Cu (III) intermediate, hence the low efficiency of the 
cyclization. 
Ito and co-workers,[28] also reported on the cyclization of the more challenging non-
activated alkenes. Interestingly, the reaction takes place with opposite 
regioselectivity providing the exo-cyclic product (Scheme 1.15a), meanwhile in the 
previous works dealing with activated alkenes the endo-cyclized products were 
obtained (Scheme 1.15b).[27] 
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Scheme 1.15 Possible borylative cyclization patways catalyzed by copper (I) salts. 
The first copper (I) catalyzed exo-cyclic carboboration process was developed using 
alkenyl bromine as substrates and Xantphos as ligand (Scheme 1.16a). However, 
strikingly, when an electron deficient monodentate phosphine ligand was used 
instead, the major compound observed was the non-cyclic borylated product with 
only traces of the desired cyclized compound (Scheme 1.16b).[29] 
 
Scheme 1.16 Effect of the phosphine in the borylative cyclization of 5-bromopentene. 
Under the optimal conditions a wide range of substrates led to the formation of the 
corresponding three-, four- and five-membered boryl substituted cyclic products. 
The preparation of boryl six-membered ring products proved challenging and was 
unsuccessful. 
Marder and co-workers[29b] suggested that the use of PPh3 as ligand could lead to 
the formation of the five-membered ring borylated compound. In order to 
understand this transformation, Ito and co-workers performed some experiments 
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to study whether the borylative cyclization goes through a radical pathway or not 
(Scheme 1.17). The difference on the mechanisim was evidenced through 
protonation experiments. Hence, adding 2 equiv of MeOH as the proton source, 
when Xantphos was used as ligand, the hydroborated compounds were now 
isolated as major products. This suggest that the cyclization proceeds through the 
borylcupration of the alkene, then the MeOH protonates the C-Cu bond to render 
the hydroborated product. In contrast, when PPh3 was used, the cyclized product 
was formed predominantly even in the presence of MeOH. From these experiments, 
it was concluded that using PPh3 the reaction would proceed through a radical 
mediated pathway, since no effect was detected by addition of MeOH as proton 
source. 
 
Scheme 1.17 Influence of the proton source in the reaction outcome. 
A mechanistic proposal has been suggested from this work (Scheme 1.18). Once the 
copper (I) alkoxide (A) is formed via reaction of CuCl, ligand and KOtBu, it reacts with 
the diboron reagent 1, which via σ-bond metathesis might form the borylcopper (I) 
reactive specie B. When Xantphos was used, due to the higher HOMO energy of 
copper complex formed, intermediate B has the ability to undergo the insertion into 
the non-activated alkene to form the alkyl copper species C with concomitant 
formation of an ionic complex D by coordination of the alkoxide. Subsequent 
intramolecular oxidative addition and elimination of bromide with inversion of the 
stereochemistry provides the copper (III) metallacycle intermediate E. Finally, 
reductive elimination of the copper species to produce the borylated cyclized 
product, and the regeneration of the catalyst to form A closes the catalytic cycle. 
The proposed mechanism explains why formation of the six-membered ring would 
not proceed, since reductive elimination would occur on a disfavored seven-
membered metallacycle (E). 
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Scheme 1.18 Proposed mechanism for the exo-borylative  
cyclization of non-activated alkenes. 
More recently, Zhong and co-workers[30] reported for the first time the 
stereoconvergent copper catalyzed borylative cyclization of α,β-unsaturated esters 
and ketones bearing a O-mesylate as leaving group (Scheme 1.19). 
 
Scheme 1.19 Stereoconvergent formation of cycloalkyl boronates. 
With the use of 10 mol% dppe, the exclusive formation of the cis-product was 
observed either starting from the E- or Z-ω-mesylate-functionalized α,β-
unsaturated ester. This methodology allows the formation of the five- and six-
membered cycloalkyl boronate esters in good yields. The authors proposed the 
reactions mechanism shown in Scheme 1.20 to explain the formation of the cis-
product from both the E- and Z-isomer. 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Introduction 
18 
 
Scheme 1.20 Plausible mechanism for the stereoconvergent formation of the cis-product. 
The addition of the boryl copper species to A or A’ involves a fast enolization process 
to form species B. From this moment, a coordination between the oxygen and the 
boryl moiety might occur, facilitating the formation of the five membered ring 
enolate. Subsequent intramolecular nucleophilic substitution reaction via transition 
state C, where the boryl moiety and the ester group are at the same side, leads to 
the cis-product. 
1.4.2 Borylative ring-closing of alkenes bearing carbonyl electrophiles 
Complementary to a nucleophilic substitution, the addition to carbonyl 
electrophiles also provides a variety of cyclic borylated products while generating 
an extra alcohol functional group. Commonly these reactions proceed through the 
regioselective addition of the boryl copper (I) species to the double bond, followed 
by intramolecular addition to the carbonyl group. 
The group of Lam[31] reported for the first time the enantioselective copper 
catalyzed tandem conjugated borylation/aldol ring-closing reaction of α,β-
unsaturated ketones providing a variety of bicyclic boronates of five- and six-
membered rings. During the formation of the bicyclic systems, a desymmetrization 
process took place with the generation of the C-B bond and the new C-C bond along 
with four contiguous stereocenters with high diastereoselectivity and 
enantioselecitivitiy (Scheme 1.21). 
 
Scheme 1.21 Borylative aldol cyclizations of enone diones to form decalines. 
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The selectivity of this reaction can be explained by a Zimmerman-Traxler-type 
model, that propose that some aldol reactions have six-membered transition states 
having a chair conformation, with the observed diastereoisomer being formed 
through the corresponding aldol cyclization in the Z-enolate transition state 
(Scheme 1.22). 
 
Scheme 1.22 Explanation through the Zimmerman-Traxler-type model. 
Ito and co-workers[32] reported the copper (I) catalyzed diastereoselective borylative 
ring-closing reaction of -alkenyl aryl ketones, providing a variety of syn-1-aryl-2-
(borylmethyl)cyclobutanol derivatives in moderate to high yields and with excellent 
diastereoselectivity (Scheme 1.23). 
 
Scheme 1.23 Borylative ring-closing of alkenyl  
aryl ketones catalyzed by copper (I) salts. 
In this transformation, the boryl copper (I) species reacts with the terminal alkene 
in a regioselective manner, followed by an intramolecular 1,2-addition of the ketone 
carbonyl group to afford the borylated cyclobutanol derivative. A longer carbon-
chain in the substrate led to the bicyclic structure containing a 1,2-oxaborolane, 
with high yield and excellent diastereoselectivity (Scheme 1.24). 
 
Scheme 1.24 Oxaborolane formation through δ-alkenyl  
phenyl ketone catalyzed by copper (I) salt. 
The mechanistic proposal for the borylative cyclization with intramolecular addition 
to carbonyl groups is shown in Scheme 1.25. The suggested catalytic cycle starts 
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with the formation of the LCuOtBu complex A, which upon reaction with 1 via σ-
bond metathesis provides the active boryl copper (I) species B. The L-Cu-Bpin 
complex has the ability to insert into the alkene to form the alkyl copper (I) species 
C. Subsequent coordination of the alkoxy group facilitates the formation of the more 
nucleophilic cuprate D. Further intramolecular nucleophilic attack of the copper (I) 
to the carbonyl carbon may occur to form the dialkylcopper (III) E, which follows a 
reductive elimination leading to the formation of the organoborane cyclized product 
and recovery of the active specie A. The syn-selectivity observed in the resulting 
products could be attributed to the favored transition state through the less 
sterically hindered pathway (Scheme 1.25). 
 
Scheme 1.25 Proposed mechanism of the borylative cyclization  
with intramolecular addition to the carbonyl. 
More recently, Lautens and co-workers[33] reported the enantioselective version of 
alkenes containing aryl ketones. This transformation involved the use of alkenes 
which have tethered different aryl groups and the use of (S,S)-BDPP as chiral ligand, 
providing a wide scope of products in moderate to excellent yields and excellent 
enantiomeric ratios (Scheme 1.26). 
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Scheme 1.26 Enantioselective borylative ring-closing trough substituted diarylpentenones. 
The same group developed the enantioselective copper catalyzed intramolecular 
borylacylation of carbamoyl chlorides giving access to chiral borylated 3,3-
disubstituted oxindoles (Scheme 1.27).[34] 
 
Scheme 1.27 Enantioselective intramolecular copper-catalyzed borylacylation. 
The position and nature of the substituents (R1) in the aromatic ring played a role in 
the reaction outcome. Thus, electron-withdrawing substituents led to lower 
reaction yields and enantioselectivities. Substituents at ortho-position to the alkene 
tend to diminish the enantioselectivities. Substituents in para-position were in 
general detrimental and a large decrease in the enantioselectivities, as well as 
longer reaction times, were observed.  
The influence of the alkene substituent (R2) was also examined. Slightly changes in 
this substituent affect directly to the reaction outcome in terms of yield and 
enantioselectivity. A good diversity of substituents in nitrogen atom (R3) was 
tolerated leading to the formation of the cyclized products with very good yields 
and enantioselectivities. 
1.4.3 Borylative ring-closing of alkenes bearing isocyanides 
Chatani and co-workers[35] have reported the only example of borylative cyclization 
reaction with alkenes bearing isocyanides. This transformation gives access to a 
variety of different 2-borylindoles (Scheme 1.28). 
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Scheme 1.28 Copper catalyzed borylative cyclization of 2-alkenylaryl isocyanides. 
Inverse reactivity has been observed since the boryl copper (I) species reacts first 
with the isocyanide group (Scheme 1.29), which is in contrast to the previous 
reactivity observed with alkenes bearing good leaving groups or containing carbonyl 
electrophiles where the boryl copper (I) species reacts first with the alkene. The 
proposed catalytic cycle it is shown in (Scheme 1.29). The catalytic borylation starts 
with the addition of the reactive boryl copper (I) species to the isocyanide group of 
the substrate to form B. Subsequent intramolecular 1,4-addition of imidoylcopper 
B leads to the formation of the copper enolate C. Then MeOH is required to generate 
the borylated indole product E and the Cu-OMe (D) to end up with the 
transmetallation that regenerate the species A  
 
Scheme 1.29 Plausible mechanism for the borylative cyclization of alkenes bearing isocyanides. 
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1.4.4 Borylative ring-closing of alkenes bearing imines 
Due to the pharmaceutical interest of 2,3-disubstituted indoles two examples of 
synthesis have been reported through borylative ring-closing of alkenes bearing 
imines. 
Xu and co-workers[36] developed the first borylative ring-closing reaction bearing 
imines with different functional groups providing a wide range of 2,3-disubstituted 
indolines (Scheme 1.30). 
 
Scheme 1.30 Borylative cyclization of substituted  
N-(2-vinylaryl)benzaldimines catalyzed by copper. 
The proposed reaction mechanism involves the insertion of L-Cu-Bpin species in the 
alkene and subsequent addition to the electrophilic position of the imine, providing 
the 2,3-disubstituted indoline derivatives with high diastereoselectivities, with the 
exclusive formation of the cis-product (Scheme 1.31).  
 
Scheme 1.31 Suggested explanation for the diatereoselectivity 
It has been suggested that the diastereoselectivity might be controlled in the step 
coming from the favored cis-transition state established after the Cu-Bpin insertion 
into the C=C bond. Observing the two transition states formed, the trans-TS suffers 
from steric hindrance between the CH2Bpin moiety and the hydrogen from the 
imine. Contrarily, the cis-TS has the CH2Bpin moiety pointing out and the two 
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hydrogens in the same direction being more favored than the analogous mentioned 
trans-TS. 
Following this reactivity the group of Zhang[37] developed the enantioselective 
version of the reaction. 
Some modifications in the catalytic system as well as, the use of a chiral ligand as 
(S,S)-Ph-BPE and the use of an ethereal solvent allowed the preparation of boryl 
indolines with high chemoselectivity, diastereoselectivity and enantioselectivity 
(Scheme 1.32). A wide scope of different products was prepared containing aryl and 
heteroaryl systems, with substituents placed in ortho-, meta- and para-position. 
However, the efficiency of the reaction is directly affected to modifications around 
the substrate. 
 
Scheme 1.32 Enantioselective synthesis of 2,3-disubstituted boryl indoles. 
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2.1. Specific objectives of the thesis 
The specific objectives of the thesis are:  
 
 The generation of a method for the insertion of the diazo compound 
CH(N2)(SiMe3) into B-S σ-bonds of pinB-SR reagents to promote a direct 
synthesis of multisubstituted sp3 carbons in CH(Bpin)(SiMe3)(SR). The 
objective also involves the selective derivatization of CH(Bpin)(SiMe3)(SR) 
via base-mediated alkylation including intramolecular cyclizative reactions. 
 
 The study of the borylative cyclization of alkenes containing good leaving 
groups to form spiro-bicyclic compounds. This objective is based on the 
copper (I) catalyzed reaction, searching for optimized reaction conditions 
and general scope. 
 
 The application of borylative cyclization methodologies to the preparation 
of spiro-cyclic scaffolds and their derivatization towards a series of O-
GlcNAcase inhibitors with potential interest for the treatment of 
Alzheimer’s disease. 
 
 The development of a synthetic methodology towards the borylative 
cyclization of alkenes containing an aldehyde group via copper (I) 
complexes, with a special emphasis on the diastereoselectivity of the 
process. 
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Inter and intramolecular selective 
alkylations of CH(Bpin)(SiMe3)(SR) with 
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3.1. State of the art 
The discovery of new and efficient processes that assure the access to complex 
molecular entities involving low number of chemical stages keeps constituting one 
of the main challenges of organic synthesis. Researchers have intensively focused 
on methodologies based on distinguishing reactivity patterns thus providing the 
convenient route in a stereocontrolled manner. Hence, it is necessary to synthesize 
substrates endowed with various substituents capable to undergo chemoselective 
reactivity, as the geminal organodimetallic compounds, for instance. Such kind of 
species presents two reactive and versatile nucleophiles which allow the 
straightforward preparation of diverse and useful building blocks for biomedical and 
material science needs.  
For decades, the symmetrical or non-symmetrical geminal dimetallic reagents have 
been prepared using metals as lithium, magnesium, aluminum, copper, zinc or 
zirconium, among others. Despite all the possible combinations, and according to 
the experimental studies later described, we became interested in the use of 
metalloid species, such as boron and silicon, which provide a higher stability in terms 
of handling and storing, when compare with the rest of purely metallic species. They 
also provide multiple controlled reactivity, offering a great opportunity for their 
application in different selective demetallative alkylation sequences and/or in 
transition metal catalysis (Scheme 3.1). 
 
Scheme 3.1 Interest of bismetalloid compounds in a geminal arrangement. 
In this context, along the next sections we will review some of the possible selective 
transformations that can be applied to gem-bismetalloid species. More precisely 
some selective alkylation reactions that are closely related to this work are going to 
be highlighted.  
For instance, the type of gem-silyl boryl bismetalloid showed in Figure 3.1, could be 
selectively functionalized following three different strategies: a) deborylative-
alkylation sequence in the presence of an oxygenated base, b) in the case of Y = 
silicon, and making use of the appropriate base, a selective desilylation-alkylation 
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could be envisaged, and c) thanks to the acidity of the C-H bond located adjacent to 
the metalloid fragments, a classic deprotonation-alkylation approach could be as 
well imagined, thus giving access to interesting building blocks.[1] 
 
Figure 3.1 Selective functionalization of polymetalloids. 
3.1.1 Selective deborylative alkylation of geminal diboron compounds 
Geminal bis(boronate) compounds have demonstrated the ability to behave as 
nucleophilic partners in cross-coupling reactions. The outcome of this type of 
reactions is consistent with a mechanism involving the formation of an ate complex 
and its subsequent transmetallation. The possibility to generate in situ the 
corresponding ate complex of a geminal bis(boronate) that reacts with and 
electrophilic Pd complex, opens the door to the reaction of this type of species with 
other electrophiles like alkyl halides as we illustrate along the next sections. 
a) Intermolecular deborylative alkylation  
Morken and co-workers[2] have taken advantage of the use of stable geminal 
bis(boronate) esters and reported the alkoxide assisted monodeborylative 
alkylation of these species with alkyl halides as electrophiles (Scheme 3.2). 
Experimental evidences demonstrate that these alkylations proceed through 
alkoxide induced deborylation and subsequent generation of the α-boryl stabilized 
carbanion that it is in equilibrium with the formed ate complex, which, in turn, could 
be trapped with an alkyl halide electrophile (Scheme 3.2). To validate the versatility 
of the reaction, the transformation was applied to primary and secondary alkyl 
halides. The use of di-, mono- and non-substituted gem-diboron reagents was well 
tolerated. 
 
Scheme 3.2 Formation of α-boryl carbanion by alkoxy assisted deborylation. 
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Interestingly, the same group was able to apply this deborylative functionalization 
to a series of 1,1,2-tris(boronates), compounds that also present two boronate 
fragments in a geminal disposition.[3] While using these substrates, it has been 
observed that their reactivity is partially governed by the relationship between the 
neighboring boronate units. Hence, the internal chelation by the adjacent boron 
units is proposed to enhance their Lewis acidity of one of the geminal boryl units, 
therefore facilitating the cross-coupling reaction in a highly efficient manner. On the 
other hand, the ability of three-coordinate boron to stabilize adjacent carbanions 
appears to facilitate deborylation of geminal bis(boronate) esters providing reactive 
α-boryl carbanions. Since the carbanion formed is stable enough, it can be alkylated 
by addition of an electrophile. Moreover, these products were finally oxidized to 
produce the corresponding diols with enhanced diastereoselectivity (Scheme 3.3). 
 
Scheme 3.3 Steroelective deborylative alkylation of 1,1,2-tris(boronate) derivatives. 
Complementary, Huang and co-workers[4] reported the access to α-boryl carbanions 
by the base-assisted deborylation of 1,1,1-tris(boronates) substrates. Noticeable, 
the 1,1,1-tris(boronate) esters seem to be more reactive than the corresponding 
1,1,2-tris(boronate) compounds (Scheme 3.3) or 1,1-bis(boronate) compounds 
(Scheme 3.2), since lesser excess of the base is required to the formation of the ate 
complex; the necessary species for the successive alkylation to happen in an 
efficient manner (Scheme 3.4). 
 
Scheme 3.4 Selective deborylative alkylation of 1,1,1-tris(boronate) derivatives. 
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b) Intramolecular deborylative alkylation  
The rich reactivity demonstrated by the monodeborylative alkylation of gem-
bis(boronates) could be even used in an intramolecular manner. Hence, if 1,n-
dihalides are used in the first alkylation reaction, the product obtained can undergo 
subsequent ring forming reaction through intramolecular deborylative alkylation as 
reported by Morken and co-workers (Scheme 3.5).[2] 
 
Scheme 3.5 Intramolecular stereoselective deborylative 
 alkylation of gem-bis(boronate) compouunds. 
The same group[3] demonstrated the feasibility of the intramolecular deborylative 
alkylation using 1,1,2-tris(boronate) compounds that presented an alkyl halide in 
their structure as substrates. One of the most reactive Bpin fragments among the 
three boryl moieties present in the molecule can be, in fact, alkylated in an 
intramolecular fashion by means of the use of an excess of NaOtBu. In this way, a 
series of cyclic 1,2-bis(boronates) can be accessed. After the corresponding 
oxidative treatment, this transformation enables the formation of a range of cyclic 
diols in anti-disposition of different ring sizes (Scheme 3.6). 
 
Scheme 3.6 Intramolecular stereoselective deborylative alkylation of 1,1,2-tris(boronate) esters to 
construct cyclic diols. 
The investigation of the real nature of these α-boryl carbanions was object of a 
recent and very elegant study carried out by the group of Morken.[5] On the bases 
of some spectroscopic techniques the authors suggested that the boron stabilized 
carbanion might display significant -bonding between the carbanionic carbon atom 
and the three coordinate boron center, thus indicating that the anion can be 
alternatively represented as boron alkylidene (Scheme 3.7). 
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Scheme 3.7 Boron-alkylidene formation in the deborylative alkylation processes. 
In principle, the proposed boron-alkylidene species should be able to participate in 
cycloaddition processes. To probe this hypothesis, a gem-diborylalkane bearing a 
tethered alkene was designed. In the presence of an alkoxide base, a deborylative 
cyclization was observed after 14 hours. Since the cycloadduct species is itself an 
ate complex, if an electrophile is added at this point, such bora-bicyclic intermediate 
could be efficiently trapped (Scheme 3.8). Overall the cyclization is conceived as a 
[2+2] cycloaddition between an unactivated alkene and the boron alkylidene. 
 
Scheme 3.8 Deborylative [2+2] cyclization via boron-alkylidene formation. 
3.1.2 Desilylative alkylation 
Silyl groups are often used as protecting groups due to their straightforward 
removal with fluorinated bases. Fluoride induced desilylation is particularly efficient 
because the formation of the strong Si-F bond is a highly selective procedure.[6] On 
the basis of this premise, a series of selected desilylative alkylation processes 
reported in the literature are going to be listed in this section. This particular 
synthetic approach is directly related to some of the functionalizations that will be 
described in the results and discussion section of this memory. 
The first synthetic desilylative alkylation approach reported, involved β-ketosilanes 
as substrates.[7] These highly reactive species underwent efficient intermolecular 
desilylative alkylation with benzyl bromide. The reaction used cesium fluoride as 
base and the corresponding α-benzyl ketones were nicely obtained (Scheme 3.9). 
 
Scheme 3.9 Desilylative-alkylation of β-ketosilanes. 
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On the other hand, Sarkar and co-workers[8] reported an interesting intermolecular 
desilylative alkylation of azaphthalans. In this case, cesium fluoride was, once more, 
the fluorinated base responsible to promote the sequential introduction of two alkyl 
groups, thus enabling a double desilylation-alkylation strategy of the gem-(bis)silyl 
azaphthalane (Scheme 3.10). However, besides the formation of the double 
desilylated product, the mono-alkylated compound was observed as byproduct of 
the reaction (Scheme 3.10). 
 
Scheme 3.10 Mono- and di-alkyalation of azaphthalanes through  
intermolecular desilylative fluorination. 
3.1.3 Selective deprotonative alkylation sequence α to a boryl moiety  
The examples gathered in section 3.1.1 have involved a series of deborylative 
alkylations assisted by an alkoxide base. These type of oxygenated bases, owing the 
high boron-oxygen affinity, are able to coordinate to the boryl fragment thus 
generating a nucleophilic ate complex in equilibria with the corresponding α-boron 
stabilized carbanion that undergoes alkylation (Scheme 3.11, left). However, with 
the switch to a bulky lithium amide, a less borophilic base in comparison with an 
alkoxide, the outcome of the reaction can be totally altered. In this case, a simple 
deprotonation of any proton located α to the metalloid fragments could be 
achieved. In this way, an α-boryl carbanion susceptible of being alkylated by regular 
electrophiles can be generated (Scheme 3.11, right). Some examples of this type of 
reactivity, related to the behavior of the bimetalloid species included in this chapter, 
are described in this section. 
 
Scheme 3.11 Selective functionalization of gem-silyl boryl polymetalloids as a function of the base 
employed: deborylative alkylation versus α-boryl deprotonation. 
Matteson and co-workers reported the first deprotonation of gem-diboronic esters 
with the use of a bulky nitrogenated base as lithium tetramethylpiperidide (LTMP).[9] 
The deprotonation turned out to be quite efficient and the resulting 
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diborylcarbanion generated underwent straightforward alkylation with alkyl halides 
(Scheme 3.12). When using a bis(boronate)methane derivative (R1= H in Scheme 
3.12), the resulting monoalkylated product could be in turn deprotonated and 
alkylated twice.[9] The alkylation reaction takes place with different types of 
boronates and the use of primary alkyl iodides, bromides and tosylates affording the 
desired alkylated gem-diboronate products. Instead, the reaction proved to be 
more sluggish with secondary halides, therefore, these reactions yielded little or no 
alkylated product.[10] 
 
Scheme 3.12 First deprotonation-alkylation of bis(boronate) esters reported using LTMP. 
Additionally, the use of (bis)heterometalloid species containing two different 
metalloid fragments, such as silicon and boron, in combination with LTMP resulted 
in the generation of the doubly stabilized α-boryl / α-silyl carbanion. This reactive 
carbanion underwent the alkylation reaction with primary alkyl chlorides, bromides 
and iodides (Scheme 3.13).[11] 
 
Scheme 3.13 Deprotonation of gem-trimethylsilylboryl methane  
followed by selective alkylation with alkyl halides. 
Other substrates such as the pinacolboryl (phenylthio)methane compounds could 
be effectively deprotonated by the use of a less hindered base, such as lithium 
diisopropylamide (LDA). This base is able to induce the formation of the doubly 
stabilized α-boryl / α-sulfide carbanion showed in Scheme 3.14. Subsequent 
addition of primary alkyl halides to the reaction mixture promoted the formation of 
α-(phenylthio)alkane boronic esters. This methodology was able to provide a series 
of tetrasubstituted methane products (Scheme 3.14).[12] 
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Scheme 3.14 Selective deprotonation-alkylation sequence of pinacol 
(phenylthio)methaneboronates. 
Recently, the group of Morken[13] developed the idea to explore the reactivity of a 
series of gem-lithiated bis(boronates) anions towards the diiodomethane reagent. 
In this way a family of 1,1-disubstituted vinyl boronates could be accessed. From the 
mechanistic point of view, the lithiated substrate first undergoes alkylation with the 
diiodomethane, and subsequent B−I elimination results in formation of the vinyl 
boronate product (Scheme 3.15). 
 
Scheme 3.15 Synthesis of vinyl boronates by deprotonative-alkylation/B-I elimination sequence. 
3.1.4 Synthesis of germinal diboryl alkanes by insertion of diazo 
compounds into boron containing reagents 
One of the possible synthesis of gem-containing boryl species point to the insertion 
of diazo compounds into B-X σ-bonds. Aliphatic diazo compounds are not always 
easy to handle. Hence, one interesting way to use these reactive species is to 
generate them in situ by thermal decomposition of N-tosylhydrazone salts. Research 
along this line, led to Wang and co-workers[14] to develop a highly and efficient 
transition metal-free insertion of aliphatic diazo species into diboron reagents such 
as B2pin2 (1) or Me2PhSiBpin. In this way a series of gem-bis(boronate) esters have 
been prepared (Scheme 3.16). From the mechanistic point of view, in this 
transformation are involved three important steps: the in situ generation of the 
diazo reagent, followed by the coordination of the diazo compound to the boron 
reagents (B2pin2 (1) or Me2PhSiBpin) and the consequent 1,2-migration of one of the 
boryl or silyl fragment of the dimetalloid reagent to the adjacent carbon.  
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Scheme 3.16 Generation of gem-bis(metalloids) by in situ  
generation of diazo compounds. 
Our group has also contributed to the field of the insertion of non-stabilized diazo 
compound into the B−B σ-bond.[15] In fact, we reported the insertion of a series of 
aliphatic diazo compounds generated by decomposition of N-tosylhydrazone salts 
into the non-symmetrical B−B σ-bond of pinB-Bdan (Bdan = 1,8-
naphthalenediaminatoboryl). The N-tosylhydrazones employed in such study were 
derived either from aliphatic aldehydes or cyclic ketones (Scheme 3.17). 
Noteworthy, high diastereoselectivity can be achieved in the case of unsymmetrical 
substituted cyclohexanones. 
 
Scheme 3.17 Diazo insertion into unsymmetrical  
diboron reagents such as Bpin-Bdan. 
In the field of nucleophilic diazo species, the trimethylsilyl diazomethane 
[CH(N2)(SiMe3)] (7) is particularly interesting since is an stable liquid (b.p. 96 °C) 
recognized as a safe diazomethane surrogate, with its enhanced stability 
rationalized by the α-silyl carbanion stabilization (α-silicon effect).[16] Such diazo 
compound contains an additional SiMe3 fragment that could be introduced in the 
insertion reaction with diboranes. This kind of transformation, opened the door to 
the introduction of many functional and reactive groups for further 
derivatizations.[17] 
Hence our group expanded this reactivity by performing the insertion of 
trimethylsilyldiazomethane into the boron-boron σ-bond of B2pin2 (1).[18] Such 
reaction rendered a very versatile multisubstituted [CH(Bpin)2(SiMe3)] (5) species. 
The synthesis of this new reagent can be efficiently performed on gram scale simply 
by mixing B2pin2 (1) and [CH(N2)(SiMe3)] (7) under heating. The [CH(Bpin)2(SiMe3)] 
(5) can be deprotonated in the presence of bulky lithiated bases to generate a 
boron- and silicon-stabilized carbanion able to add to ketones to form a series of 
gem-silyl borylalkenes following a B-O elimination. Through this methodology 
several different gem-(sp2)-silylboronates were prepared, most of them with high 
degree of Z/E-diastereoselection.[18] This methodology allowed for modular and 
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stereocontrolled synthesis of all carbon tetrasubstituted alkenes, as was illustrated 
by the synthesis of Tamoxifen (Scheme 3.18). 
 
Scheme 3.18 Insertion of trimethylsilyl diazomethane into B-B σ-bond followed by Boron-Wittig-
type olefination of ketones. Simple access to Tamoxifen drug. 
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3.2. Aim of the Chapter 
With all these precedents in mind, and based on the experience of our group in the 
insertion of diazo compounds into the pinB-Bdan σ-bond, as well as the insertion of 
trimethylsilyldiazomethane into B2pin2 (1), we became interested in the insertion of 
this commercially available diazomethane equivalent into B-S σ-bond. 
More specifically, due to the efficient insertion of [CH(N2)(SiMe3)] (7) in the B-X σ-
bond in a transition metal-free context, we propose to explore the insertion of 
trimethylsilyldiazomethane (7) into pinB-SPh (6a) and pinB-STol (6b) bonds. This 
approach could represent a straight forward access to the formation of 
multisubstituted sp3 carbons (Si, B, S). If successful, the study would help to prepare 
a series of structurally diverse molecules endowed with high synthetic potential. In 
fact, subsequent selective base-mediated functionalizations that includes 
intermolecular or intramolecular cyclizative alkylations, could be envisaged (Scheme 
3.19). 
 
Scheme 3.19 Strategic trimethylsilyldiazomethane insertion into pinB-S- σ-bond followed by 
selective functionalizations. 
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3.3. Results and discussion 
On the basis of the previously described main objective of this chapter we started 
the study by exploring the insertion of the commercially available [CH(N2)(SiMe3)] 
(7) with pinB-SPh (6a). This B-S reagent was supplied by the group of Prof. Westcott, 
within a collaborative project. This group prepared series of B-S reagents by means 
of rhodium catalysis mixing HBpin and the benzenethiol derivative (Scheme 3.20).[19] 
 
Scheme 3.20 Preparation of pinB-SR reagents. 
The initial insertion experiments were carried out working at 0.2 mmol scale and, 
on the bases of some preliminary experiments carried out in the group with similar 
insertion reactions, it was found that the use of an excess of the diazo compound 7 
(2 equiv) in the reaction along with 1 equiv of 6a(diazo/borane = 2/1) was beneficial 
for the reaction completion. By means of this stoichiometry, full conversion of 6a 
towards the insertion product was observed. When the reaction was performed at 
50 °C during 16 hours, compound CH(Bpin)(SiMe3)(SPh) (8a) was obtained in almost 
quantitative yield. Nevertheless, we found that decreasing the reaction time to 6 
hours the conversion was not significantly affected (94%) (Scheme 3.21, left). 
Similarly, the reaction was also performed with pinB-STol (6b), also supplied by the 
group of Prof. Westcott.[19] The inserted product [CH(Bpin)(SiMe3)(STol)] (8b) was 
also isolated in high yield (89%). However, for this B-S reagent, slightly higher 
temperatures (70 °C) were required to achieve full conversion towards the 
formation of 8b (Scheme 3.21, right). 
 
Scheme 3.21 Optimized reactions conditions for the insertion of CH(N2)(SiMe3) into pinB-SR. 
Conditions: pinB-SR (0.2mmol, 1 equiv), 7 (2 equiv), 50 – 70 °C, 6 - 16 h. 
From the mechanistic point of view, the insertion of 7 into the interelement B-S σ-
bond might be understood as an initial interaction of the nucleophilic diazo carbon 
to the electron deficient boron of the Bpin moiety. Subsequently, the polarization 
of the boron-sulfur σ-bond would give rise to the 1,2-migration of the adjacent SR 
moiety to yield the α,α-substituted methane product with concomitant dinitrogen 
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release (Scheme 3.22). An analogous mechanism was already postulated by Dr. J. 
Carbó through DFT calculations[20] using pinB−Bpin or pinB−Bdan and CH(N2)(CH3) as 
the model diazo alkane, suggesting a concerted asynchronous mechanism.[15] 
 
Scheme 3.22 Suggested concerted mechanism for the insertion of CH(N2)(SiMe3) into pinB-SR. 
Moreover, it was possible to scale up the insertion of 7 into B-S σ-bonds to a gram 
quantities, thus providing the formation of reagent 8a in 95% isolated yield and 8b 
in 89% isolated yield. In this case, for safety reasons, a careful evaluation of reaction 
set up was applied since higher volumes of nitrogen were generated.  
At this point, we considered that these new polysubstituted species 8a-b could serve 
as an interesting entry point towards selective alkylative functionalizations. In fact, 
as mentioned in the Aim of the Chapter section, this type of gem-silyl boryl sulfides 
could, in principle, be selectively functionalized following different strategies. In first 
place, as mentioned in section 3.1.1, bis(boronate) esters exhibit a well stablished 
ability to coordinate to alkoxides and undergo deboryative alkylation due to the well 
stablished affinity of trigonal boron compounds to coordinate to oxygenated bases. 
Based on this premise, we sought to explore whether this reactivity could be 
ascribed to compounds of type of 8a-b that present a silyl group in their structure. 
This transformation was considered challenging, since the retention of the silyl 
group could be compromised in the presence of the alkoxide. If successful, this two-
step sequence would constitute an unprecedented protocol for the synthesis of α-
silyl sulfides.  
Initially, and based on the work of Morken and co-workers,[2] sodium tert-butoxide 
was selected to induce the deborylation process.  
The initial experiments were carried out employing 8a-b as substrates and 1-
bromotetradecane (9) as alkylating reagent. The reaction conditions entailed the 
mixing of 9 (1 equiv) with an excess of 8a-b (1.3 equiv) in THF and subsequent 
addition of NaOtBu (4 equiv). The excess of 8a-b versus the alkylating reagent was 
used to discard any potential decomposition along the reaction. Within 3 hours, at 
room temperature the alkylated α-silyl sulfide 10a was observed in 84% yield and 
10b in 73% yield (Scheme 3.23). Longer reaction times did not result in higher yields. 
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When a shorter alkyl halide was used instead, such as 1-bromobutane (11a), the 
alkylated product 12a was obtained in moderate yield. Nevertheless, the use of 1-
iodobutane (11b) containing a better leaving group, resulted in a more efficient 
reaction. In this way the α-silyl sulfide 12b was isolated in 80% yield (Scheme 3.23). 
Then we performed the reaction with 1-bromo-4-chlorobutane (13) and 1-bromo-
4-fluorobutane (15) with substrate 6b. The deborylative alkylation reaction took 
place selectively in both cases in the C-Br bond, giving rise to products 14 in 61% 
and 16 in 87% isolated yield, respectively (Scheme 3.23). Due to the superior leaving 
group ability of Br, the reaction allows selectively the formation of the new C-C bond 
at the C-Br site, leaving the C-F and the C-Cl bonds intact (Scheme 3.23). 
Interestingly, the SN2-type alkylation of the more activated cinnamyl chloride (17) 
was easily performed to generate E-trimethyl(4-phenyl-1-(p-tolylthio)but-3-en-1-
yl)silane (18) in 80% isolated yield. The lower ability of chloride as leaving group was 
this time compensated by the better transition state stabilization by the allylic 
nature of the electrophile (Scheme 3.23). 
In agreement with this last result, other activated allylic, benzylic or propargylic 
halides, such as 3-bromo-2-methylprop-1-ene (19), benzyl bromide (21) and 1-
bromopent-2-yne (23), nicely provided the alkylated α-silyl sulfides 20, 22 and 24 in 
moderate to high yields (Scheme 3.23). Unfortunately, product 20 could not be 
isolated due to decomposition during the purification process, even though, its 
efficient generation was undoubtable proved by NMR spectroscopy (Scheme 3.23). 
The compatibility of unsaturated functional groups with respect to the base-
mediated deborylative alkylation was demonstrated with the use of a substrate 
containing a double bond in the terminal position of the alkyl chain, substrate 25. 
Hence, the efficient preparation of the corresponding gem-silyl sulfide derivative 26 
was performed in 72% isolated yield (Scheme 3.23). 
Even more remarkable is the example with 2-(bromomethyl)oxirane (27), where the 
alkylated product (28) was isolated in 42% yield leaving the epoxide functional group 
unaltered (Scheme 3.23). 
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Scheme 3.23 Substrate scope of deborylative alkylation of derivatives 8a-b via SN2 pathway. 
We also conducted the deborylative alkylation with a secondary alkyl halide, a more 
challenging substrate due to the steric hindrance present around the halogen. 
Nevertheless, when isopropyl iodide (29) was chosen as alkylating agent, the 
anticipated lower reactivity due to the steric effects seemed to be balanced by the 
better leaving group ability of the iodide group, and trimethyl(2-methyl-1-(p-
tolylthio)propyl)silane (30) was isolated in 67% yield (Scheme 3.23). 
Overall, the results shown in Scheme 3.23 demonstrate that the deborylative 
alkylation of 8a-b tolerates a broad substrate scope, even combining different 
functional groups in the same substrate as well as the use of more challenging and 
sterically hindered secondary alkyl halides. 
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The two-step insertion/base-assisted deborylative alkylation constitutes an 
unprecedented protocol for the synthesis of alkylated α-silyl sulfides in a very 
straightforward manner. 
Next, we turned our attention to the alkylations involving the generation of double 
stabilized α-boron / α-silyl carbanions engendered through deprotonation of gem-
polymetalloid 8a-b. As introduced above (section 3.1.3), the switch from an alkoxide 
base to a bulky lithium amide, comparatively less borophilic, might influence the 
reaction outcome. In this case, a simple deprotonation of any α-proton to the 
metalloid fragments could be achieved. 
Hence, substrates 8a-b can be efficiently deprotonated by the presence of lithium 
tetramethylpiperidide (LTMP) and subsequently alkylated with cinnamyl chloride. In 
this way, the alkylated α-boryl silyl sulfides 32a and 32b could be obtained in 79% 
and 74% yield, respectively (Scheme 3.24). The reaction proved to be feasible with 
a series of substrates featuring allylic (19) and benzylic (21) electrophiles albeit 
providing the formation of 33, 34a and 34b only in moderate yields (Scheme 3.24). 
Nevertheless, the alkylation reaction with propargylic systems proved sluggish and 
the corresponding tetrafunctionalized methane was only observed by NMR (10% 
NMR yield) (Scheme 3.24). Nonetheless, the alkylation was compatible with the 
presence of a monosubstituted terminal double bond, substrate 25, giving access to 
the desired derivative 36 in 30% isolated yield (Scheme 3.24). The use of longer alkyl 
chain in substrate 31 provided the formation of the alkylated product 37 in 
moderate yield (Scheme 3.24). 
Noteworthy is the use of more hindered secondary halides. In this case, isopropyl 
iodide (29) lead to the formation of the alkylated compound 38 in a good 43% 
isolated yield (Scheme 3.24). 
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Scheme 3.24 Substrate scope of deprotonation-alkylation of derivatives 8a-b via SN2 pathway. 
Encouraged by these results, we turned our attention to the use of dihalogenated 
alkanes, such as dibromo and diiodo alkyl derivatives. With the objective to prevent 
the double incorporation of 8a-b at both ends of the alkyl chain, a higher excess of 
the electrophile was employed (1.75 equiv). The reaction proved to be quite 
efficient, affording exclusively the mono-alkylated products. When butyl dihalides 
were used such as 39 (X= Br) or 43 (X= I) products 40a, 40b, 44a, and 44b were 
obtained in high yields (Scheme 3.25). Moreover, extending the alkyl chain one 
atom (41 X= Br and 45 X= I) did not have an effect on the reaction outcome, and the 
corresponding mono-alkylated products 42 and 46 could be isolated in good yields 
(Scheme 3.25). 
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Scheme 3.25 Substrate scope of deprotonation-alkylation of derivatives 8a-b  
via SN2 pathway with dihaloalkanes. 
Interestingly, when 1,n-dihalides are employed in these alkylation reactions, the 
reaction products (compounds 40a-b, 42, 44a-b and 46 in Scheme 3.25) are suitable 
substrates for an intramolecular ring forming deborylative alkylation. As depicted in 
Scheme 3.26, this strategy would enable a straigforward synthesis of cyclic gem-silyl 
sulfides that are not readily available by other methods. 
 
 
Scheme 3.26 Intramolecular deborylative alkylation with 1,n-dihalides: 
 construction of cyclic gem-silyl sulfides. 
To study this posibility, substrate 44a containing an iodine leaving group was treated 
with 4 equiv of KOtBu in THF at room temperature. Unfortunately, the desired 
cyclized product was not detected after 3 hours of reaction and only the product 48 
was clearly observed. The formation of 48 could be explained as a result of the 
presence of different competititve reactions, the E2 elimination to give an alkene, 
the protodeborylation and the desired alkylation pathways. Based on the 
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experimental result, in the reaction with substrate 44a the intramolecular SN2 
alkylation seems to be the less favoured reaction. 
To our deligth, when the corresponding C(Bpin)((CH2)4Br)(SiMe3)(SPh) (40a) was 
subjected to the same deborylative conditions, the five-membered ring α-silyl 
sulfide was nicely produced and compound 47 was isolated in 70% yield (Scheme 
3.27).  
 
Scheme 3.27 Intramolecular deborylative cyclization. Reaction conditions: 40a/44b (0.2 mmol, 1 
equiv), KOtBu (4 equiv), THF (1 mL), rt, 3 h. 
Moreover, the transformation could be extended to the formation of the analogous 
six-membered ring gem-silyl sulfides. Thus, when substrate 42 was treated with 4 
equiv of KOtBu in THF at room temperature the corresponding six-membered ring 
α-silyl sulfide 49 was isolated in 65% yield (Scheme 3.28). Once more, however, the 
reaction with the iodo-substrate 46 provieded the unwanted product 50 as 
observed previously in the formation of the five-memebered ring. The better leaving 
group ability of iodine compared to the bromine atom seems to accelerate the 
participation of 46 into the side elimination reaction. 
 
Scheme 3.28 Intramolecular deborylative cyclization. Reaction conditions: 42/46 (0.2 mmol, 1 
equiv), KOtBu (4 equiv), THF (1 mL), rt, 3 h. 
Additionally, we decided investigate the analogous, but more challenging and rather 
unprecedented, desilylative intramolecular cyclization. As detailed in Scheme 3.29, 
this strategy would yield an straigforward route to cyclic gem-boryl sulfides, 
compounds that are not readily prepared by other methods. 
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Scheme 3.29 Intramolecular desilylative alkylation with 1,n-dihaloalkanes: 
 construction of cyclic gem-boryl sulfides. 
Based on this premise, we selected Br-substrates 40a and 42 and I-substrates 44a 
and 46 to test the potential desilylative cyclization. As in the case of the deborylative 
cyclization, a significant effect of the leaving group was observed. Thus, when 
bromo derivatives (40a/42) were subjected to desilylative cyclization conditions 
using tetra-n-butylammonium fluoride (TBAF), only proto-desilylated products 
(51/53) were observed, leaving the bromine atom unreacted. On the other hand, 
the more activated iodine-containing substrates 44a and 46 underwent desilylative 
cyclization leading to the corresponding five- and six-membered carbocycles. More 
specifically, in the case of substrate 44a, after addition of 4 equiv of TBAF at 0 °C and 
stirring during 1.5 hours, the desired five-membered ring product 52 was observed 
in 41% NMR yield (Scheme 3.30a). The formation of the cyclohexane derivative 54 
was found to be more challenging, and under the same reaction conditions the 
product could only be observed in 18% yield by GC-MS analysis (Scheme 3.30b). 
 
Scheme 3.30 Intramolecular desilylative cyclization. Conditions: Substrate (0.2 mmol, 1 equiv), 
TBAF (1 M, 4 equiv), THF (0.3 mL), 0 °C - rt, 1.5 h. 
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In summary, a series of selective functionalizations of gem-silyl boryl sulfides have 
been explored. These reactions included innovative demetallative cyclizations that 
allowed access to new boryl containing cyclopentane and cyclohexane derivatives.  
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3.4. Conclusions 
The insertion of trimethylsilyldiazomethane into B-S σ-bond of pinB-SPh (6a) and 
pinB-STol (6b) has been achieved in quantitative yield. The reaction is amenable to 
scale up (gram scale) in a very efficient manner (Scheme 3.31A).  
A careful selection of the base has allowed the selective alkylation of trisubstituted 
methanes of molecular formula CH(Bpin)(SiMe3)(SR) (8a-b): 
 NaOtBu assisted deborylative alkylation of CH(Bpin)(SiMe3)(SR) (8a-b) was 
nicely performed in a series of alkyl halides promoted by the high boron-
oxygen affinity (Scheme 3.31B).  
 The deprotonation-alkylation of CH(Bpin)(SiMe3)(SR) (8a-b) with a series of 
alkyl halides and 1,n-dihalides was carried out under mild conditions. The 
use of a bulky lithium amide base alters the outcome of the reaction 
allowing for a boron-retentive alkylation reaction. In this way, a range of 
tetrasubstituted methanes can be accessed. (Scheme 3.31C).  
The use of 1,n-dihaloalkanes as electrophiles, allowed for the synthesis of series of 
functionalized carbocyclic compounds from the first deborylative alkylation 
intermediate.  
 An intramolecular ring forming deborylative alkylation was developed by 
the use of an alkoxide base. Through this method, a series of cyclic α-silyl 
sulfides have been prepared (Scheme 3.31D)  
 An intramolecular desilylative cyclization procedure has been achieved in 
the presence of a more silicophilic fluoride base. This new methodology, 
albeit in moderate yields, gives access to the synthesis of α-boryl sulfides 
(Scheme 3.31E).  
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Scheme 3.31 Graphical conclusions of trimethylsilyldiazomethane insertion and selective 
functionalizations.  
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Inter and Intramolecular selective alkylations of CH(Bpin)(SiMe3)(SR) with alkyl 
halides  
58 
3.5. References Chapter 3 
[1] a) N. Miralles, R. J. Maza, E. Fernández, Adv. Synth. Catal. 2018, 360, 1306-1327; b) 
J. Royes, A. B. Cuenca, E. Fernández, Eur. J. Org. Chem. 2018, 2018, 2728-2739; c) 
R. Nallagonda, K. Padala, A. Masarwa, Org. Biomol. Chem. 2018, 16, 1050-1064; d) 
C. Wu, J. Wang, Tetrahedron Lett. 2018, 59, 2128-2140. 
[2] K. Hong, X. Liu, J. P. Morken, J. Am. Chem. Soc. 2014, 136, 10581-10584. 
[3] J. R. Coombs, L. Zhang, J. P. Morken, J. Am. Chem. Soc. 2014, 136, 16140-16143. 
[4] L. Zhang, Z. Huang, J. Am. Chem. Soc. 2015, 137, 15600-15603. 
[5] X. Liu, T. M. Deaton, F. Haeffner, J. P. Morken, Angew. Chem. Int. Ed. 2017, 56, 
11485-11489. 
[6] I. H. Krouse, P. G. Wenthold, J. Am. Soc. Mass Spectrom. 2005, 16, 697-707. 
[7] M. Fiorenza, A. Mordini, S. Papaleo, S. Pastorelli, A. Ricci, Tetrahedron Lett. 1985, 
26, 787-788. 
[8] T. K. Sarkar, S. Basak, Org. Lett. 2004, 6, 2925-2927. 
[9] D. S. Matteson, R. J. Moody, J. Am. Chem. Soc. 1977, 99, 3196-3197. 
[10] D. S. Matteson, R. J. Moody, Organometallics 1982, 1, 20-28. 
[11] a) D. S. Matteson, D. Majumdar, J. Chem. Soc., Chem. Commun. 1980, 39-40; b) D. 
S. Matteson, D. Majumdar, Organometallics 1983, 2, 230-236. 
[12] D. S. Matteson, K. Arne, J. Am. Chem. Soc. 1978, 100, 1325-1326. 
[13] J. R. Coombs, L. Zhang, J. P. Morken, Org. Lett. 2015, 17, 1708-1711. 
[14] a) H. Li, X. Shangguan, Z. Zhang, S. Huang, Y. Zhang, J. Wang, Org. Lett. 2014, 16, 
448-451; b) H. Li, L. Wang, Y. Zhang, J. Wang, Angew. Chem. Int. Ed. 2012, 51, 2943-
2946. 
[15] A. B. Cuenca, J. Cid, D. García-López, J. J. Carbó, E. Fernández, Org. Biomol. Chem. 
2015, 13, 9659-9664. 
[16] D. M. Wetzel, J. I. Brauman, J. Am. Chem. Soc. 1988, 110, 8333-8336. 
[17] a) C. H. Burgos, E. Canales, K. Matos, J. A. Soderquist, J. Am. Chem. Soc. 2005, 127, 
8044-8049; b) A. Sekiguchi, W. Ando, Organometallics 1987, 6, 1857-1860; c) D. 
Seyferth, T. C. Flood, J. Organometal. Chem. 1971, 29, C25-C28. 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Chapter 3 
 59 
[18] E. La Cascia, A. B. Cuenca, E. Fernández, Chem. Eur. J. 2016, 22, 18737-18741. 
[19] S. A. Westcott, J. D. Webb, D. I. McIsaac, C. M. Vogels, 2006/089402 A1 Patent. 
[20] Calculations were performed using a Gaussian09 (B03LYP functional) and 06-
31g(d,p) basis set. 
 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
  
 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
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Intramolecular borylative ring-closing   
C-C coupling toward spiro- and dispiro-
heterocycles 
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4.1. State of the art 
4.1.1. Intramolecular carboboration 
Within the borylative ring-closing reactions, the 1,2-carboboration reaction has 
been the most widespread explored. Copper (I) salts are able to activate diboron 
reagents in a specific manner to transfer one boryl unit to unsaturated substrates 
favoring the concomitant cross-coupling pathway.[1] Borylative cyclization of alkenes 
containing good leaving groups in their structure is considered an intramolecular 
1,2-carboboration reaction, that provides highly substituted 3- to 5-membered 
rings. The stereoselectivity in the transformation can be efficiently controlled by the 
nature of the catalyst. In fact, this is a highly efficient methodology for the synthesis 
of organoboronates with complex carbon skeletons.[2]  
Over the last decades, many efforts have been devoted to the development of 
catalytic borylative cyclization reactions and, in particular, to understand their 
reaction mechanisms. The reaction sequence for such transformations starts with 
the boryl cupration of the unsaturated double bond, followed by oxidative addition 
to afford the corresponding metallocyclic intermediate that generates the cyclic 
organoboron product via reductive elimination sequence (Scheme 4.1). 
 
Scheme 4.1 General borylative cyclization mechanism catalyzed by copper (I) salt. 
The borylcupration step can lead to two possible cyclizations: endo- and exo-
cyclization. The reaction outcome is fixed by the substrate.[3] Thus, alkene containing 
electron rich substituents favor the coordination of the copper close to that 
substituent and the boron to the internal position of the C=C, promoting the endo-
cyclization pathway (Scheme 4.2a). 
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On the other hand, when non-activated alkenes are used, as reported by Ito and co-
workers,[4] the coordination of the copper goes to the internal position of the alkene 
leaving the boryl group placed at the more external position of the unsaturated 
substrate, leading to the formation of the exo-cyclic product upon the reductive 
elimination step (Scheme 4.2b). 
 
Scheme 4.2 Possible borylative cyclizations pathways depending on the nature of the substrate. 
4.1.2. The interest of spiro-bicyclic motifs 
Recently, advances in molecular sciences have exerted an enormous influence in the 
availability of new molecular entities.[5] The key for the success in the investigations 
in different areas, is the identification of the targets and their synthesis. Due to the 
infinite number of combinations and structures, this big range of possibilities opens 
a broad chemical space to be discovered. Organic chemistry, has been always 
working to provide routes of access to new synthetic building blocks.  
Traditionally, spiro-bicyclic motifs have been scarcely explored in drug discovery, 
mostly due to their challenging synthesis.[6] Design and availability of new spiro-
bicycles is a challenging task, since it involves the synthesis of a quaternary carbon 
as intersection point between the two cycles.[7] 
Spiro-bicyclic compounds are characterized by their compactness and their 
potential for spatial diversification through isomerism. The tetrahedral carbon in the 
spiro-linked center positions the planes of the two rings nearly perpendicular. This 
characteristic spatial disposition of the molecule, could be an important aspect in 
biological activities. Careful design of spiro-compounds could offer a wide range of 
possibilities for diversification, such as, the presence of defined exiting vectors, 
different ring size combinations, different point of intersection between the two 
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rings, a center of diastereoisomerism and a wide variety of substituents and 
functional groups.[8]  
Due to their well-defined exit vectors, spiro-bicyclic molecules are considered to 
have reduced symmetry, that results in more divers coverage of space around the 
scaffold. Moreover, this is directly expressed as their compactness, engendering 
shape diversity looking to access to uncharted pharmacological space.[6] 
Nowadays, the design of new spiro-bicyclic molecules is a growing area in modern 
organic synthesis. Spiro-compounds are present in the structures of many natural 
products and pharmaceutical companies consider them privileged scaffolds due to 
their biological activities and possibilities for modulation in terms of 
physicochemical properties and hence optimization of pharmacokinetic 
properties.[9]  
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4.2. Aim of the Chapter 
Based on the growing interest towards the synthesis of new spiro-bicyclic 
molecules, in this work we focus our efforts in the preparation of [m.n]-spiro-
heterobicyclic structures (m,n = 3−5) with a methylene boronate unit bound to an 
all-carbon cyclic backbone, aiming to expand the pharmacopeia library. 
 
For the preparation of the target spiro-heterocyclic structures, we envisaged a 
synthetic strategy whereby an O- or N-containing heterocycle is already present in 
the starting material. The mentioned heterocycle would contain a quaternary 
carbon substituted with an alkene function and a leaving group, such as, an halide. 
The spiro-bicycle would then be formed through a Cu-catalyzed intramolecular 
borylative ring-closing C−C coupling of the alkenyl halide moiety (Scheme 4.3). 
 
Even though Cu-catalyzed borylative exo-cyclization had been previously explored 
to build spiro-cyclobutane rings onto saturated carbocycles, only one example 
leading to a spiro-heterocyclic based skeleton has been reported.  
 
In addition to cover the gap on the synthesis of heterocyclic spiro-compounds, we 
decided to explore the challenging formation of 5- and 6-membered spiro-bicyclic 
rings. 
 
 
Scheme 4.3 Graphical objectives of the chapter. 
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4.3. Results and discussion 
Our studies started with the selection of O- or N- containing heterocyclic ester 
derivatives to be used as precursors of the required haloalkenes. Figure 4.1 shows 
diverse 5- and 6-membered heterocyclic rings (55-60) with O- or N- located on 
position 2, 3 or 4 with respect to the ester function. Substrates 55, 56, 59 and 60 
were commercially available. Compounds 57 and 58 were synthesized from the 
commercially available piperidine hydrochloric salts by reaction with the 
corresponding sulphonyl chloride using N,N-diisopropylethylamine (DIPEA) as base 
(See Experimental Part in Chapter 8).[10]  
 
Figure 4.1 Heterocyclic carboxylic esters. 
The next step was the alkylation of substrates 55-60 from Figure 4.1. This 
transformation was performed using in situ generated lithium diisopropyl amine 
(LDA) to deprotonate on α-position to the ester group (Scheme 4.4). The carbanion 
was then trapped with several alkenyl halides of different chain length (a-c) allowing 
access to a variety of spiro-bicycles after ring-closing.[11] Substrate 55 was alkylated 
with 3-bromoprop-1-ene (a), 4-bromobut-1-ene (b) and 5-bromopent-1-ene (c) 
providing the corresponding alkylated products (61-63) in good to excellent yields. 
Then, methyl tetrahydrofuran-2-carboxylate (56) was satisfactorily alkylated with a 
providing methyl 2-allyltetrahydrofuran-2-carboxylate (64) in 60% isolated yield. 
The reaction with b proved to be more challenging and product 65 could only be 
isolated in 20% yield. Moreover, methyl 1-(phenylsulfonyl)piperidine-4-carboxylate 
(57) presented similar behavior as substrate 55, allowing the formation of 66, 67 
and 68 in high isolated yields (83-85%). Other systems containing the nitrogen atom 
at 3-postion with respect to the ester (58-60) only tolerated the alkylation with a 
forming the corresponding allyl-intermediates 69-71 in moderate yields. Attempts 
of alkylation on 58 with b and c were unsuccessful, recovering in all cases the 
starting material.  
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Scheme 4.4 General procedure and scope of the alkylation step. 
Next the reduction of the carboxylic ester functions in 61-71 was explored. For this 
purpose, LiAlH4 was used as reducing agent in anhydrous Et2O at 0 °C (Scheme 4.5). 
Short reaction times of about 1.5 h were required to obtain the hydroxymethyl 
compounds in quantitative yields. These alcohols were used for the next reaction 
step without need to be purified.[12] At this point, aiming to study the effect of the 
leaving group in the borylative cyclization step, a number of alcohol containing 
scaffolds were converted to their corresponding brominated (Scheme 4.5) and / or 
iodinated substrates (Scheme 4.6). 
Thus, the bromination of the hydroxymethyl intermediates (Scheme 4.5)[13] was 
achieved by the use of CBr4 and PPh3 in THF as solvent. In general, the expected 
brominated derivatives were isolated in excellent yields. The chain length and the 
heteroatom present in the heterocycle did not have a significant effect on the 
reaction efficiency. Substrates 61, 62, 63 containing a tetrahydropyrane ring were 
converted into 72, 73 and 75 in high yields. Also the 4-piperidine substrates were 
satisfactorily transformed to the bromo derivatives 79, 80 and 82. However, the 
reaction was sensitive to the presence of a nitrogen atom in position 3 respect to 
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the quaternary carbon, and the alkylated 3-piperidine 83 and 3-pyrrolidne 84, were 
obtained in only moderate yields. We hypothesized that this decrease in the 
reaction yields could be attributed to the steric hindrance created by the nitrogen 
protecting groups, hence hampering the bromination reaction. 
 
Scheme 4.5 Sequential reduction/ bromination reactions 
In addition several iodo derivatives were prepared for the alkylated products 61-71 
(Scheme 4.6).[14] In this procedure the iodinated compounds derived from 
tetrahydropyrane, tetrahydrofurane and piperidine were obtained in excellent 
yields. Only in the case of the morpholine derivative a slight decrease in yield was 
observed, with product 85 in 67% isolated yield. 
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Scheme 4.6 Sequential reduction-iodination reactions 
With the alkenyl halide derivatives in hand we conducted the preliminary studies on 
the copper catalyzed borylative ring-closing reaction. We selected as model 
substrates those based on the tetrahydropyrane architecture (72-76) to find the 
optimal reaction conditions (Table 4.1). This reaction optimization phase was done 
in collaboration with the master student Albert Farré. 
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Table 4.1 Optimization process for the Cu-catalyzed borylative cyclization.a 
 
Entry 
Time 
(h) 
      
     n 
   
      X Substrate 
Boron 
source 
(B2(OR)2) 
Ligand Product 
IY 
[%]b 
1 
 
4 1 OH  B2pin2 Xantphos 86a -- 
2 
 
4 1 Br 72 B2pin2 Xantphos 86a 93% 
3 
 
4 1 Br 72 B2hex2 Xantphos 86b 65% 
4 
 
4 1 Br 72     B2neop2 Xantphos 86c 54% 
5 
 
4 2 Br 73 B2pin2 Xantphos 87 45% 
6 
 
4 2 I 74 B2pin2 Xantphos 87 65% 
7 
 
16 2 I 74 B2pin2 Xantphos 87 80% 
8 
 
16 2 I 74 B2pin2 PCy3 87 80% 
9 
 
16 2 I 74 B2pin2 tBu-Xantphos 87 85% 
10 
 
16 2 I 74 B2pin2 IPr 87 67% 
11 
 
4 3 Br 75 B2pin2 Xantphos 88 20% 
12 
 
4 3 I 76 B2pin2 Xantphos 88 28% 
13 
 
16 3 I 76 B2pin2 Xantphos 88 36% 
 
aReaction conditions: CuCl (5 mol%), Xantphos (5 mol%), B2(OR)4 (1.2 equiv), KOtBu (1.2 equiv), 
THF (1 M), 30 °C, 4 - 16 h. 
bIY= isolated yields. 
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First, the Cu / Xantphos catalyzed borylative ring-closing C-C coupling reaction was 
not successful on the hydroxyalkene derivative obtained from the reduction of ester 
61. In this case the corresponding spiro-bicycle 86 was not observed (Table 4.1, 
entry 1). Gladfully, the borylative ring-closing took place with the corresponding 
bromo derivative 72 using Xantphos as copper ligand and B2pin2 (1) as the boron 
source. The desired product 86a was isolated in excellent yield (93%) after 4 hours 
reaction time (Table 4.1, entry 2). The use of a different boron source, such as, 
B2hex2 (3) or B2neop2 (2) did not provide better results than those obtained with 1, 
affording the desired spiro-cyclized products 86b and 86c in 65% and 54% isolated 
yield respectively (Table 4.1, entries 3,4). The lower yields observed with diboron 
reagents 2 and 3 might be related to a lower stability of products 86b and 86c under 
the purification conditions. 
Since the formation of the 4-membered spiro-bicyclic ring was almost quantitative, 
we turned our attention to the borylative ring-closing reaction leading to 5-
membered spiro-bicyclic compounds. The first trial with substrate 73 using B2pin2 as 
the boron source, the C-C coupling reaction was successful and the 5-memebered 
spiro-bicyclic scaffold 87 was obtained, albeit in moderate 45% isolated yield (Table 
4.1, entry 5). Slightly better results were obtained when using substrate 74 having 
an iodine instead of a bromine as leaving group, and compound 87 could be 
obtained in 65% isolated yield after 4 hours (Table 4.1, entry 6). This result was 
further improved after a prolonged reaction time of 16 hours leading to a 
80%isolated yield (Table 4.1, entry 7). A similar effect has been reported in the 
palladium-catalyzed ring forming aromatic C-H alkylations with unactivated alkyl 
halides.[14]  
Switching from Xantphos to PCy3 or tBu-Xantphos led to comparable isolated yields 
of spiro-bicycle 87 (Table 4.1, entries 8-9). The use of a carbene ligand, such as 1,3-
bis(2,6-diisopropylphenyl)-1H-imidazol-3-ium-2-ide (IPr), was detrimental for the 
borylative spiro-cyclization, lowering the performance of the reaction to 67% 
isolated yield (Table 4.1, entry 10). 
As it could be anticipated, the C-C coupling reaction to form spiro-bicyclic products 
containing 6-membered ring such as 8-methylboryl-3-oxaspiro [5.5]undecane (88) 
proved to be more challenging. Both brominated (75) and iodinated (76) alkenyl 
substrates provided the formation of the targeted product under standard reaction 
conditions, however in only 20% and 28% isolated yields respectively (Table 4.1, 
entries 11-12). In the case of substrate 76 longer reaction times slightly increased 
the efficiency of the transformation up to 36% isolated yield (Table 4.1, entry 13). A 
plausible explanation accounting for the lower yields observed on the formation of 
the 6-membered spiro-bicyclic rings would be the required formation of an 
unfavoured 7-membered metallocycle prior to the reductive elimination step. It has 
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to be highlighted that the formation of product 88 represents the first example of a 
copper catalyzed borylative ring-closing C-C coupling leading to the formation of a 
6-membered spiro-bicyclic ring. 
With the optimized reaction conditions in hand, we then proceeded to extend the 
scope of the transformation using the different substrates prepared in Scheme 4.5 
and Scheme 4.6. The results obtained are presented in Scheme 4.7.  
 
Scheme 4.7 Substrate scope of the borylative spiro-cyclization transformation. 
Thus, the iodo derivative precursor 77 provided 2-methylboryl-5-oxaspiro 
[3.4]octane (89) in moderate yield (45%) as a 1 to 1 mixture of diastereoisomers 
(Scheme 4.7). Similarly, compound 78 having a longer spacer, provided the 
formation of the spiro-bicycle 90 in 54% on a diastereomeric ratio of 6:1. We 
hypothesized that the major flexibility of the longer alkene chain might favor a more 
stable conformation towards one of the diastereoisomers in the transition state 
intermediate. The nitrogen containing heterocycles as the bromo alkenyl piperidine 
derivative 79 were also suitable substrates in the spiro-cyclization process and the 
spiro-fused 4-membered-bicycle 91 was isolated in excellent yield (Scheme 4.7).  
Several reaction conditions were tested for the synthesis of the 5-membered ring 
spiro-fused piperidine. The use of the alkenyl bromo derivative 80 under standard 
reaction conditions (4 h) provided the desired product 92 in moderate 42% isolated 
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yield. Again, longer reaction times increased the yield of 92 up to 55%. Moreover, 
the use of the alkenyl iodo derivative 81 favored the process towards the formation 
of the 5-membered spiro-bicycle 92 in 60% isolated yield, within 4 hours (Scheme 
4.7). The longer chain alkene 82 was also successfully converted into the 6-
membered spiro-bicycle 93, however the yield of this transformation was moderate 
(35%) (Scheme 4.7). Additionally, the alkenyl bromo 3-piperidine (83) and 3-
pyrrolidine (84) derivatives underwent the borylative ring-closing reaction providing 
the corresponding spiro-bicyclic derivatives 94and 95, in good isolated yields as 1:1 
mixtures of diastereoisomers (Scheme 4.7). Finally, the spiro-cyclization reaction 
also took place on the iodo morpholine derivative 85, affording compound 96 in 68% 
yield as a 4:6 mixture of diastereoisomes.  
From the previous synthetic study it could be concluded that the efficiency of the 
spiro-cyclization process decreases as the size of the new ring increases from a 4- to 
a 6-membered ring carbocycle. KOtBu was found to be the optimal base, since 
NaOtBu favored the borylative debromination byproducts and LiOtBu gave negligible 
conversion toward the spiro-cyclization process. From the results obtained it can 
also be concluded that Cu-catalyzed borylative ring-closing C-C coupling is favored 
for alkenyl iodides over the matched pair alkenyl bromides. This could be attributed 
to the properties of iodide as better leaving group than bromide.  
To prove the synthetic versatility of the synthesized spiro-boronate compounds 
further functionalizations of the C-B bond were explored. First, simple oxidative 
reaction conditions using NaBO3,[15] gave access to the corresponding hydroxylated 
products 97-100 in high isolated yields (Scheme 4.8). 
 
Scheme 4.8 Selective oxidation of the spiro-heterocyclic boronate compounds. 
Furthermore, product 97 was selectively oxidized to the corresponding aldehyde 
101 using Dess-Martin periodinane (DMP) (Scheme 4.9).[16] The aldehyde 101 was 
transformed into the tri-substituted alkene 102 following a new olefination reaction 
developed in our group. This strategy is based on the deprotonation of 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Chapter 4 
 75 
[CH(Bpin)2(SiMe3)] (5) with LTMP to generate an α-boron / α-silyl stabilized 
carbanion capable of adding to the carbonyl group in compound 101.[17] Then, upon 
addition, the B-O elimination takes place through the Boron-Wittig pathway to 
generate the gem-silylborane spiro-bicycle 102 in 88% isolated yield in a 85 (E) to 15 
(Z) diastereomeric ratio. Finally, the tethered boronate was subjected to Suzuki-
Miyaura cross coupling conditions in the presence of 1-iodo-4-methyl benzene, 
Pd(PPh3)4, KOH in 1,4-dioxane as solvent at 90 °C for 16 hours, providing the desired 
tri-substituted alkene 103 with total stereocontrol, in a 85 (E) to 15 (Z) 
diastereomeric ratio (Scheme 4.9).[18] 
 
Scheme 4.9 Selective olefination / arylation of spiro-heterobicycle 97. 
Finally, since spiro-tricyclic structures are also present in many bioactive natural 
products[19] and to prove the value of this methodology we explored an iterative Cu-
catalyzed borylative ring-closing C-C coupling for the preparation of a dispiro-
heterotricyclic scaffold with a pendant methyl boronate. The targeted molecule 
would have three spiro-cyclic rings of different size, one of which would be 
heterocyclic. Our reaction sequence started with the Jones oxidation of the spiro-
bicyclic compound 99.[20] The oxidation product 104 has now a pendant carboxylic 
acid that was transformed into the methyl ester derivative 105 in moderate yield 
(61%).[21] Next, the spiro-bicyclic ester 105 was further elaborated into compound 
106 by alkylation with allyl bromide following the procedure reported in Scheme 
4.4.[11] Reduction of the ester function in 106 to the alcohol derivative[12] with 
concomitant iodination into compound 107, which was achieved using the reaction 
conditions reported in Scheme 4.6.[14] The obtained spiro-bicyclic iodo derivative 
107 successfully underwent intramolecular borylative cyclization to form the spiro-
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tricyclic structure 108 in 64% isolated yield in a 1 to 1 diastereomeric ratio (Scheme 
4.10). 
 
Scheme 4.10 Stepwise sequence for the synthesis of the dispiro-heterocycle scaffold. 
The tricyclic structure of product 108, was fully characterized by standard analysis 
and X-Ray diffraction techniques (Figure 4.2), confirming the presence of the spiro-
fused four-, five-, and six-membered rings. Notably the piperidine core is an 
heterocycle motif commonly found in several spiro-tricycles employed in medicinal 
chemistry and agrochemicals.[19] The spiro-bicyclic derivative ester intermediate 
105, represents an attractive precursor for the synthesis of potent preclinical 
candidates used for prevention and treatment of hemorrhage.[22] 
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Figure 4.2 ORTEP of the X-Ray diffraction analysis for dispiro-tricycle 108. 
With the aim to fully understand the mechanistic aspects of this transformation we 
established a collaboration with Prof. Feliu Maseras and Mr. Shaofei Ni from Institut 
Català d'Investigació Química (ICIQ), who carried out a DFT study[23] on the reaction 
mechanism. 
A total of 28 different free energy profiles were computed varying the nature of the 
organic substrate, the leaving group, the counter ion from the base as well as the 
number of explicit THF molecules in the calculations. Figure 4.3 shows a 
representative free energy profile and the general features of the mechanism for 
the synthesis of the 5-memebered ring spiro-bicyclic product 87.  
 
The starting point of the free energy profile is intermediate I1, this diphosphine 
copper (I) alkoxide complex should be readily formed upon mixing CuCl, the alkoxy 
base and the ligand, Xantphos. Then by the subsequent addition of B2pin2, through 
σ-bond metathesis, the Cu-B species I2 would then be readily formed. The first key 
step of this free energy profile might involve the coordination and insertion of the 
C=C double bond of the substrate 73 into the Cu-B specie (I2) via transition state 
TS1. The second key step of this transformation involves mostly a concerted step 
consisting in the halogen abstraction and ring closure facilitated by the copper 
through transition state TS2. Remarkably, it was possible to optimize the Cu (III) 
intermediate proposed previously by Ito and co-workers.[4, 24] This intermediate is 
shown as I6 in Figure 4.3, since its energetic barrier is lower than 2 kcal mol-1 for a 
reductive elimination, hence it could not be considered kinetically relevant. The 
highest energetic barrier in the free energy profile (Figure 4.3) is measured between 
TS2 and I4, and is the one that affects directly to the overall efficiency of the process.  
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Figure 4.3 Computed free energy profile (in kcal mol-1) for the formation of the 5-membered ring 
spiro-bicycle 87 with Br as the leaving group and KOtBu as base (with the coordination of two THF 
solvatation molecules). Energy profile calculated by Prof. Maseras and Mr. Ni at ICIQ. 
A Heck-type mechanism was also considered[25] in the first activation of the C-X bond 
rather than activation from the C=C double bond. Much higher energetic barriers 
were obtained for the activation of the C-Br bond than for the mechanism on the 
activation of the C=C double bond. 
The model energetic profile was validated with the introduction of different number 
of THF solvation molecules. It was found that the most favorable situation involves 
two molecules of THF, with an associated free energy barrier as illustrated in Figure 
4.3 between I4-TS2 of 25.7 kcal·mol-1. 
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4.4. Conclusions 
In this study we evaluated diverse borylative cyclizations on unactivated alkenes 
through regioselective borylcupration followed by intramolecular ring-closing via 
halide displacement. The reaction exhibited high functional group tolerance, with 
central cores containing oxygen or nitrogen heteroatoms. The efficiency of the 
spiro-cyclization process was dependent on the size of the ring formed, with smaller 
rings (4-membered) being more favorable than larger ones (6-membered). This 
reactivity pattern was attributed to the required formation of the Cu (III) 
metallocyclic intermediate preceding the reductive elimination step. The present 
methodology enables the synthesis of new spiro-bicyclic cores, with different ring 
sizes in the new spiro-bicyclic motif formed. An iterative process gave access to a 
new dispiro-heterotricyclic structure fully characterized by X-Ray diffraction. 
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5.1. State of the art 
Among the most facing challenges for medicinal chemists is the discovery and 
development of compounds for the prevention and treatment of fatal diseases. An 
intense area of research focusses on Alzheimer´s disease (AD), a devastating age-
related neurodegenerative disorder. AD is characterized by common symptoms 
related with a slow but inexorable loss of memory and cognition.[1] 
AD affects over 40 million people worldwide and currently there is no an available 
cure. Current pharmacological treatments have a temporarily mild effect in slowing 
down the progression of cognitive decline. This makes of AD one of the main unmet 
medical needs of the 21st century, hence there is an urgent need to identify disease 
modifying therapies, which should slowdown or treat the neurodegenerative 
process.[2] 
5.1.1 Alzheimer’s disease 
The concept of dementia had been generally recognized over a thousand years. 
Alöis Alzheimer, a German pathologist and neuropsychiatrist, changed the 
understanding of dementia after studying the evolution of symptoms of his patient 
Auguste Deter, a 51 years old woman that was admitted in the Frankfurt asylum on 
November 25th 1901. Dr. Alzheimer, after an initial examination, described the first 
neuropsychological characterization of this demented patient as follows:[3] 
 
“Her memory is seriously impaired. If objects are shown to her, she names them 
correctly, but almost immediately afterwards she has forgotten everything. When 
reading a text, she skips from line to line or reads by spelling the words individually, 
or by making them meaningless through her pronunciation. In writing she repeats 
separate syllables many times, omits others and quickly breaks down completely. In 
speaking, she uses gap-fills and a few paraphrased expressions (“milk-pourer” 
instead of cup); sometimes it is obvious she cannot go on. Plainly, she does not 
understand certain questions. She does not remember the use of some objects.” 
 
Dr. Alzheimer (Figure 5.1 left) followed the case of Auguste (Figure 5.1 right), over a 
period of four and a half years until April 8th 1906 when she passed away. 
Postmortem analysis of Auguste’s brain using a new histological staining technique 
allowed Dr. Alzheimer to identify by the first time the presence of two different 
classes of protein aggregates. These aggregates are now recognized as the two main 
pathophysiological characteristics of the disease: amyloid plaques and 
neurofibrillary tangles.[4] 
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Figure 5.1 Dr. Alöis Alzheimer (left) and his patient Auguste Deter (right). 
5.1.2 Epidemiology 
Epidemiology studies have proven that AD it is not a contagious disease, even 
though an exponential increase in the number of AD patients has been observed. 
Currently, 40 million people over 60 years old suffer from dementia. This figure is 
expected to triple and reach over 131 million in 2050 (Figure 5.2). An equal 
distribution of AD around the world has been observed, with non-differentiation in 
terms of proportion for each continent.[5] 
 
Figure 5.2 Prevalence of AD around the world and estimation in the future. 
In 2018 the total estimated worldwide cost of AD was 1 trillion of dollars, which is 
expected to triple in 2050. If no treatment becomes available in the coming years 
the prevalence of AD will create a social and economic problem worldwide. 
In terms of gender, AD has higher incidence in women than men, with two-thirds of 
new cases being diagnosed in women.[6] Moreover, related with the diet, it has been 
observed that people who developed type II diabetes are more prone to develop 
AD, even though there are not clear associations between the two diseases.[7]  
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A confirmed evidence is that the age is the most notable risk factor. Based on age, 
when the first symptoms of AD appear, the disease is classified in early-onset AD 
(EOAD, people younger than 65 years old) and late-onset AD (LOAD, people older 
than 65 years old). Commonly, EOAD is often related to mutations in specific genes, 
meanwhile LOAD is more associated to a combination of factors, as the ones 
previously commented.[8] 
5.1.3 Pathophysiology 
Since the discovery of the protein aggregates by Alöis Alzheimer, the main focus for 
researches has been to identify the protein(s) or enzyme(s) responsible for the 
accumulation of these deposits, ultimately though to be a contributing factor to the 
appearance of AD. From all these studies, it has been concluded that the two major 
neuropathological hallmarks of AD are the presence of extracellular β-amyloid (Aβ) 
plaques made of Aβ peptides of variable length and the formation of intracellular 
neurofibrillary tangles (NFTs) (Figure 5.3), constituted by paired helical filaments 
(PHFs) of abnormally hyperphosphorylated Tau protein. 
 
Figure 5.3 Healthy neurons (left) and neurons in AD surrounded by Aβ plaques and containing 
intracellular NFTs (right). 
In addition to the abnormal accumulation of protein aggregates, there are other 
events that aggravate the course of the disease, like neuro-inflammation processes, 
a great neuronal loss resulting in a diminished cerebral volume (Figure 5.4), and 
failure in the vascular system.[9] 
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Figure 5.4 Graphical comparative between a healthy brain (left) and a brain with severe AD 
(right). 
Initially, most research was based in preventing the production and accumulation 
of Aβ peptides leading to the formation of extracellular senile plaques.[10] Amyloid 
β accumulation (red curve, Figure 5.5) starts early in life and has reached close to 
maximum levels when the first clinical symptoms of the disease are observed and 
signs of mild cognitive decline start.[10] However, Aβ accumulation alone does not 
correlate well with the progression of the disease, as maximum levels are present 
well before mild cognitive impairment (MCI) is diagnosed (purple curve, Figure 5.5). 
Tau deposition also starts early in life, but it is when Aβ deposition starts reaching 
maximum levels that an accelerated Tau deposition is observed (blue curve, Figure 
5.5).  
 
Figure 5.5 Correlation between the accumulations of Aβ peptides  
and Tau protein and the clinical stage of AD. 
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Early stages of AD are characterized by the accumulation of amyloid β-protein in the 
brain. Then, several years after, Tau aggregates start accumulating and spreading 
from the entorhinal cortex throughout outer brain regions. At the point that the Aβ 
accumulation reaches almost the maximum level, and significant Tau pathology has 
developed, the first symptoms of AD, MCI stage, can be observed. 
Considering that Aβ accumulation is the initiator of the disease and that Tau 
deposition occurs downstream, most pharmacological approaches have focused on 
preventing or halting the formation of senile Aβ plaques. Inhibiting beta-secretase 
1 (BACE-1), a protease that performs the initial cleavage of the amyloid precursor 
protein (APP) which ultimately leads to the production of Aβ peptides, has been the 
focus of research for mayor pharmaceutical companies over the last two decades. 
However, despite of all efforts all BACE-1 inhibitors reaching the clinic have fallen 
short in phase III clinical trials. [11] 
Nowadays it is recognized that blocking Aβ production at this late disease stage, 
were the accumulation of plaques in brain is already at maximum levels, could be 
analogous to treat with cholesterol lowering statins a congestive heart failure in the 
emergency room. For that reason, targeting a population of asymptomatic 
individuals but at high risk of developing AD is crucial to intersect the progression of 
the disease. Patient selection based on early biomarkers of the disease is a critical 
element to the design of appropriate clinical trials.[2] 
In the last decade, interfering with the progression of Tau pathology has become an 
important area of research in AD due to the better correlation between Tau 
pathology with neurodegeneration than the one of Aβ deposition. 
5.1.4 Tau hypothesis 
Tau is an intraneuronal unfolded and highly soluble protein. Its principal function is 
the assembly and stabilization of the microtubules in the axons of neurons (Figure 
5.6). The microtubules are essential in neurons for the distribution of proteins and 
nutrients along them.[12] 
 
Figure 5.6 Illustration of the different general parts from healthy neuron. 
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The accumulation of neurofibrillary tangles (NFTs) in the brain is a hallmark of AD. 
Postmortem analysis of AD brains has shown abnormal levels of 
hyperphosphorylated Tau protein. In a healthy brain Tau contains around 2-3 moles 
of phosphates per mole of protein, whereas an AD brain it contains 3- to 4-fold more 
phosphates.[13] Hence, it is believed that in the course of AD Tau gets 
hyperphosphorylated, which causes its detachment from the microtubules 
rendering phospho-Tau in the cytosol. This phosphorylated Tau protein starts 
templating and aggregating additional Tau monomers and oligomers, ultimately 
leading to the formation of pair helical filaments (PHFs) that subsequently aggregate 
to form the characteristic NFTs found in AD brain. (Figure 5.7).[14] The formation of 
NFTs and accumulation in the neuronal cell body eventually leads to apoptosis.[15]  
 
Figure 5.7 Process of Tau hyperphosphorylation causing the apoptosis of the neuron cell. 
Great efforts have been made to understand and regulate Tau phosphorylation. The 
inhibition of kinases responsible for installing phosphate groups in Tau has been 
considered a fundamental therapeutic strategy to rescue Tau mediated 
neurodegeneration.[16] However, this strategy has proven challenging, which 
suggest that there might be other underlying mechanisms regulating the number of 
sites phosphorylated that remain unknown.[17] 
Recent studies have shown that Tau protein is hypo-O-GlcNAcylated in AD brains, 
suggesting that the presence of O-linked-β-N-acetylglucosamine (O-GlcNAc) 
residues on Tau in healthy brains could be protective.[18] O-GlcNAcylation and 
phosphorylation are mutually exclusive on the same residue, hence an amino acid 
residue cannot be phosphorylated once a molecule of O-linked-β-N-
acetylglucosamine is present. As consequence, in AD brains where hypo-O-
GlcNAcylation occurs, Tau phosphorylation sites are freely exposed to kinases, as 
described previously in Figure 5.7, resulting in Tau abnormal hyperphosphorylation, 
detachment from microtubules and subsequent aggregation. 
O-GlcNAcylation is a posttranslational modification that affects hundreds of 
proteins. Opposed to phosphorylation, where hundreds of kinases and 
phosphatases are known to add and remove a phosphate molecule, GlcNAcylation 
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is mediated by two enzymes: O-GlcNAc transferase (OGT) responsible for adding the 
sugar residue and O-GlcNAcase (OGA) which removes the O-linked-N-
acetylglucosamine (O-GlcNAc) residue. The reciprocal relationship between the 
removal of O-GlcNAc and the hyperphosphorylation state of Tau, has encouraged 
researchers to identify OGA inhibitors as an approach to keep phosphorylation sites 
in Tau unavailable for the action of kinases.[19] 
OGT, OGA and O-GlcNAcylated proteins are particularly abundant in the brain, 
suggesting they could be the key regulatory modifications which contribute to 
neuronal communications, memory, and the responsible players of the apparition 
of neurodegenerative diseases (Scheme 5.1).[20] 
 
Scheme 5.1 Regulation of Tau O-GlcNAcylation by OGT and 
 OGA enzymes (UDP= urinine diphosphate). 
Therefore, maintaining “healthy levels” of O-GlcNAcylation in Tau proteins by the 
cooperation of small-molecule inhibitors of OGA, could represent a potential 
approach to decrease the levels of hyperphosphorylated Tau protein. Thereby, 
rendering Tau less prone to detaching from the microtubules, avoiding its 
aggregation into neurotoxic tangles and ultimately blocking the neurotoxicity and 
apoptosis of the neuron.[12] 
Preventing the formation of Tau aggregates may also reduce the cell-to-cell 
spreading of Tau-aggregates released by neurons, which has been discussed to 
increase the velocity of propagation in Tau related dementias.[21] 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Synthesis and application of novel spiro-boronate compounds for the treatment 
of Alzheimer’s disease  
92 
Treatment with sub-optimal OGA inhibitors has already demonstrated in preclinical 
studies a decrease in Tau phosphorylation by preventing the removal of O-GlcNAc 
from Tau protein. These observations spurred the interest of the scientific 
community to identify an optimal OGA inhibitor able to control Tau 
phosphorylation. 
5.1.5 Spiro-bicyclic scaffolds as source of OGA inhibitors: rationale 
Several OGA inhibitors have been developed during the last years and profiled in 
vitro and in vivo models of neurodegenerative diseases. Thiamet G (109) (Figure 
5.8), a potent and highly selective sugar-based inhibitor (hOGA Ki = 0.41 nM, rOGA 
cell EC50 = 13.5 nM),[22] has been used as a good tool compound for hypothesis 
validation. Compound 109 has demonstrated to increase Tau O-GlcNAcylation 
levels, with a concomitant decrease in Tau phosphorylation, reducing the formation 
of Tau aggregates and neuronal cell loss in vivo.[23]  
However, Thiamet G is a poorly brain penetrant compound and preclinical efficacy 
studies in rodents have required chronic administration of doses of 500 mg/kg to 
significantly increase Tau O-GlcNAcylation levels.[24] 
 
Figure 5.8 Structure of Thiamet-G a potent inhibitor of OGA. 
Given the increasing interest in identifying OGA inhibitors Janssen performed a high 
throughput screening (HTS) of the corporate compound collection using an 
enzymatic assay. Among other hits identified the diazaspiro-nonane (110a) as a 
weak OGA inhibitor with a IC50 of 2239 nM in the OGA enzymatic assay. Compound 
110a was inactive in the OGA cellular assay at the highest concentration tested (10 
μM) (Figure 5.9).  
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Figure 5.9 HTS hit 110a and advanced lead 110b from an early SAR exploration. 
The early Medicinal Chemistry strategy to improve the activity of hit 110a consisted 
in the preparation of a library of compounds exploring a variety of substituents on 
the spiro-cyclic core nitrogen atoms. Aromatic and heteroaromatic groups on R1 
were combined with a diverse set of alkyl-, (het)aryl- and benzyl like substituents in 
R2. 
Interestingly, when a 4-pyridyl R1 substituent was combined with an 
acetamidothiazolyl-containing substituent in R2 the single-digit nanomolar inhibitor 
110b was obtained (hOGA IC50 = 6 nM). Moreover, 110b presented a much improved 
activity in the cellular assay with an IC50 of 141 nM (Figure 5.9) and was stable in 
human and mouse liver microsomes.[25]  
Compound 111 from the same chemical series, where the south spiro-pyrrolidine 
has been replaced by a spiro-azetidine ring (Figure 5.10) could be co-crystallized 
with CpOGA, a bacterial orthologue from C. perfringens of hOGA. [26] 
 
Figure 5.10 Spiro-azetidine compound 111. 
The co-crystal obtained provided useful information on the ligand interactions in 
the catalytic pocket of the bacterial enzyme, which shows a very high sequence 
homology with the one of hOGA. The spiro-cyclic core distributes the two 
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heteroaromatic substituents along the right vectors. Thus, the acetamidothiazole 
group in 111 goes deep into the catalytic pocket, where the O-GlcNAc residue in 
OGA client substrates is hydrolyzed, and the triazolopyrimidine ring occupies an 
open area of the protein where the enzyme accommodates the backbone of the 
natural substrates bearing the O-GlcNAc residue (Figure 5.11a) 
 
 
 
 
 
 
 
 
In Figure 5.11b, are highlighted the key interactions between compound 111 and 
the enzyme. As it can be seen there are two hydrogen-bond interactions between 
the acetamide substituent, and Asn396 and Asp297. Moreover, the basic nitrogen 
of the azetidine ring, which is protonated at the physiological pH, establishes a 
dominant ionic interaction with Asp401 that anchors the core in the catalytic pocket. 
An extra - stacking interaction between the triazolopyrimidine ring and Tyr189 
can also be observed. Interestingly, the pyrrolidine nitrogen does not seem to make 
any interactions in the co-crystal structure. 
  
a) b) 
Figure 5.11 X-Ray co-crystal of compound 111 and CpOGA. a) Protein surface; b) Key 
interactions between compound 111 and protein aminoacid residues. 
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5.2. Aim of the Chapter 
With all these precedents in mind and encouraged by the results obtained with 
Thiamet G (109), as well as with the interesting in vitro activity of the diazospiro-
nonane 110b, a collaboration with the Medicinal Chemistry team of Janssen in 
Toledo was started. The aim of this collaboration was to apply the methodology 
described in Chapter 4 for the synthesis of target spiro-compounds and expand the 
available structure activity relationship (SAR) around the novel series of OGA spiro-
bicyclic inhibitors. 
The research plan consisted on the preparation of novel spiro-compounds applying 
our reported methodology, which would enable several modifications on the spiro-
bicyclic core while deleting the nitrogen atom of the diazospiro-nonane scaffolds 
that does not make an interaction with the protein (Figure 5.12). In addition, the 
nitrogen deletion could contribute to increase the permeability and penetration in 
the brain-cell matrix of these inhibitors, while maintaining the good response on the 
enzymatic and cellular assays. 
 
Figure 5.12 Graphical objectives of the chapter. 
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5.3. Results and discussion  
Since the hit 110a and a good number of derivatives from this chemical series 
presented low cellular permeability and limited brain penetration we hypothesized 
that a reduction in the number of nitrogen atoms in the central spiro-bicyclic core 
could be beneficial for these properties. For this purpose, five different spiro-
bycyclic motifs having different ring sizes and heteroatoms where designed (Figure 
5.13). 
 
Figure 5.13 Designed spiro-bicyclic motifs. 
The synthesis of scaffolds 112, 113, and 114 could be possible via the copper 
borylative cyclization reaction reported in Chapter 4. However, this methodology 
cannot be applied to the synthesis of compounds 115 and 116 and these were 
accessed following a iodo-cyclization method reported in the literature.[27] 
5.3.1 Synthesis of spiro-bicyclic central scaffolds 
Our studies started with the synthesis of compound 112 (Figure 5.13). Since a very 
close analogue (95) of compound 112 was synthetized in Chapter 4, the same 
synthetic route was explored introducing slight changes to increase the efficiency of 
the process. Thus, pyrrolidine 117 was N-Boc protected with excellent yield by 
treatment with Boc2O in the presence of triethylamine (TEA) as a base, leading to 
compound 118 in excellent yield (Scheme 5.2).[28] The reason for changing the 
nitrogen protecting group from phenylsulfonyl in 59 to Boc in 118 was the easier 
removal on the later stages under acidic conditions. Then, allylation on the α-
position to the ester was achieved in 50% isolated yield by treatment with lithium 
bis(trimethylsilyl)amide and allylbromide to give compound 119 (Scheme 5.2).[29] 
Reduction of the ester function in 119 to the alcohol was performed with LiBH4 using 
a mixture of THF / MeOH providing tert-butyl 3-allyl-3-(hydroxymethyl)pyrrolidine-
1-carboxylate (120) in quantitative yield (Scheme 5.2).[30] Aiming to improve the 
copper (I) borylative cyclization pathway, alcohol 120 was converted into the 
iodomethyl pyrrolidine 121, using reaction conditions previously reported in 
Chapter 4 (Scheme 5.2).[31] Finally, the copper borylative spiro-cyclization of 121 
applying the optimal conditions identified in Chapter 4 afforded the target tert-butyl 
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2-methylboryl-6-azaspiro[3.4]octane-6-carboxylate (112) in a 60% isolated yield in 
a diastereomeric ratio of 45:55.[32] 
 
 
Scheme 5.2 Synthetic route for obtaining spiro-bicyclic scaffold 112. 
Then, the synthesis of compound 113 bearing a spiro-bicyclic cyclopentane ring was 
attempted. This spiro-bicyclic compound has not been previously reported, neither 
by using the methodology described in Chapter 4 or by other methods.[32] Since the 
-alkylation to the ester function in pyrrolidine 118 with 4-bromo-1-butene failed 
to form the expected compound in satisfactory yield, a different synthetic strategy 
was designed (Scheme 5.3). The synthesis started with pyrrolidin-2-one (122), which 
was protected with Boc2O using DMAP as base to give the N-Boc-protected 
pyrrolidin-2-one (123) in good yield (Scheme 5.3).[33] Then functionalization at 
position 3 of the pyrrolidone core with methyl chloroformate in the presence of 
LHMDS gave access to the 1,3-dicarbonylic compound 124 in excellent yield.[34] 
Subsequent alkylation of 124 with 4-bromo-1-butene afforded the desired 
pyrrolidone 125 in 90% yield.[35] Of note is the importance of the nucleophilicity and 
stability of the carbanion formed in the reaction with 4-bromo-1-butene, going from 
no reaction in the case of 118 (Scheme 5.2) to almost quantitative yield for 124 
(Scheme 5.3). The reduction of the two carbonyl groups in 125 proved to be a 
challenging process. Different reducing agents were tested affording only the N-
methylated compound, resultant of the carbamate reduction, and different 
byproducts with decomposition of the starting material being the most observed 
reaction outcome. For these reasons, we decided to change the Boc protecting 
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group of the lactam nitrogen by a simple benzyl substituent, a group expected to be 
unreactive under the reduction conditions of a carbonyl function. Thus treatment 
of 125 with an acidic solution of HCl 4 N in 1,4-dioxane, led compound 126 in 
excellent yield within 2 hours (Scheme 5.3).[36] N-benzylation of 126 with 
benzylbromide using Cs2CO3 in acetonitrile at 90 °C gave access to the N-benzyl 
protected lactam 127 (Scheme 5.3).[37]  
 
Scheme 5.3 Synthetic route for obtaining spiro-bicyclic central core 113. 
Then the use of an excess of the reducing agent such as LiAlH4, demonstrated high 
ability to reduce the ester and the ketone in one step giving access to compound 
128 in 80% isolated yield after flash chromatography.[38] Transformation of the 
hydroxy group in 128 to the iodo derivative 129 under standard Appel reaction 
conditions occurred with moderate yield.[31] Gladly, the formation of the 5-
membered ring spiro-bicycle was successfully achieved under copper (I) borylative 
conditions leading to compound 113 in 73% isolated yield in a 1 to 1 diastereomeric 
ratio (Scheme 5.3).[32] 
Finally, the last spiro-bicyclic motif prepared under copper (I) borylative conditions 
was product 114 (Scheme 5.4). This spiro-bicyclic scaffold was synthetized following 
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a similar procedure to the one previously described for compound 94 in Chapter 4. 
Thus, allylation of commercially available ethyl-N-Boc-piperidine-3-carboxylate 
(130) with allylbromide and LHMDS provided the piperidine 131 in nearly 
quantitative yield.[29] Then, the ester function in 131 was reduced using LiBH4 in a 
mixture of THF/MeOH to give alcohol 132 that was further transformed to the 
iododerivative 133 in satisfactory yield.[30-31] Finally, the copper (I) borylative 
cyclization was performed on the corresponding alkenyl iodo derivative 133[32] 
rendering the targeted spiro-bicyclic derivative 114 in moderate yield in a 1 to 1 
diastereomeric ratio (Scheme 5.4). 
 
Scheme 5.4 Synthetic route for obtaining spiro-bicyclic central core 114. 
Additionally, compounds containing a spiro-tetrahydrofuran ring in the north part 
of the scaffold were synthetized following a reported procedure.[27] Thus, 
commercially available tert-butyl-3-oxopyrrolidine-1-carboxylate (134) was mixed 
with zinc dust and 3-bromo-propene in NH4Cl in THF as solvent to yield a tertiary 
alcohol derivative that, after reaction work up, was used for the next step without 
further purification. Next, addition of Na2S2O5/NaIO4 in a mixture of tBuOH/water as 
solvent provided the spiro-bicycle 115 in low, but sufficient yield in a 1 to 1 
diastereomeric ratio (Scheme 5.5). 
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Scheme 5.5 Synthetic route for obtaining spiro-bicyclic scaffold 115. 
Compound 116 was synthesized starting from ketone 135 following the same 
reaction procedure as for the preparation of 115.[27] Isolation and purification of the 
tertiary alcohol 136 did not has any influence in the outcome of the spiro-cyclization 
reaction and the target spiro-bicycle was obtained in 29% isolated yield in a 1 to 1 
diastereomeric ratio (Scheme 5.6). 
 
Scheme 5.6 Synthetic route for obtaining spiro-bicyclic scaffold 116. 
5.3.2 Synthesis of target molecules by derivatization of the spiro-bicyclic 
central scaffolds 
Structure activity relationships (SAR) were initiated by modification of the spiro-
bicyclic scaffolds prepared (112-116). The diversification strategy consisted on the 
introduction of preferred based on Janssen’s available SAR (het)aryl-substituents in 
the north part of the bicycle in combination with spacers of different lengths and 
nature. In most cases, the acetamidothiazolyl group was kept constant as 
substituent on the south part of the scaffold since this substituent provided good 
activity in the OGA enzymatic and cellular assays. 
a) Final targets from spiro-bicyclic central core 112 
The spiro-bicyclic core 112 was used for the synthesis of the final products 138 and 
141 where the linker connecting, the north heteroaryl ring and the spiro-
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cyclobutane was varied (Scheme 5.7). The acetamidothiazole was kept as the 
preferred N-linked substituent for the pyrrolidine ring and a 2,6-pyridin-4-yl as distal 
heterocycle in the north area. 
 
Scheme 5.7 Final targets from spiro-bicycle 112. 
The synthesis of 138 containing a methylene spacer is outlined in (Scheme 5.8). First, 
arylation of the Bpin fragment with 4-bromo-2,6-dimethylpyridine under standard 
Suzuki-Miyaura cross-coupling conditions provided the spiro-compound 137 in 
moderate yield.[39] Then, N-Boc deprotection upon acidic treatment using a 
commercially available solution of HCl 4 N in 1,4-dioxane, gave access to the Boc 
free pyrrolidine fragment in quantitative manner.[36] This crude pyrrolidine was 
subjected to reductive amination with N-(5-formylthiazol-2-yl)acetamide using 
sodium triacetoxybrohydride as reductant to form the desired product 138 as a 1 to 
1 mixture of diastereoisomers, albeit in low yield (Scheme 5.8).[40] Compound 138 
was further purified by reverse phase HPLC to isolate the two diastereoisomers for 
biological testing. 
 
Scheme 5.8 Synthesis of final target 138. 
Next, to explore the effect of a longer linker in the biological activity, compound 141 
(Scheme 5.9) bearing a –CH2O- spacer was targeted. First, the Bpin function was 
transformed to the hydroxyl group under very mild oxidative conditions, giving 
efficient access to the desired spiro-bicyclic alcohol 139.[41] Then, O-arylation with 
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4-chloro-2,6-dimethylpyridine under basic conditions in DMSO at 70 °C afforded 
compound 140 in 70% isolated yield.[42] Finally, Boc cleavage under acidic 
conditions[36] followed by reductive amination of the deprotected pyrrolidine 
hydrochloric salt with N-(5-formylthiazol-2-yl)acetamide afforded spiro-compound 
141 in 23% isolated yield in a 1 to 1 diastereomeric ratio.[40] The diastereomeric 
mixture was separated by reverse-phase HPLC (Scheme 5.9). 
 
Scheme 5.9 Synthesis of final target 141. 
Moreover, the preparation of analogues where the distal heteroaryl substituent is 
directly linked to the spiro-bicyclic core was also envisaged. For that purpose, 
several synthetic approaches were tested from compound 112. Derivatizations 
towards the alcohol derivative (reaction a) followed by further oxidation to the 
corresponding carboxylic acid (reaction b)[43] and the activation of the carboxylic 
acid by reaction with N-hydroxyphthalimide (reaction c) followed by 
decarboxylarive arylation coupling failed in the last step reaction (reaction d), with 
no observation of the directly arylated product by LC-MS analysis of the reaction 
crude (Scheme 5.10).[44]  
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Scheme 5.10 Unsuccessful access to directly linked spiro-bicyclic core. 
Considering these results our attention turned to commercially available N-Boc 
spiro-bicyclic ketone 142 which, gladly, could be transformed into the final target 
compounds 145 and 146 (Scheme 5.11).  
 
Scheme 5.11 Possible routes of access to directly linked heteroaryl motif. 
Thus, NaBH4 reduction of the ketone function in compound 142 in methanol led to 
alcohol 143[45] which after aqueous work up was used for the next reaction step 
without purification (Scheme 5.12). Appel reaction on the alcohol group to form the 
iodocyclopentane derivative 143[31] followed by cross-coupling arylation with 2,6-
dimethlypyridine boronate ester under nickel catalyzed Suzuki conditions afforded 
compound 144 although in low yield.[46] Then, Boc cleavage [36] followed by reductive 
amination with N-(5-formylthiazol-2-yl)acetamide target compound 145 in 43% 
isolated yield in a diastereomeric ratio 1 to 1.[40] 
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Scheme 5.12 Synthesis of final target 145 and 146. 
Compound 146 (Scheme 5.12) was also synthesized from the corresponding 
pyridine boronate ester and the iodo derivative 143 following the same reaction 
sequence. Product 146 was obtained in a 1 to 1 diastereomeric mixture. 
Diastereoisomers were separated by reverse phase HPLC chromatography. 
b) Final targets from spiro-bicyclic central core 113 
Similar to scaffold 112, the spiro-bicyclic core 113 was used for the synthesis of the 
final products 149 and 152 containing methylene and a -CH2O- linkers (Scheme 
5.13).  
 
Scheme 5.13 Final products from spiro-bicycle 113. 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Chapter 5 
 105 
Product 149 (Scheme 5.14) was prepared from the boronate ester 113 following in 
the first reaction step the arylation procedure already reported in Scheme 5.8 for 
the synthesis of product 138. The deprotection of the pyrrolidine nitrogen in 
compound 147 was achieved by cleavage of the benzyl protecting group under flow-
hydrogenation conditions on a Pd(OH)2/C cartridge using an H-cube reactor. In this 
example, since the deprotected amine 148 is a free base, no TEA was added in the 
reductive amination step leading to compound 149. Product 149 was obtained as a 
1 to 1 mixture of diastereosiomers, which were separated by reverse-phase HPLC 
chromatography. 
 
Scheme 5.14 Synthesis of final target 149. 
Finally target 152, containing a –CH2O- linker (Scheme 5.15) was prepared following 
the procedure previously described in Scheme 5.9, the only difference being the 
benzyl deprotection step that was performed on H-cube reactor as in the previous 
example. Compound 152 was obtained in moderate yield as a 1 to 1 mixture of 
diastereoisomers. 
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Scheme 5.15 Synthesis of final target 152. 
Analogous to spiro-compound 112, the spiro-boronate 113 did not allow access to 
the final target 156. Following the sequential derivatizations shown in Scheme 5.10, 
the reaction failed in the last step where the nickel catalyzed decarboxylative 
coupling was unsuccessful (Scheme 5.16).[44] 
 
Scheme 5.16 Unsuccessful access to directly linked spiro-bicyclic core. 
A more successful approach started from commercially available N-Boc spiro-
bicyclic ketone 153 which, gladly, could be transformed into the final target 
compound 156 (Scheme 5.17). Instead of following the synthesis route used with N-
Boc spiro-bicyclic ketone 142, a new reaction sequence was designed aiming to 
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increase the efficiency of the overall transformation. Thus, lithiation of 4-bromo-
2,6-dimethylpiridine followed by addition to the keto-spiro-bicycle led to alcohol 
154 in moderate yield.[47] To capitalize on the structure of compound 154, the 
tertiary alcohol was deoxyfluorinated with (diethylamino)sulfur trifluoride 
(DAST).[48] The deoxyfluorination reaction was not clean and a cyclopentene 
derivative was formed along the expected fluorine-containing compound. The 
elimination can occur since the fluorination pathway proceeds through a SN1 
mechanism and the attack of the fluorine to the carbocation competes with the 
elimination pathway. Unfortunately, we did not succeed with the purification of the 
mixture, hence this mixture was subjected to hydrogenation with Pd/C at 
atmospheric pressure.[49] Surprisingly, the mixture converged to product 155, were 
the fluorinated product suffered an unpredictable hydrogenation and the 
unsaturated product was hydrogenated as expected. Then, as reported in previous 
procedures, the Boc group was cleaved. This time using an acidic modified 
Amberlyst-15 resin, the deprotected amine was obtained and used for the next step 
without purification.[50] Then, reductive amination provided compound 156 in 63% 
isolated yield in a diastereomeric ratio 1 to 1 (Scheme 5.17).[40] The diasereomeric 
mixture was sent to chiral SFC separation to get each enantiomer in a pure form. 
However, only the diastereomeric mixture was fully characterized. 
 
Scheme 5.17 Synthesis of final target 156. 
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c) Final targets from spiro-bicyclic central core 114 
Analogous to the previous central scaffolds, the spiro-bicyclic core 114 was 
derivatized towards the formation of 158 and 160 compounds containing a 
methylene linker, 163 introducing the –CH2O- linker and, for the first time, product 
167 which contains a –CH2N- group as spacer (Scheme 5.18).  
 
Scheme 5.18 Final targets from spiro-bicycle 114. 
The synthesis of products 158 and 160 is outlined in Scheme 5.19. Starting from the 
spiro-bicyclic boronate 114 and the corresponding pyridine derivatives, following 
procedure reported for the synthesis of compound 138 in Scheme 5.8, 
intermediates 157 and 159 were obtained. The final targets 158 and 160 were 
synthesized in good yields after deprotection and reductive amination on 
intermediates 157 and 159, respectively. In both cases products were obtained in a 
1 to 1diastereomeric ratio. 
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Scheme 5.19 Synthesis of final targets 158 and 160. 
The -CH2O- linker product was also synthetized following a previously described 
reaction sequence as shown in Scheme 5.20. Thus, oxidation of the boronate ester 
114 yielded almost quantitatively the primary alcohol 161 which was then O-
arylated towards intermediate 162. Finally, deprotection and subsequent reductive 
amination afforded the target product 163 in 48% isolated yield, as 1:1 
diastereomeric mixture. 
 
Scheme 5.20 Synthesis of final target 163. 
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Aiming to study the effect of linkers of different nature on the OGA inhibitory 
activity a -CH2NH- linker containing molecule was synthesized (Scheme 5.21). 
The synthesis started from the alcohol intermediate 161 which was transformed 
into a mesylate derivative by treatment with mesyl chloride and DIPEA in DCM. This 
mesylate intermediate, after aqueous work-up, was used for the next reaction step 
without further purification.[51] Treatment of the mesylate intermediate with 
sodium azide in DMF at 70 °C for 16 hours provided the azido spiro-compound 164 
that was stable enough to be isolated after column chromatography in 75% of 
yield.[52] Next, the azide group was reduced to the amine 165 under hydrogenation 
conditions using the H-cube reactor.[53] Unfortunately, due to the high reactivity 
demonstrated by the amine it was not possible to obtain the mono-arylation target 
molecule and only a compound containing two pyridine units (166) could be 
isolated.  
Even though, we decided to go forward with this product and thus proceeded to the 
deprotection of the amine[36] and subsequent reductive amination leading to a 
spiro-compound with two distal pyridine units (167) in a diastereomeric ratio 1 to 1 
(Scheme 5.21).[40] The diastereomeric mixture of product 167 was separated by 
reverse-phase HPLC chromatography. 
 
Scheme 5.21 Synthesis of final target 167. 
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d) Final targets from spiro-bicyclic central core 115 
Next, we turned our attention to the derivatization of the spiro-bicyclic central core 
115. Despite the fact this spiro-compound had been described in the literature, no 
further derivatization and functionalization towards compounds of potential 
pharmaceutic interest has been reported. In order to study the potential of this 
bicyclic core in our OGA inhibition program the final products 169, 171, 174 and 175 
(Scheme 5.22) were prepared. Interestingly, this scaffold gives access to the new       
-O- linker not prepared previously in the program. 
 
Scheme 5.22 Final targets from spiro-bicycle 115. 
Starting from the secondary alcohol 115, the O-arylation reaction was performed 
using NaH and 4-bromo-2,6-dimethylpyridine rendering the formation of the O-
arylated product 168 in 70% isolated yield.[54] Then, deprotection and successive 
reductive amination provided the final product 169 in 52% isolated yield in a 
diastereomeric ratio 1 to 1, which was separated by reverse-phase HPLC 
chromatography (Scheme 5.23). 
 
Scheme 5.23 Synthesis of final target 169. 
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Moreover, a new heteroaromatic ring was introduced for the first time in the north 
part of the scaffold. Following the conditions used for the synthesis of 169 in Scheme 
5.23 and using 4-chloro-2,6-dimethylpyrimidine the corresponding O-arylated 
intermediate 170 was obtained in almost quantitative yield. Deprotection followed 
by reductive amination delivered the final product 171 as a 1 to 1 mixture of 
diastereoisomers in 28% isolated yield (Scheme 5.24). 
 
Scheme 5.24 Synthesis of final target 171. 
Additionally, compounds 174 and 175 in which the heteroaryl group is directly 
linked to the tetrahydrofuran ring were also prepared following the conditions used 
for the synthesis of final products 145 and 146 in Scheme 5.12. Gladly, after 
iodination (178, 78%), Suzuki-Miyaura coupling (173, R=Me, 19%), deprotection and 
subsequent reductive amination compounds 174 (54%) and 175 (5%, over three 
reaction steps) were isolated, in both cases products were obtained as a 1 to 1 
diastereomeric mixture (Scheme 5.25).  
 
Scheme 5.25 Synthesis of final target 174 and 175. 
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e) Final targets from spiro-bicyclic central core 116 
Finally, the spiro-bicyclic core 116 was modified to introduce the same set of spacers 
installed in scaffold 115, although alternative methodologies were applied to 
introduce a fluorine atom adjacent to the linker attachment point (Scheme 5.26). 
 
Scheme 5.26 Final targets from spiro-bicycle 116. 
Firstly, the product containing an -O- linker was prepared following the conditions 
reported in Scheme 5.23. Thus, the final product 177 was obtained in good yield, as 
a 1 to 1 diastereomeric mixture, in a three step reaction sequence starting from 
alcohol 116: (Reaction a) O-arylation (176, 71%), (Reaction b) deprotection and 
(Reaction c) reductive amination (Scheme 5.27). 
 
Scheme 5.27 Synthesis of final target 177. 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Synthesis and application of novel spiro-boronate compounds for the treatment 
of Alzheimer’s disease  
114 
Moreover, as described previously in Scheme 5.17, arylation of a cycloalkanone 
through lithiation of 4-bromo-2,6-dimethylpyridine renders a tertiary OH group 
susceptible to be fluorinated. Aiming to perform this transformation, oxidation of 
the spiro-cyclopentanol, using Dess-Martin periodinane (DMP) rendered the spiro-
cyclopentanone (178) in excellent yield.[55] Then, organolithium addition followed 
by deoxyfluorination of the intermediate alcohol 179 gave access to the expected 
fluorocyclopentane derivative without detection of the elimination byproduct 
(Scheme 5.28). Finally, successive deprotection and reductive amination with N-(5-
formylthiazol-2-yl)acetamide gave target 180 in 36% isolated yield in a 
diastereomeric ratio 1 to 1, obtaining for the first time a final product with a fluorine 
substituent on the spiro-bicyclic core (Scheme 5.28). 
 
Scheme 5.28 Synthesis of final target 180. 
In addition, based on relevant SAR from a different OGA-chemotype, a new 
derivative containing a benzodioxane motif in the south part of the scaffold was 
prepared. Reductive amination on the fluorine-containing deprotected spiro-
piperidine (179II) with 1,4-benzodioxan-6-yl methyl ketone, Ti(OiPr)4, NaBH3CN in 
DCE at 80 °C, yielded the final product 181 in 17% isolated yield in a diastereomeric 
ratio 1 to 1 (Scheme 5.29). 
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Scheme 5.29 Synthesis of final target 181. 
With the aim to study the influence of the fluorine atom on the biological activity of 
the molecules, the corresponding matched-pairs 183 and 184 without the fluorine 
atom were also prepared. 
Taking into account the previous observation that the fluorine atom was cleaved 
under hydrogenation conditions, the N-Boc-flurorinated spiro-piperidine 
intermediate was hydrogenated using Pd/C at atmosphere pressure, affording full 
conversion towards the defluorinated N-Boc-protected piperidine (179I) (Scheme 
5.30).[49] Consecutive deprotection and reductive amination with N-(5-
formylthiazol-2-yl)acetamide formed product 183 in moderate yield, as a 1 to 1 
mixture of diastereoisomers (Scheme 5.30). 
 
Scheme 5.30 Synthesis of final target 183. 
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Similarly, reductive amination of 182I with 1,4-benzodioxan-6-yl methyl ketone led 
to compound 184 as 1 to 1 mixture of diastereoisomers (Scheme 5.31).[56] 
 
Scheme 5.31 Synthesis of final target 184. 
5.3.3 SAR analysis from the final target spiro-compunds 
In this section the structure-activity relationship (SAR) analysis from the final targets 
prepared in section 5.3.2 is described. The criteria of evaluation starts first by 
measuring their hOGA inhibitor activity in a biochemical and cellular assays. The 
protocols for these in vitro assays are described below: 
a) OGA Biochemical assay: 
The assay is based on the inhibition of the hydrolysis of fluorescein mono-β-D-N-
Acetyl-Glucosamine (FM-GlcNAc) by the recombinant human Meningioma 
Expressed Antigen 5 (MGEA5), also referred to as O-GlcNAcase (OGA). The 
hydrolysis FM-GlcNAc results in the formation of β-D-N-glucosamineacetate and 
fluorescein. The fluorescence of the latter can be measured at excitation 
wavelength 485 nm and emission wavelength 538 nm. An increase in enzyme 
activity results in an increase in fluorescence signal. Full length OGA enzyme was 
purchased at OriGene. The enzyme was stored in 25 mM Tris.HCl, pH 7.3, 100 mM 
glycine, 10% glycerol at -20 °C. Thiamet G and GlcNAcStatin were tested as reference 
compounds. The assay was performed in 200 mM Citrate/phosphate buffer 
supplemented with 0.005% Tween-20. 35.6 g Na2HPO4 2xH2O were dissolved in 1 L 
water to obtain a 200 mM solution. 19.2 g citric acid was dissolved in 1 L water to 
obtain a 100 mM solution. pH of the sodiumphosphate solution was adjusted with 
the citric acid solution to 7.2. The buffer to stop the reaction consists of a 500 mM 
carbonate (734 mg) buffer, pH 11.0. 
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FM-GlcNAc were dissolved in 5.48 mL DMSO to obtain a 250 mM solution and was 
stored at -20 °C. OGA was used at a 2 nM concentration and FM-GlcNAc at a 100 M 
final concentration. Dilutions were prepared in assay buffer.  
50 nL of a compound dissolved in DMSO was dispensed on Black Proxiplate TM 384 
Plus Assay plates and 3 μl fl-OGA enzyme mix added subsequently. Plates were pre-
incubated for 60 min. at room temperature and then 2 μl FM-GlcNAc substrate mix 
added. Final DMSO concentrations did not exceed 1%. Plates were briefly 
centrifuged for 1 min. at 1000 rpm and incubate at room temperature for 6 h. To 
stop the reaction 5 μl STOP buffer were added and plates centrifuge again 1 min. at 
1000 rpm. Fluorescence was quantified in the Thermo Scientific Fluoroskan Ascent 
or the PerkinElmer EnVision with excitation wavelength 485 nm and emission 
wavelength 538 nm.  
For analysis a best-fit curve is fitted by a minimum sum of squares method. From 
this an IC50 value and Hill coefficient was obtained. High control (no inhibitor) and 
low control (saturating concentrations of standard inhibitor) were used to define 
the minimum and maximum values. 
b) OGA Cellular assay: 
HEK293 cells inducible for P301L mutant human Tau (isoform 2N4R) were 
established at Janssen. Thiamet-G was used for both plate validation (high control) 
and as reference compound (reference EC50 assay validation). OGA inhibition is 
evaluated through the immunocytochemical (ICC) detection of O-GlcNAcylated 
proteins using a monoclonal antibody detecting O-GlcNAcylated residues as 
previously described. Inhibition of OGA will result in an increase of O-GlcNAcylated 
protein levels resulting in an increased signal in the experiment. Cell nuclei are 
stained with Hoechst to give a cell culture quality control and a rough estimate of 
immediate compounds toxicity, if any. ICC pictures are imaged with a Perkin Elmer 
Opera Phenix plate microscope and quantified with the provided software Perkin 
Elmer Harmony 4.1.  
Cells were propagated in DMEM high Glucose following standard procedures. 2 days 
before the cell assay cells are split, counted and seeded in Poly-D-Lysine (PDL) 
coated 96-wells plate at a cell density of 12,000 cells per cm² (4,000 cells per well) 
in 100 μl of Assay Medium (Low Glucose medium is used to reduce basal levels of 
GlcNAcylation). At the day of compound test medium from assay plates was 
removed and replenished with 90 μl of fresh Assay Medium. 10 μl of compounds at 
a 10-fold final concentration were added to the wells. Plates were centrifuged 
shortly before incubation in the cell incubator for 6 hours. DMSO concentration was 
set to 0.2%. Medium is discarded by applying vacuum. For staining of cells medium 
was removed and cells washed once with 100 μl D-PBS. From next step onwards 
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unless other stated assay volume was always 50μl and incubation was performed 
without agitation and at room temperature. Cells were fixed in 50 μl of a 4% 
paraformaldehyde PBS solution for 15 min. at room temperature. The PFA PBS 
solution was then discarded and cells washed once in 10mM Tris Buffer, 150 mM 
NaCl, 0.1% Triton X, pH 7.5 (ICC buffer) before being permeabilized in same buffer 
for 10 minutes. Samples are subsequently blocked in ICC containing 5% goat serum 
for 45-60 minutes at room temperature. Samples were then incubated with primary 
antibody (1/1000 from commercial provider, see above) at 4°C overnight and 
subsequently washed 3 times for 5 min. in ICC buffer. Samples were incubated with 
secondary fluorescent antibody (1/500 dilution) and nuclei stained with Hoechst 
33342 at a final concentration of 1μg/ml in ICC for 1 hour. Before analysis samples 
were washed 2 times manually for 5 min. in ICC base buffer. 
Imaging is performed using Perkin Elmer Phenix Opera using a water 20x objective 
and recording 9 fields per well. Intensity readout at 488 nm is used as a measure of  
O-GlcNAcylation level of total proteins in wells. To assess potential toxicity of 
compounds nuclei were counted using the Hoechst staining. IC50 values are 
calculated using parametric non-linear regression model fitting. As a maximum 
inhibition Thiamet G at a 200 M concentration is present on each plate. In addition, 
a concentration response of Thiamet G is calculated on each plate. 
The following figures show the different products prepared along with their OGA 
inhibitory activity in the biochemical and cellular assays. Depending on the 
compound, in some cases this was tested as a mixture of diastereoisomers and/or 
as single diastereoisomer. 
The results obtained in these assays are discussed on the following paragraphs. First, 
we looked compounds where the distal heteroaryl ring is directly linked to the spiro-
carbocyclic ring (Figure 5.14). The replacement of the central spirocyclic diamine 
core in 110b (pIC50 = 8.22, cell pEC50 = 6.85) by the spiro-cyclopentane 156 (pIC50 = 
7.18, cell pEC50 = 6.67) and spiro-cyclobutane 145 (pIC50 = 7.44, cell pEC50 = 6.74) was 
tolerated in terms of OGA inhibitory activity, with the compounds being about one-
fold less potent in the biochemical assay. Nevertheless, it is interesting to mention 
that their activity in the OGA cellular assay was comparable to that of 110b, 
suggesting that the deletion of the north nitrogen atom in the spirocyclic core has a 
pronounced effect in the physicochemical properties of the molecules resulting in 
an increased cellular penetration. All pure stereoisomers of compound 156 were 
tested, with isomer 156a´ (pIC50 = 7.47, cell pEC50 = 6.54) being the more potent in 
the OGA biochemical assay while retaining a good cellular activity. Considering the 
good activity levels obtained with the spiro-cyclobutane derivative 145, two close 
analogues bearing a less basic pyridyl ring were tested. Unfortunately, both 146 
(pIC50 = 7.06, cell pEC50 = 6.32) and 146a´ (pIC50 = 6.48, cell pEC50 = 6.04) were found 
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to be less active, suggesting that pKa of the pyridyl nitrogen could play a role in the 
inhibitory activity of the compounds.  
 
Figure 5.14 SAR analysis from the direct linked heteroaromatic  
replacement in the carbocyclic spiranes. 
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The spiro-tetrahydrofuran derivatives 174 (pIC50 = 7.68, cell pEC50 = 6.22) and 175 
(pIC50 = 7.22, cell pIC50 < 6) showed comparable activity to spiro-cyclopentane 145 
(pIC50 = 7.44, cell pEC50 = 6.74) in the OGA biochemical assay, however this 
modification led to a reduction in the cellular activity of the compounds.  
Remarkably, enlarging the pyrrolidine ring to a piperidine one was clearly 
detrimental for the activity, with compound 183 (pIC50 = 5.60, cell pEC50 = 6.16) being 
two orders of magnitude less potent than 145. Compound 184 (pIC50 = 5.06, cell 
pEC50 < 6) containing a benzodioxane substituent an active motif when placed at 
110b did not improve activity. Introduction of a fluorine substituent adjacent to the 
heteroaromatic ring (180, pIC50 = 5.74, cell pEC50 = 6.4 and 181, pIC50 = 5.17, cell pEC50 
< 6) did not have an influence on the activity of the compounds (Figure 5.15).  
 
Figure 5.15 SAR analysis from the direct linked heteroaromatic replacement in the containing THFs 
spiranes. 
The insertion of an oxygen atom between the spiro-tetrahydrofuran scaffold and 
the pyridyl ring did not have an effect on the activity, with the most active 
diastereoisomer 169a´ (pIC50 = 7.52, cell pEC50 = 6.27) being equipotent to the 
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directly linked analogue 174 (pIC50 = 7.68, cell pEC50 = 6.22), albeit the latter being 
screened as a 1 to 1 mixture of diastereoisomers. Replacement of the pyridyl ring 
for a pyrimidine one (171, pIC50 = 7.11, cell pEC50 < 6) was tolerated in terms of 
biochemical but not cellular activity (Figure 5.16). Moreover, as previously 
observed, product 177 (pIC50 = 5.97, cell pIC50 = 6.88) containing a spiro-piperidine 
ring was significantly less potent that the corresponding spiro-pyrrolidine matched 
pair 169a´. 
 
Figure 5.16 SAR analysis from the –O- linked heteroaromatic replacement. 
In addition, introduction of a methylene linker between the pyridyl ring and the 
spiro-cycloalkane core was detrimental for activity (Figure 5.17). Compounds 138 
(pIC50 = 6.69) and 149 (pIC50 = 6.51) were slightly less potent than their 
corresponding matched pairs 145 (pIC50 = 7.44) and 156 (pIC50 = 7.18), where the 
pyridyl ring is directly linked to the spiro-cycloalkane ring. The isolated 
diastereoisomers 138a, 138a´, 149a and 149a´were also tested leading to similar 
inhibitory values than the corresponding diastereoisomeric mixtures (Figure 5.17).  
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Figure 5.17 SAR analysis from the –CH2- linked heteroaromatic replacement.  
Furthermore, the use of a one atom longer spacer -CH2O- led to comparable results 
to those obtained with the methylene linked compounds. Thus compounds 141 
(pIC50 = 6.89) and 152 (pIC50 = 6.87) showed similar inhibitory activity than their 
corresponding matched pairs 138 (pIC50 = 6.69) and 149 (pIC50 = 6.51). Interestingly 
the pure diastereoisomer 141a’ showed a nice inhibitory activity in the biochemical 
assay (pIC50 = 7.13), but more important, this activity was kept in the OGA cellular 
assay (cell pEC50 = 7.34). To demonstrate the key role of acetamidothiazole group in 
the OGA inhibitory activity of the compounds, the synthesis intermediate 151, 
containing a N-benzyl substituent in the pyrrolidine ring, was tested in the 
enzymatic assay and found to be inactive (pIC50 < 5).  
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Figure 5.18 SAR analysis from the –CH2O- linked heteroaromatic replacement. 
Finally, the spiro-bicyclic boronate 114 proved to be the central scaffold to source 
potent OGA inhibitors with balanced enzymatic and cellular activities. As can be 
seen in Figure 5.19, both, analogues containing methylene (158: pIC50 = 7.38, cell 
pEC50 = 7.13 and 160: pIC50 = 7.08, cell pEC50 = 6.66) or -CH2O- (163: pIC50 = 7.13, cell 
pEC50 = 7.34) linkers, displayed in most cases comparable enzymatic and cellular 
activities with pIC50 and pEC50 values above 7. Nevertheless, the most potent 
compounds identified in this collaborative project came from the introduction of a 
-CH2N- linker, where the unexpected double heteroarylation of the linker led to 
compound 167 that after separation of diastereoisomers rendered the pure 
diastereoisomer 167a (pIC50 = 8.36, cell pEC50 = 8.1), a single digit nanomolar 
inhibitor in both the enzymatic and cellular assays.  
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Figure 5.19 SAR derived from the spiro-cyclobutylpiperidine scaffold 114.  
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5.4. Conclusions 
In summary, 5-central scaffolds have been synthesized in gram scale by two 
different spiro-cyclization methods. These scaffolds were derivatized introducing a 
distal hereroaromatic ring as substituent in the north cycle and in most cases an 
acetamidotiazole substituent on the south part of the scaffold. The boronate and 
hydroxy substituents on the spiro-cyclic core were used as handles to explore linkers 
of different length and nature as spacers between the distal heteroaromatic and the 
spiro-cyclic core. This exploration identified a spiro-cyclobutylpiperidine as an 
optimal central scaffold for the preparation of potent OGA inhibitors. 
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6.1. State of the art 
6.1.1 1,2-Carboboration of alkenyl ketones 
Formation of small rings through 1,2-carboboration process has fascinated organic 
chemists during the last decade because of their strain and rigid framework.[1] 
Recent works have demonstrated the efficiency of the copper mediated borylative 
cyclization of multiple C-C bonds through -alkenyl ketones towards the formation 
of cyclic products with the in situ incorporation of the boryl unit and the alcohol 
group, being considered of high interest in medicinal chemistry.  
The group of Ito and co-workers[2] pioneered the field with the regioselective boryl 
cupration of -alkenyl aryl ketones. The alkylcopper species is formed with complete 
regioselectivity in the presence of CuCl, Xantphos, KOtBu and B2pin2, placing the 
boryl unit at the terminal position of the olefin. The catalytic system promoted the 
intramolecular 1,2-addition to the carbonyl group to give 2-
(borylmethyl)cyclobutanols with excellent syn-diastereoselectivity (Scheme 6.1). 
 
Scheme 6.1 Borylative ring-closing of -alkenyl aryl ketones catalyzed by copper. 
However, the scope of the reaction was limited to few examples, with only some 
modifications along the nature of the aryl group. Moreover, the authors reported 
one example of borylative cyclization through δ-alkenyl aryl ketones which provided 
the formation of a 1,2-oxaborolane bicyclic structure in high yield and good 
diastereoselectivity (Scheme 6.2). 
 
Scheme 6.2 Borylative ring-closing of δ-alkenyl aryl ketones catalyzed by copper. 
The authors proposed a reaction mechanism for this intramolecular 1,2-
carboboration (Scheme 6.3). The catalytic cycle might starts with the formation of 
the copper alkoxide complex, via σ-bond metathesis between LCuOR (A) and B2pin2 
affording the boryl copper (I) active species (B). Intermediate C might be next 
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formed by chemo- and regioselective 1,2-addition of Cu-B to C=C bond. 
Subsequently, an extra coordination of the alkoxide base could form a more 
nucleophilic cuprate intermediate D. It has been suggested that a Cu (III) species E, 
formed via oxidative addition, evolves into the desired cyclic product via reductive 
elimination and closing the catalytic cycle by regenerating the species A. The syn-
selectivity observed, could be explained through the less sterically hindered 
transition state postulated and included in Scheme 6.3. 
 
Scheme 6.3 Suggested mechanism for the borylative cyclization of alkenyl aryl ketones.[2] 
In contrast, an opposite anti-diastereoselection has been reported by Lautens and 
co-workers[3] for the borylative cyclization of -alkenyl aryl/alkyl ketones. The use of 
Cu(MeCN)4PF6/NaOtBu as precursor of the catalytic system gave access to a wide 
variety of boryl arylated cyclobutanols. Interestingly, as the asymmetric addition of 
boron to alkenes is an important tool to readily introduce molecular complexity and 
flexibility,[4] the use of (S,S)-BDPP as ligand allowed for the enantioselective 
preparation of these cyclobutanol derivatives (Scheme 6.4). 
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Scheme 6.4 Enantioselective borylative ring-closing of substituted -alkenyl  
aryl/alkyl ketones catalyzed by copper. 
In this study, the use of MTBE (methyl tert-butyl ether) as the optimal solvent was 
reported, although comparable results were obtained with THF. Interestingly the 
use of iPrOH as additive was critical to obtain good conversions. Lautens and co-
workers proposed a complementary mechanism to the one reported by Ito and co-
workers.[2] However no justification of the anti-diastereoisomerism was provided 
(Scheme 6.5). 
 
 
Scheme 6.5 Suggested mechanism for the borylative cyclization  
substituted -alkenyl aryl ketones.[3] 
The boryl copper (I) active species B promotes the coordination and concomitant 
insertion to the styrene moiety of the substrate to give the benzylic copper specie 
C. Then intramolecular cyclization to the tethered aryl ketone might form 
intermediate D. Subsequently, the intermediate D might undergo 
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protodemetallation assisted by the alcoholic additive (iPrOH) to furnish the arylated 
cycobutanol product and recycle the catalyst. 
More recently this group has also developed the enantioselective copper catalyzed 
borylation/1,2-imide addition cascade reaction to assemble boron-containing 
indolines.[5] However, in this Cu (I) catalytic system (S,S)-Ph-BPE as chiral ligand and 
MeOH as additive resulted more efficient. The authors also observed that the use 
of bulkier alcohols as additive provided lower enantioselectivities. The 
transformations were found to be highly diastereoselective and enantioselective, as 
well as tolerant with a variety of aryl substituents (Scheme 6.6). 
 
Scheme 6.6 Enantioselective borylative ring-closing of substituted  
alkenyl phenyl pyrrolidindiones catalyzed by copper. 
This group also reported previously the enantioselective boryl acylation process for 
accessing chiral 3,3-disubstituted oxindoles.[6] 
6.1.2 1,2-Borylation of aldehydes catalyzed by copper complexes 
Copper (I) complexes can also catalyze the 1,2-diboration of aldehydes. However, 
the use of aldehydes as substrates have proved complex due to the lack of success 
in the isolation of 1,2-diborated products.[7] Sadighi and co-workers[8] reported for 
the first time the 1,2-diboration of aliphatic and aromatic aldehydes. The use of a 
carbene copper (I) complex catalyzes the formation of 1,2-diborated products in 
high yields (Scheme 6.7). These diborated compounds could be isolated by 
recrystallization and showed high stability when stored under argon. However, they 
have a tendency to decompose in the presence of oxygen as well as during 
purification by flash column chromatography. 
 
Scheme 6.7 1,2-diboration of aldehydes catalyzes by copper complexes. 
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Molander and co-workers[9] improved the reaction conditions reported by Sadighi 
performing the reaction in toluene and using MeOH as additive. The reaction was 
accelerated and full converted after 1.5 hours. Subsequent addition of KHF2 
provided the corresponding mono-trifluoroborated products in moderate to 
excellent yield (Scheme 6.8). 
 
Scheme 6.8 . Preparation of potassium 1-(hydroxy)alkyltrifluoroborates. 
In that context, Clark and co-workers[10] reported the one pot direct 1,2-diboration/ 
homologation to provide β-hydroxyboronate esters in moderate to good yields. 
More recently, Ito and co-workers[11] reported the enantioselective borylation of 
aldehydes using a Cu (I) salt and (R)- or (S)-DTBM-SEGPHOS as chiral ligand. These 
studies evidenced excellent enantioselectivities and a broad substrate scope 
towards the formation of borylated protected alcohols (Scheme 6.9).  
 
Scheme 6.9 Enantioselective borylation of aliphatic aldehydes catalyzed by copper. 
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6.2. Aim of the Chapter 
With all these precedents in mind and based in our previous work, we decided to 
study the potential of alkenyl aldehydes as synthetic precursor to spiro-cyclic 
products with vicinal borylmethyl and hydroxyl functional groups (Scheme 6.10). 
Despite the fact that copper catalyzed borylative addition to aldehydes or alkenes 
had been previously explored, to the best of our knowledge, this would be the first 
example of a borylcupration followed by intramolecular electrophilic trapping of the 
alkylcopper intermediate with an aldehyde, although intermolecular versions are 
already known.[12]  
 
Scheme 6.10 Graphical objective of the chapter. 
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6.3. Results and discussion 
We began with the synthesis of the alkenyl aldehydes from the corresponding 
derivative esters 55, 185, 130 and from commercially available aldehyde 186 (Figure 
6.1). Substrates 185 and 130 were obtained from the commercially available 
hydrochloric amine salts by N-protection with tosylchloride/TEA[13] and 
Boc2O/DIPEA[14] respectively. 
 
Figure 6.1 Derivative esters and aldehydes used as starting materials. 
The alkylation of substrates 55 and 185 with 3-bromopro-1-ene was performed with 
the in situ generated LDA in THF (Scheme 6.11). The desired alkylated products 61 
and 187 were isolated in 90% and 62% yield respectively. Moreover substrate 55 
was alkylated with 4-bromobut-1-ene under the same reaction conditions giving 
access to the alkylated ester 62 in 75% isolated yield. For the alkylation of ester 130 
the use of lithium bistrimethylsilyl amide (LHMDS)[15] instead of LDA[16] resulted in 
higher isolated yields of product 131 (98%) (Scheme 6.11).  
 
Scheme 6.11 General procedure and scope of the alkylation step. 
Subsequently, the alkylated derivative ester intermediates 61, 62, 187 and 131 were 
reduced to the hydroxymethylene products with lithium aluminum hydride (LiAlH4) 
as reducing agent in anhydrous Et2O at 0 °C (Scheme 6.12). The hydroxylated 
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intermediates were obtained in quantitative yields after aqueous work up and were 
subjected to the next reaction step without further purification.[17] Oxidation of the 
alcohols was achieved using Dess-Martin periodinane leading to the corresponding 
aldehydes 188-191 in good to excellent yields (Scheme 6.12).[18] The lower 52% yield 
for substrate 188 was due to partial decomposition of the product during the 
purification step. 
 
Scheme 6.12 General procedure for the synthesis of alkenyl aldehydes  
by sequential reduction-oxidation. 
The alkenyl aldehyde 192 was prepared from substrate 186 by reaction with allyl 
alcohol under catalytic amounts of Ni(COD)2 and dppf as ligand in MeOH. After 15 
hours at 80 °C the cyclohexyl alkenyl aldehyde (192) was obtained in 82% isolated 
yield (Scheme 6.13).[19] 
 
Scheme 6.13 Synthesis of alkenyl aldehyde 192. 
The borylative ring-closing reaction conditions previously described were applied to 
substrates 188-192. Gratifyingly, substrate 188 underwent the borylative ring-
closing catalyzed by CuCl / Xantphos, in the presence of B2pin2 and KOtBu in THF. 
After 16 hours reaction time, the desired cyclized product 193 was isolated in high 
yield (Scheme 6.14). The analogous 4-piperidine alkenyl aldehyde substrate 190 
exhibited similar reactivity providing the target product 194 in 67% isolated yield 
(Scheme 6.14). To our surprise a decrease of the reaction efficiency was observed 
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in the case of the 3-piperidine alkenyl aldehyde substrate 191, obtaining the 
expected product 195 in only 25% isolated yield. The cyclohexyl substrate 192 was 
successfully transformed into the desired product 196 but in low 32% isolated yield.  
 
Scheme 6.14 Borylative ring-closing of alkenyl aldehydes catalyzed by copper. 
Having in mind Lauten’s work where the addition of iPrOH was found essential to 
produce the borylative cyclization of alkenyl ketones,[3] we decided to add 2 
equivalents of iPrOH with the aim to accelerate the catalytic process in the 
protonolysis step. Interestingly, 196 was now isolated in 49% yield (Scheme 6.14). 
Moreover, we extend the methodology to the synthesis of 5-membered ring 
containing spiro-cycles. Using 189 as substrate, under the same catalytic conditions, 
the spiro-bicycle 197 was obtained in 45% isolated yield. The addition of iPrOH 
resulted in higher conversion towards the spiro-cyclized product, however the 
boron unit was lost during the process and compound 198 was formed in 75% 
isolated yield (Scheme 6.14). 
Interestingly, the reaction outcome indicates that initial borylcupration takes place 
chemoselectively on the alkene without altering the aldehyde functionality. This is 
an important point to validate in the new methodology, since the present copper 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Intramolecular diastereoselective borylative spiro-cyclization through alkenyl 
aldehydes  
142 
catalyzed method is similar to the one reported for the 1,2-diboration of 
aldehydes.[8-11]  
Impressively, the borylative cyclization of alkenyl aldehydes was completely 
diastereoselective with both the borylmethyl and hydroxyl group in anti-position. 
The relative configuration of these two groups was determined by NOE experiments 
of product 193 (Figure 6.2, NOE). For instance, a negative NOE between Ha and Hb, 
was observed upon irradiation of Ha. However, when Hb was irradiated selectively 
it was observed a positive NOE with the protons from the pinacol unit (Figure 6.2, 
NOE 2). 
 
 
Figure 6.2 NOE experiments of product 193. 
Next, to prove the synthetic utility of this functionalized spiro-bicycles, compounds 
193, 194 and 196 were selectively oxidized with NaBO3·H2O under very mild 
conditions to form the corresponding dihydroxylated products 199, 200 and 201 in 
high yields (Scheme 6.15).  
NOE 1 
NOE 2 
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Scheme 6.15 Selective oxidation of the spiro-compounds. 
X-Ray diffraction of product 200 allowed the complete characterization of the diol 
product and confirmed the anti-diastereoselectivity (Figure 6.3). 
        
Figure 6.3 X-Ray diffraction of anti-2-(hydroxymethyl)-7- 
(phenylsulfonyl)spiro[3.5]nonan-1-ol (200). 
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6.4. Conclusions 
In this preliminary study, we have been able to synthetize a variety of alkenyl 
aldehyde substrates in an efficient manner. Moreover, we have gained access to a 
new synthetic method via borylative ring-closing catalyzed by copper complexes 
modified with Xantphos ligand. The present methodology has demonstrated total 
catalyst control in terms of chemoselectivity and diastereoselectivity, which was 
confirmed by X-Ray diffraction on a diol derivative. Additionally, good functional 
group tolerance has been proved with the successful spiro-ciclyzation of central 
cores containing oxygen or nitrogen, as well as different protecting groups. This 
transformation represents an unprecedented method to the preparation of new 
functionalized spiro-bicycles and also expands the pharmacopeia library for 
potential biomedical applications. 
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In chapter 3, we performed for the first time the insertion of 
trimethylsilyldiazomethane into the B-S σ-bond of pinB-SPh (6a) and pinB-STol (6b). 
The reaction was performed efficiently and was amenable for scale up to a gram 
scale. The corresponding tri-substituted methanes, CH(Bpin)(SiMe3)(SR) (8a-b), 
were selectively functionalized by means of a series of selective alkylation reactions 
after careful choice of the base employed. The use of an alkoxy base, assisted the 
deborylative alkylation of CH(Bpin)(SiMe3)(SR) (8a-b) with a series of alkyl halides. 
The use of a bulky nitrogenated base altered the outcome of the reaction allowing 
for a boron-retentive alkylation reaction. In this way, a range of highly substituted 
methanes were accessed. Additionally, when 1,n-dihaloalkanes were employed as 
electrophiles, the first deborylative alkylation intermediate could be subsequently 
transformed into a series of functionalized carbocyclic compounds. In this sense, an 
intramolecular ring forming deborylative alkylation was observed when an alkoxide 
base is used. Furthermore, an intramolecular desilylative cyclization could be 
achieved in the presence of a more silicophilic fluoride base.  
 
In chapter 4, a series of compounds containing unactivated alkenes and a C-X moiety 
were prepared. Those substrates were suitable substrates to conduct a borylative 
cyclization through a regioselective borylcupration followed by subsequent 
intramolecular ring closing via halide displacement. The transformation exhibited 
high functional group tolerance, with central cyclic substrates containing oxygen 
and nitrogen as heteroatoms. The transformation revealed a direct dependence on 
the size of ring formed, which was directly dependent on the metallocyclic 
intermediate based on Cu (III) species. The present methodology opened the door 
to the preparation of new spiro-bicyclic cores allowing for ring size variation in both 
cycles. Iteration of optimized protocol gave access to a structurally complex dispiro-
heterotricyclic structure fully characterized by X-Ray diffraction. 
 
In chapter 5, an application of several spiro-heterobicyclic cores synthesized in 
chapter 4 was explored in the context of a Medicinal Chemistry program targeting 
OGA inhibitors to treat Alzheimer’s disease. Up to 5-central spiro-bicyclic scaffolds 
were prepared in multi-gram scale by two different spiro-cyclization methods. These 
central cores were derivatized introducing a distal hereroaromatic ring as 
substituent in the north cycle and in most cases an acetamidotiazole substituent on 
the south part of the scaffold. The boronate and hydroxy substituents on the spiro-
cyclic core proved to be good synthetic handles to anchor linkers of different length 
and nature as spacers between the distal heteroaromatic and the spiro-cyclic core. 
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This exploration identified a spiro-cyclobutylpiperidine as an optimal central 
scaffold for the preparation of potent OGA inhibitors.  
In chapter 6, the preliminary studies on a novel intramolecular borylative ring 
closing reaction of alkenyl aldehydes by chemoselective borylcupration followed by 
C=O insertion is reported. The results obtained have demonstrated a total catalyst 
control in terms of chemoselectivity and diastereoselectivity, which was confirmed 
by X-Ray diffraction of a diol containing derivative. Additionally methodology has 
demonstrated high functional group tolerance, with central cores containing oxygen 
or nitrogen, as well as different protecting groups. This transformation opens the 
door to new functionalized spiro-compounds and also expands the pharmacopeia 
library to be studied for appropriate biomedical applications. 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
  
 
 
 
 
 
 
 
 
Chapter 8                                                      
Experimental part 
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
UNIVERSITAT ROVIRA I VIRGILI  
COMPLEMENTARY SYNTHESIS OF ORGANOBORANES TO POPULATE THE CHEMICAL 
FUNCTIONALITY TO A GIVEN AREA OF BIOMEDICAL INTEREST 
Jordi Royes Buisan
Chapter 8 
 153 
8.1. General considerations 
Solvents and reagents: Solvents and reagents were obtained from commercial 
suppliers and dried and/or purified (if needed) by standard procedures, as specified 
in “Purification of Laboratory Chemicals”.[1] Tetrahydrofuran was dried by 
distillation from sodium benzophenone ketyl. All reactions were conducted in oven 
and flame-dried glassware under an inert atmosphere of argon, using Schlenk-type 
techniques. Flash chromatography was performed on standard silica gel (Merck 
Kieselgel 60 F254 400-630 mesh). Thin layer chromatography was performed on 
Merck Kieselgel 60 F254 which was developed using standard visualizing agents: UV 
fluorescence (254 and 366 nm) or potassium permanganate/Δ. 
NMR spectra were recorded at a Varian Goku 400 or a Varian Mercury 400 
spectrometer, in the work done at the URV and on Bruker DPX-400 or Bruker AV-
500 spectrometers with standard pulse sequences, operating at 400 MHz and 500 
MHz respectively, in the work done at Janssen Cilag center. 1H NMR and 13C{1H} NMR 
chemical shifts (δ) are reported in ppm with the solvent resonance as the internal 
standard (CHCl3: 7.26 ppm (1H) and CDCl3: 77.16 ppm (13C)). 11B{1H} NMR chemical 
shifts (δ) are reported in ppm relative to (CH3)2O···BF3. 29Si{1H} NMR chemical shifts 
(δ) are reported in ppm relative to (CH3)4Si. Data are reported as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, hept = heptuplet, 
br = broad, m = multiplet), coupling constants (Hz) and integration.  
High resolution mass spectra (HRMS) were recorded using a 6210 Time of Flight 
(TOF) mass spectrometer from Agilent Technologies (Waldbronn, Germany) with an 
ESI interface and it was performed at the Servei de Recursos Científics i Tècnics 
(Universitat Rovira i Virgili, Tarragona) or using a BIOTOF II  Time of Flight (TOF) mass 
spectrometer from Bruker with an APCI interface or EI interface and it was 
performed at the Unidade de Espectrometría de Masas e Proteómica (Universidad 
de Santiago de Compostela, Santiago de Compostela). GC-MS analyses were 
performed on a HP6890 gas chromatograph and an Agilent Technologies 5973 Mass 
selective detector (Waldbronn, Germany) equipped with an achiral capillary column 
HP-5 (30m, 0.25mm i. d., 0.25 µm thickness) using He as the carrier gas. 
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8.2. Experimental procedures and spectral data of Chapter 3 
8.2.1 General procedure for the insertion of trimethylsilyldiazo methane 
into pinB-SR σ-bonds. 
In the glove-box, an oven-dried resealable Teflon screw-cap Schlenk reaction tube 
equipped with a magnetic stir bar was charged with 2 mmol of RS-Bpin (R = Ph, Tol, 
Bn). Then, a 2 M solution in hexanes of (trimethylsilyl)diazomethane (1 mmol, 2 
equiv) was added dropwise. After stirring in the glove-box for 5 min. the Schlenk 
tube was sealed and heated at the corresponding temperature (PhS-Bpin at 50 °C, 
TolS-Bpin and BnS-Bpin at 70 °C) for the appropriated time (PhS-Bpin for 6 h, TolS-
Bpin and BnS-Bpin for 16 h). The reaction was cooled down to room temperature 
and the solvent was evaporated to dryness. The crude residue was analyzed by GC-
MS and 1H NMR. Then the products were purified by silica gel flash chromatography. 
8.2.2 General procedure for the deborylative alkylation reaction. 
In the glove box, a 7.5 mL screw cap vial equipped with a magnetic stir bar was 
charged with CH(Bpin)(SiMe3)(SR) (0.1 mmol, 1.3 equiv) and NaOtBu (0.31 mmol, 4 
equiv). Then, 0.5 mL of THF was incorporated and finally the halogenated reagent 
was added (0.077 mmol, 1 equiv). The reaction was stirring at room temperature 
for 3 h and quenched with 2 mL of saturated Na2S2O4 and extracted 3 times with 3 
mL of Et2O. All the organic layers were collected and dried over MgSO4 and 
evaporated to dryness. The crude residue was analyzed by GC-MS and yields of 
products were calculated based on relative integration on the 1H NMR compared to 
an internal standard (1,4-dinitrobenzene or naphthalene). Then, the products were 
purified by silica gel flash chromatography. 
8.2.3 General procedure for the deprotonation-alkylation reaction. 
In the glove box, an oven-dried resalable Teflon screw-cap Schlenk reaction tube 
equipped with a magnetic stir bar was charged with LTMP (0.21 mmol, 1.05 equiv) 
and 0.8 mL of dried THF. The flask was sealed, removed from the glove box and the 
reaction mixture was cooled to 0 oC. Under Argon, a solution of gem-substrates (0.2 
mmol, 1 equiv) in THF (0.2 mL) was added via syringe and the mixture was allowed 
to stir at 0 °C for 10 min. The corresponding electrophile (0.24 mmol, 1.2 equiv) was 
added dropwise and the reaction was allowed to stir at 0 oC for 15 min. Upon 
completion, the reaction mixture was warmed to room temperature, filtered 
through a silica gel plug, rinsed with diethyl ether and dichloromethane, and 
concentrated in vacuo. The crude reaction mixture was purified on silica gel. 
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8.2.4 General procedure for the deborylative cyclization reaction. 
In the glove box, a 7.5 mL screw cap vial equipped with a magnetic stir bar was 
charged with the corresponding alkylated products (0.2 mmol, 1 equiv) and KOtBu 
(0.8 mmol, 4 equiv). Then 1.0 mL of THF was incorporated. The reaction was stirring 
at room temperature for 3 h and quenched with 2 mL of saturated Na2S2O4 and 
extracted 3 times with 3 mL of Et2O. All the organic layers were collected and dried 
over MgSO4, filtered and evaporated to dryness. The crude residue was analyzed by 
GC-MS and yields of cyclized compounds were calculated based on relative 
integration on the 1H NMR compared to an internal standard (1,4-dinitrobenzene). 
Then, the products were purified by silica gel flash chromatography. 
8.2.5 General procedure for the desilylative cyclization reaction. 
An oven-dried resalable Teflon screw-cap Schlenk reaction tube equipped with a 
magnetic stir bar was charged, under Argon, with the corresponding alkylated 
products (0.2 mmol, 1 equiv). Then, 0.3 mL of THF was incorporated and 4 equiv (0.8 
mmol) of a 1M solution of TBAF in THF were added dropwise at 0 °C. The reaction 
was then stirring for 1 h at 0 °C, followed by another 30 min. of stirring at room 
temperature. Next, the mixture was quenched with saturated NH4Cl aq. sat. and 
passed over a silica gel plug. The crude residue was analyzed by GC-MS and yields 
of cyclic species were calculated based on relative integration on the 1H NMR 
compared to an internal standard (naphthalene). Then, the product was purified by 
silica gel flash chromatography. 
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8.2.6 Spectral data of Chapter 3 
Trimethyl((phenylthio)(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)methyl)silane  
Flash column chromatography (hexane to 20:1 hexane : 
EtOAc) yielded 8a (612.1 mg, 94 %) as a white solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.32–7.29 (m, 2H), 7.24–7.19 (m, 
2H), 7.09–7.04 (m, 1H), 1.16 (s, 6H), 1.06 (s, 6H), 0.22 (s, 
9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 140.2, 128.6, 126.8, 
124.8, 83.9, 24.9, 24.8, -1.2. 11B NMR (128.3 MHz, CDCl3) δ 33.4. 29Si NMR (CDCl3, 
80 MHz) δ 3.0.HRMS (ESI) for C16H28BO2SSi [M+H]+: calculated: 323.1672, found: 
323.1680. 
Trimethyl((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)(p-tolylthio)methyl)silane 
Flash column chromatography (hexane to 20:1 hexane : 
EtOAc) yielded 8b (598.7mg, 89 %) as a white solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.21 (d, J = 8.0 Hz, 2H), 7.03 (d, 
J = 8.0 Hz, 2H), 2.27 (s, 3H), 2.18 (s, 1H), 1.15 (s, 6H), 1.07 
(s, 6H), 0.21 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 
136.3, 134.5, 129.1, 127.0, 83.6, 24.7, 24.6, 20.9, -1.4. 11B NMR (128.3 MHz, CDCl3) 
δ 34.3. 29Si NMR (CDCl3, 80 MHz) δ 2.8. HRMS (ESI) for C17H30BO2SSi [M+H]+: 
calculated: 337.1829, found: 337.1828. 
Trimethyl(1-(phenylthio)pentadecyl)silane 
Flash column chromatography (hexane) yielded 10a (25.5 mg, 
65% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 
7.38–7.33 (m, 2H), 7.29–7.23 (m, 2H), 7.17–7.12 (m, 1H), 2.47 
(dd, J = 6.9, 5.2 Hz, 1H), 1.77–1.54 (m, 2H), 1.50–1.36 (m, 2H), 
1.34–1.13 (m, 22H), 0.88 (t, J = 6.9 Hz, 3H), 0.13 (s, 9H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 138.6, 129.4, 128.8, 125.7, 34.4, 32.1, 31.9, 29.9, 29.8 
(3 x C), 29.7, 29.6, 29.5, 28.4, 22.9, 14.3, -1.9. 29Si NMR (CDCl3, 80 MHz) δ 4.0. 
Trimethyl(1-(p-tolylthio)pentadecyl)silane 
 Flash column chromatography (hexane) yielded 10b (27.6 
mg, 68% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) 
δ 7.29–7.24 (m, 2H), 7.10–7.05 (m, 2H), 2.39 (dd, J = 6.9, 5.2 
Hz, 1H), 2.31 (s, 3H), 1.74–1.53 (m, 2H), 1.49–1.36 (m, 2H), 
1.32–1.14 (m, 22H), 0.88 (t, J = 6.9 Hz, 3H), 0.12 (s, 9H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 135.8, 134.8, 130.2, 129.6, 35.2, 32.1, 31.8, 29.8 (4 x 
C), 29.6, 29.5, 28.4, 22.9, 21.2, 14.3, -1.9. 29Si NMR (CDCl3, 80 MHz) δ 3.8. HRMS 
(APCI) C25H47SSi [M+H]+: calculated: 407.3162, found: 407.3151. 
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Trimethyl(1-(phenylthio)pentyl)silane 
Flash column chromatography (hexane) yielded 12a (14.1 mg, 
56% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 
7.37–7.33 (m, 2H), 7.28–7.23 (m, 2H), 7.17–7.11 (m, 1H), 2.47 
(dd, J = 6.9, 5.2 Hz, 1H), 1.77–1.56 (m, 2H), 1.47–1.36 (m, 2H), 
1.28–1.19 (m, 2H), 0.83 (t, J = 7.3 Hz, 3H), 0.13 (s, 9H). 13C {1H} NMR (CDCl3, 100 
MHz) δ 138.6, 129.4, 128.8, 125.6, 34.3, 31.5, 30.6, 22.9, 14.1, -1.9. 29Si NMR 
(CDCl3, 80 MHz) δ 4.0. HRMS (EI) C14H24SSi [M]+: calculated: 252.1368, found: 
252.1368. 
Trimethyl(1-(p-tolylthio)pentyl)silane 
Flash column chromatography (hexane) yielded 12b (21.3 
mg, 80% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) 
δ 7.27 (d, J = 7.9 Hz, 2H), 7.07 (d, J = 7.9 Hz, 2H), 2.40 (dd, J = 
6.9, 5.2 Hz, 1H), 2.31 (s, 3H), 1.74–1.54 (m, 2H), 1.51–1.32 (m, 
2H), 1.30–1.17 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H), 0.12 (s, 9H). 
13C {1H} NMR (CDCl3, 100 MHz) δ 135.2, 134.2, 129.6, 129.1, 34.7, 31.0, 30.0, 22.4, 
20.6, 13.6, -2.3. 29Si NMR (CDCl3, 80 MHz) δ 3.3. HRMS (APCI) for C15H27SSi [M+H]+: 
calculated: 267.1594, found: 267.1597. 
(5-Fluoro-1-(p-tolylthio)pentyl)trimethylsilane 
Flash column chromatography (hexane) yielded 14 (17.3 
mg, 61% yield) as a colourless oil. 1H NMR (CDCl3, 400 
MHz) δ 7.27 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 7.9 Hz, 2H), 
4.47–4.25 (m, 2H), 2.40 (q, J = 5.1 Hz, 1H), 2.31 (s, 3H), 
1.77–1.61 (m, 2H), 1.42 (m, 2H), 1.39–1.27 (m, 2H), 0.13 
(s, 9H).13C {1H} NMR (CDCl3, 100 MHz) δ 135.8, 134.3, 130.1, 129.5, 83.9 (d, J = 164.3 
Hz), 35.1, 30.5, 30.4 (d, J = 19.5 Hz), 23.7 (d, J = 5.4 Hz), 21.0, -2.1. 19F NMR (CDCl3, 
377 MHz) δ -217.9 (m). 29Si NMR (CDCl3, 80 MHz) δ 3.4. HRMS (APCI) for C15H26FSSi 
[M+H]+: calculated: 285.1509, found: 285.1494. 
(5-Chloro-1-(p-tolylthio)pentyl)trimethylsilane 
Flash column chromatography (hexane) yielded 16 (26.1 
mg, 87 % yield) as a colourless oil. 1H NMR (CDCl3, 400 
MHz) δ 7.27 (dd, J = 8.3, 2.1 Hz, 2H), 7.13–7.04 (d, 2H), 
3.49–3.41 (m, 2H), 2.41 (t, J = 5.6 Hz, 1H), 2.32 (s, 3H), 
1.76–1.65 (m, 4H), 1.64–1.52 (m, 2H), 0.17–0.09 (s, 
9H).13C {1H} NMR (CDCl3, 100 MHz) δ 135.9, 134.2, 130.2, 129.5, 44.7, 35.0, 32.6, 
30.9, 25.3, 21.0, -2.1. 29Si NMR (CDCl3, 80 MHz) δ 3.9. HRMS (EI) for C15H25ClSSi [M]+: 
calculated: 300.1135, found: 300.1133. 
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Trimethyl(4-phenyl-1-(p-tolylthio)but-3-en-1-yl)silane 
Flash column chromatography (hexane) yielded 18 
(26.1 mg, 80% yield) as a colourless oil. 1H NMR (CDCl3, 
400 MHz) δ 7.32–7.28 (m, 2H), 7.27 (q, J = 1.6 Hz, 1H), 
7.26 –7.24 (m, 2H), 7.23 (t, J = 1.6 Hz, 1H), 7.21–7.15 (m, 
1H), 7.10–7.04 (m, 2H), 6.36 (d, J = 16.0 Hz, 1H), 6.28–
6.19 (m, 1H), 2.65-2.60 (m, 2H), 2.57–2.49 (m, 1H), 2.31 (s, 3H), 0.16 (s, 9H).13C {1H} 
NMR (CDCl3, 100 MHz) δ 137.9, 137.3, 134.7, 130.5, 130.2, 128.9, 128.3, 126.6, 
125.9, 25.4, 24.7, 21.0, -1.6. 29Si NMR (CDCl3, 80 MHz) δ 4.4. HRMS (EI) for C20H26SSi 
[M]+: calculated: 326.1525, found: 326.1513. 
Trimethyl(2-phenyl-1-(p-tolylthio)ethyl)silane 
Flash column chromatography (hexane) yielded 22 (23.7 
mg, 79% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) 
δ 7.25–7.08 (m, 7H), 7.02–6.97 (m, 2H), 3.06–2.82 (m, 2H), 
2.70–2.61 (m, 1H), 2.28 (s, 3H), 0.05–0.02 (m, 9H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 140.8, 135.9, 133.7, 130.6, 129.4, 
129.2, 128.0, 126.0, 38.0, 37.4, 20.9, -2.2. 29Si NMR (CDCl3, 80 MHz) δ 6.5. HRMS 
(APCI) for C18H25SSi [M+H]+: calculated: 301.1441, found: 301.1441. 
Trimethyl(1-(p-tolylthio)hex-3-yn-1-yl)silane 
Flash column chromatography (hexane) yielded 24 
(16.5 mg, 60% yield) as a colourless oil. 1H NMR (CDCl3, 
400 MHz) δ 7.32–7.28 (m, 2H), 7.09 (d, J = 7.9 Hz, 2H), 
2.64–2.38 (m, 3H), 2.31 (s, 3H), 2.22–2.06 (m, 2H), 1.09 
(t, J = 7.5 Hz, 3H), 0.22–0.19 (m, 9H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 136.2, 134.9, 130.5, 129.5, 34.57, 30.2, 21.4, 21.2, 14.4, 12.9, -
1.9. 29Si NMR (CDCl3, 80 MHz) δ 5.0. HRMS (EI) for C16H24SSi [M]+: calculated: 
276.1368, found: 276.1372. 
Trimethyl(1-(p-tolylthio)undec-10-en-1-yl)silane 
Flash column chromatography (hexane) 
yielded 26 (25.1 mg, 72% yield) as a 
colourless oil. 1H NMR (CDCl3, 400 MHz) 
δ 7.26 (dd, J = 4.3, 3.9 Hz, 2H), 7.07 (d, J = 
8.3 Hz, 2H), 5.81 (ddt, J = 16.9, 10.1, 6.7 
Hz, 1H), 5.06–4.95 (m, 1H), 4.95–4.88 (m, 1H), 2.39 (dd, J = 6.9, 5.1 Hz, 1H), 2.31 (s, 
3H), 2.02 (dd, J = 14.0, 6.6 Hz, 2H), 1.28–1.18 (m, 12H), 0.14–0.11 (m, 9H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 139.2, 135.6, 134.6, 130.0, 129.3, 114.0, 35.0, 33.8, 31.6, 
29.6, 29.4, 29.0, 28.8, 28.1, 22.6, 14.1, -2.0. 29Si NMR (CDCl3, 80 MHz) δ 3.8. HRMS 
(EI) for C18H25SSi [M]+: calculated: 348.2307, found: 348.2312. 
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Trimethyl(2-(oxiran-2-yl)-1-(p-tolylthio)ethyl)silane 
Flash column chromatography (hexane) yielded 28 (11.1 mg, 
42% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 
7.29–7.26 (m, 2H), 7.21 (d, J = 8.2 Hz, 2H), 7.09 (d, J = 7.9 Hz, 
2H), 7.03 (d, J = 7.8 Hz, 2H), 3.09 (m, 1H),2.68 (m, 1H), 2.65–
2.53 (m, 1H), 2.41 (dd, J = 5.0, 2.7 Hz, 1H), 2.31 (s, 3H), 2.27 
(s, 3H), 1.95–1.80 (m, 4H), 0.21 (s, 9H), 0.19 (d, J = 3.3 Hz, 9H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 136.1, 133.7, 130.0, 129.6, 129.1, 127.1, 50.8, 47.6, 34.5, 32.3, 31.4, 
30.9, 29.7, 24.7, 24.6, 21.0, -1.3, -2.2. 29Si NMR (CDCl3, 80 MHz) δ 4.4, 2.8. HRMS 
(EI) for C14H22OSSi [M]+: calculated: 266.1161, found: 266.1161. 
Trimethyl(2-methyl-1-(p-tolylthio)propyl)silane 
Flash column chromatography (hexane) yielded 30 (16.9 mg, 
67% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 7.27 
(q, J = 2.2 Hz, 2H), 7.05 (dd, J = 11.4, 3.5 Hz, 2H), 2.45 (d, J = 3.5 
Hz, 1H), 2.30 (s, 3H), 2.17–2.07 (m, 1H), 0.99 (dd, J = 6.8, 5.0 Hz, 
6H), 0.18–0.15 (m, 9H).13C {1H} NMR (CDCl3, 100 MHz) δ 136.0, 
135.4, 129.6, 129.4, 43.6, 31.2, 22.0, 20.9, -0.8. 29Si NMR (CDCl3, 
80 MHz) δ 2.4. HRMS (EI) for C14H24SSi [M]+: calculated: 252.1368, found: 252.1370. 
E-trimethyl(4-phenyl-1-(phenylthio)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)but-3-en-1-yl)silane 
Flash column chromatography (50:1 hexane : EtOAc) 
yielded 32a (61.3 mg, 70 % yield) as a colourless oil. 
1H NMR (CDCl3, 400 MHz) δ 7.58–7.53 (m, 2H), 7.31–
7.25 (m, 4H), 7.22–7.16 (m, 4H), 6.57–6.40 (m, 2H), 
2.89–2.72 (m, 2H), 1.19 (s, 6H), 1.17 (s, 6H), 0.20 (s, 
9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 138.0, 136.0, 
133.8, 130.8, 130.2, 128.5, 128.3, 127.0, 126.8, 126.1, 83.8, 37.2, 25.5, 24.9, -1.5. 
11B NMR (128.3 MHz, CDCl3) δ 33.9. 29Si NMR (CDCl3, 80 MHz) δ 6.1. HRMS (ESI) for 
C25H35BNaO2SSi [M+Na]+: calculated: 438.2334, found: 438.2336. 
E-trimethyl(4-phenyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)but-3-en-1-yl)silane 
Flash column chromatography (50:1 hexane : 
EtOAc) yielded 32b (66.0 mg, 73 % yield) as a 
colourless oil. 1H NMR (CDCl3, 400 MHz) δ 7.50–
7.46 (m, 2H), 7.31-7.26 (m, 4H), 7.22–7.15 (m, 1H), 
7.04–6.98 (m, 2H), 2.82–2.67 (m, 2H), 2.28 (s, 3H), 
1.20 (s, 6H), 1.19 (s, 6H), 0.18 (s, 9H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 138.0, 137.4, 134.9, 131.8, 130.7, 130.4, 129.1, 128.5, 126.8, 
126.0, 83.8, 37.3, 25.5, 24.9, 21.2, -1.5. 11B NMR (128.3 MHz, CDCl3) δ 33.9. 29Si NMR 
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(CDCl3, 80 MHz) δ 5.9. HRMS (ESI) for C26H37BNaO2SSi [M+Na]+: calculated: 
475.2270, found: 475.2274. 
Trimethyl(3-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)but-3-en-1-yl)silane 
Flash column chromatography (hexane to 500:1 hexane : 
EtOAc) yielded 33 (40.6 mg, 52% yield) as a yellow sticky 
oil. 1H NMR (CDCl3, 400 MHz) δ 7.51–7.45 (m, 2H), 7.01 
(d, J = 7.9 Hz, 2H), 5.01 (s, 1H), 4.87 (s, 1H), 2.64 (d, J = 14.9 
Hz, 1H), 2.49–2.33 (m, 1H), 2.30 (s, 3H), 1.73 (s, 3H), 1.23 
(s, 6H), 1.21 (s, 6H), 0.12–0.07 (m, 9H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 144.9, 137.3, 135.4, 131.2, 128.7, 114.0, 83.6, 40.2, 25.1, 24.0, 
21.1, -1.7. 11B NMR (CDCl3, 128.3 MHz) δ 33.2. 29Si NMR (CDCl3, 80 MHz) δ 6.1. 
HRMS (ESI) for C42H70B2NaO4S2Si2 [2M+Na]+: calculated: 803.4344, found: 
803.4338. 
Trimethyl(2-phenyl-1-(phenylthio)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)ethyl)silane 
Flash column chromatography (hexane to 500:1 hexane : 
EtOAc) yielded 34a (34.6 mg, 42% yield) as a colourless oil. 
1H NMR (CDCl3, 400 MHz) δ 7.53–7.49 (m, 3H), 7.22–7.12 
(m, 2H), 7.02–6.93 (m, 3H), 6.87–6.80 (m, 2H), 3.38 (d, J = 
13.6 Hz, 1H), 2.92 (d, J = 13.6 Hz, 1H), 1.18 (s, 6H), 1.09 (s, 
6H), 0.16 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 141.1, 
137.3, 131.2, 131.1, 127.8, 127.8, 126.3, 125.6, 83.9, 38.8, 25.4, 25.1, -1.9. 11B NMR 
(128.3 MHz, CDCl3) δ 32.8. 29Si NMR (CDCl3, 80 MHz) δ 6.2. HRMS (ESI) for 
C23H33BNaO2SSi [M+Na]+: calculated: 435.1961, found: 435.1957. 
Trimethyl(2-phenyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)ethyl)silane 
Flash column chromatography (hexane to 500:1 hexane 
: EtOAc) yielded 34b (31.5 mg, 37% yield) as a yellow 
sticky oil. 1H NMR (CDCl3, 400 MHz) δ 7.55–7.48 (m, 
2H), 7.27–7.14 (m, 4H), 6.84 (t, J = 3.6 Hz, 3H), 3.32 (d, 
J = 13.8 Hz, 1H), 2.94 (d, J = 13.8 Hz, 1H), 2.22 (s, 3H), 
1.17 (s, 6H), 1.10 (s, 6H), 0.13 (s, 9H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 141.0, 135.9, 132.8, 132,4, 131.0, 128.5, 126.0, 83.6, 38.5, 25.1, 
24.8, 20. -2.0. 11B NMR (CDCl3, 128.3 MHz) δ 33.8. 29Si NMR (CDCl3, 80 MHz) δ 5.88. 
HRMS (ESI) for C24H35BNaO2SSi [M+Na]+: calculated: 449.2117, found: 449.2119. 
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Trimethyl(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-tolylthio)undec-
10-en-1-yl)silane 
Flash column chromatography (hexane 
to 500:1 hexane : EtOAc) yielded 36 
(28.4 mg, 30% yield) as a colourless oil. 
1H NMR (CDCl3, 400 MHz) δ 7.40 (d, J = 
8.1 Hz, 2H), 7.03 (d, J = 7.9 Hz, 2H), 5.82 
(ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.04–
4.96 (m, 1H), 4.95–4.90 (m, 1H), 2.30 (s, 3H), 2.04 (dd, J = 14.5, 6.9 Hz, 2H), 1.87–
1.65 (m, 2H), 1.39–1.31 (m, 2H), 1.27–1.22 (m,10H), 1.19 (s, 12H), 0.10 (s, 9H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 139.2, 137.2, 134.4, 132.2, 128.9, 114.0, 83.5, 33.8, 
32.9, 30.3, 29.5, 29.4, 29.1, 28.9, 27.4, 25.2, 24.8, 21.1, -1.4. 11B NMR (CDCl3, 128.3 
MHz) δ 30.6. 29Si NMR (CDCl3, 80 MHz) δ 5.8. HRMS (ESI) for C54H94B2NaO4S2Si2 
[2M+Na]+: calculated: 971.6215, found: 971.6220. 
Trimethyl(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)nonadecyl)silane 
Flash column chromatography (hexane to 500:1 hexane 
: EtOAc) yielded 37 (43.4 mg, 36% yield) as a colourless 
oil. 1H NMR (CDCl3, 400 MHz) δ 7.43–7.38 (m, 2H), 7.06–
7.01 (m, 2H), 2.29 (d, J = 10.0 Hz, 3H), 1.64–1.52 (m, 2H), 
1.25 (s, 32H), 1.19 (s, 12H), 0.88 (t, J = 6.9 Hz, 3H), 0.10 
(s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 137.0, 134.4, 
132.1, 128.9, 83.5, 32.9, 31.9, 30.3, 29.7, 29.6, 29.3, 27.4, 25.2, 24.8, 22.6, 21.1, 14.1, 
-1.4. 11B NMR (CDCl3, 128.3 MHz) δ 35.0. 29Si NMR (CDCl3, 80 MHz) δ 4.9. HRMS 
(ESI) for C35H65BNaO2SSi [M+Na]+: calculated: 611.4483, found: 611.4465. 
Trimethyl(2-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)propyl)silane 
Flash column chromatography (hexane to 500:1 hexane : 
EtOAc) yielded 38 (32.5 mg, 43% yield) as a colourless oil. 1H 
NMR (CDCl3, 400 MHz) δ 7.59–7.51 (m, 2H), 7.01 (d, J = 7.9 Hz, 
2H), 2.30 (s, 3H), 1.25 (m, 1H), 1.21 (d, J = 6.8 Hz, 3H), 1.20 (s, 
6H), 1.17 (s, 6H), 1.04 (d, J = 6.8 Hz, 3H), 0.17 (s, 9H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 137.1, 135.5, 132.7, 128.6, 83.3, 
32.6, 25.1, 25.0, 22.9, 21.1, 21.0, 0.3. 11B NMR (CDCl3, 128.3 MHz) δ 33.6. 29Si NMR 
(CDCl3, 80 MHz) δ 4.0. HRMS (ESI) for C20H35BNaO2SSi [M+Na]+: calculated: 
401.2127, found: 401.2117. 
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(5-bromo-1-(phenylthio)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)pentyl)trimethylsilane 
Flash column chromatography (hexane to 500:1 
hexane : EtOAc) yielded 40a (58.5 mg, 64% yield) as a 
pale yellow sticky oil. 1H NMR (CDCl3, 400 MHz) δ 7.49 
(m, 2H), 7.21 (m, 3H), 3.39 (t, J = 6.7 Hz, 2H), 2.01–
1.63 (m, 6H), 1.18 (s, 6H), 1.17 (s, 6H), 0.14 (s, 9H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 136.1, 133.4, 128.2, 
126.9, 83.7, 34.3, 32.1, 28.6, 25.3, 24.8, 7.2, -1.5. 11B NMR (CDCl3, 128.3 MHz) δ 33.9. 
29Si NMR (CDCl3, 80 MHz) δ 5.4. HRMS (APCI) for C20H35BBrO2SSi [M+H]+: calculated: 
457.1402, found: 457.1399. 
(5-bromo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)pentyl)trimethylsilane 
Flash column chromatography (hexane to 500:1 
hexane : EtOAc) yielded 40b (61.2 mg, 65% yield) 
as a pale yellow sticky oil. 1H NMR (CDCl3, 400 
MHz) δ 7.41 (dd, J = 8.4, 1.9 Hz, 2H), 7.05 (t, J = 9.3 
Hz, 2H), 3.40 (t, J = 6.8 Hz, 2H), 2.30 (s, 3H), 1.91–
1.64 (m, 6H), 1.19 (s, 6H), 1.18 (s, 6H), 0.12 (s, 9H). 
13C {1H} NMR (CDCl3, 100 MHz) δ 137.2, 134.4, 131.7, 129.0, 83.6, 33.5, 33.5, 32.1, 
26.1, 25.2, 24.7, 21.0, -1.5. 11B NMR (CDCl3, 128.3 MHz) δ 34.4. 29Si NMR (CDCl3, 80 
MHz) δ 5.2. HRMS (APCI) for C21H37BBrO2SSi [M+H]+: calculated: 471.1559, found: 
471.1559. 
(6-bromo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)hexyl)trimethylsilane 
Flash column chromatography (hexane to 500:1 
hexane : EtOAc) yielded 42 (69.8 mg, 72% yield) 
as a yellow sticky oil. 1H NMR (CDCl3, 400 MHz) 
δ 7.40 (d, J = 7.6 Hz, 2H), 7.04 (d, J = 7.6 Hz, 2H), 
3.39 (t, J = 6.9 Hz, 2H), 2.30 (s, 3H), 1.94–1.52 
(m, 6H), 1.48–1.36 (m, 2H), 1.19 (s, 6H), 1.18 (s, 
6H), 0.16 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 137.1, 134.3, 131.8, 128.9, 83.5, 
33.9, 32.7, 32.6, 28.6, 26.4, 25.2, 24.7, 21.1, -1.5. 11B NMR (CDCl3, 128.3 MHz) δ 34.3. 
29Si NMR (CDCl3, 80 MHz) δ 5.1. HRMS (APCI) for C22H39BBrO2SSi [M+H]+: calculated: 
485.1715, found: 485.1714. 
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5-iodo-1-(phenylthio)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)pentyl)trimethylsilane  
Flash column chromatography (hexane to 500:1 hexane 
: EtOAc) yielded 44a (67.5 mg, 67% yield) as a yellow 
sticky oil. 1H NMR (CDCl3, 400 MHz) δ 7.49 (m, 2H), 
7.25–7.17 (m, 3H), 3.18 (t, J = 7.0 Hz, 2H), 1.93–1.68 (m, 
6H), 1.19 (s, 6H), 1.18 (s, 6H), 0.14 (s, 9H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 136.1, 133.4, 128.2, 126.9, 83.7, 
34.3, 32.1, 28.6, 25.3, 24.8, 7.2, -1.5. 11B NMR (CDCl3, 128.3 MHz) δ 34.6. 29Si NMR 
(CDCl3, 80 MHz) δ 5.5. HRMS (ESI) for C20H34BINaO2SSi [M+Na]+: calculated: 
527.1084, found: 527.1087. 
(5-iodo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)pentyl)trimethylsilane 
Flash column chromatography (hexane to 500:1 
hexane : EtOAc) yielded 44b (64.2 mg, 62% yield) as 
a yellow sticky oil. 1H NMR (CDCl3, 400 MHz) δ 7.41 
(d, J = 8.1 Hz, 2H), 7.04 (d, J = 8.3 Hz, 2H), 3.18 (t, J = 
7.0 Hz, 2H), 2.30 (s, 3H), 1.88–1.62 (m, 6H), 1.19 (s, 
6H), 1.18 (s, 6H), 0.12 (s, 9H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 137.2, 134.4, 131.7, 128.9, 83.5, 34.2, 31.9, 28.5, 25.2, 24.7, 21.0, 7.2, -
1.5. 11B NMR (CDCl3, 128.3 MHz) δ 34.8. 29Si NMR (CDCl3, 80 MHz) δ 5.1. HRMS 
(APCI) for C21H37BIO2SSi [M+H]+: calculated: 519.1420, found: 519.1416. 
(6-iodo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-
tolylthio)hexyl)trimethylsilane 
Flash column chromatography (hexane to 500:1 
hexane : EtOAc) yielded 46 (75.6 mg, 71% yield) 
as a yellow sticky oil. 1H NMR (CDCl3, 400 MHz) δ 
7.40 (d, J = 8.1 Hz, 2H), 7.04 (d, J = 7.9 Hz, 2H), 
3.17 (t, J = 7.1 Hz, 2H), 2.30 (s, 3H), 1.87–1.51 (m, 
6H), 1.44–1.32 (m, 2H), 1.19 (s, 6H), 1.18 (s, 6H), 
0.15–0.07 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 137.1, 134.3, 131.9, 128.9, 83.5, 
33.3, 32.7, 31.0, 26.2, 25.2, 24.78, 21.09, 7.33, -1.55. 11B NMR (CDCl3, 128.3 MHz) δ 
34.4. 29Si NMR (CDCl3, 80 MHz) δ 5.1. HRMS (APCI) for C22H39BIO2SSi [M+H]+: 
calculated: 533.1577, found: 533.1579. 
Trimethyl(1-(phenylthio)cyclopentyl)silane 
Flash column chromatography (hexane) yielded 47 (29.0 mg, 58% 
yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 7.58–7.54 
(m, 2H), 7.34–7.30 (m, 2H), 7.29–7.26 (m, 1H), 1.90–1.81 (m, 4H), 
1.59–1.44 (m, 4H), 0.04 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 
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137.1, 134.0, 128.4, 128.3, 45.7, 35.8, 25.8, -2.8. 29Si NMR (CDCl3, 80 MHz) δ 6.7. 
HRMS (APCI) for C14H23SSi [M+H]+: calculated: 251.1284, found: 251.1284. 
Trimethyl(1-(p-tolylthio)cyclohexyl)silane 
Flash column chromatography (hexane) yielded 49 (36.2 mg, 
65% yield) as a colourless oil.1H NMR (CDCl3, 400 MHz) δ 7.41 (d, 
J = 8.0 Hz, 2H), 7.06 (d, J = 8.0 Hz, 2H), 2.33 (s, 3H), 2.06–1.89 (m, 
2H), 1.73-1.66 (m, 4H), 1.48–1.42 (m, 2H), 1.29 (m, 2H), -0.10 (s, 
9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 138.2, 136.9, 130.1, 129.1, 
41.9, 31.4, 26.2, 21.2, 21.1, -2.8. 29Si NMR (CDCl3, 80 MHz) δ 6.7. 
HRMS (APCI) for C16H27SSi [M+H]+: calculated: 279.1597, found: 279.1600. 
4,4,5,5-tetramethyl-2-(1-(phenylthio)cyclopentyl)-1,3,2-dioxaborolane 
Flash column chromatography (hexane to 200:1 hexane : EtOAc) 
yielded 52 (15.2 mg, 25% yield) as a colourless oil. 1H NMR 
(CDCl3, 400 MHz) δ 7.45 (m, 2H), 7.26–7.21 (m, 2H), 7.19 (m, 1H), 
2.16–2.04 (m, 2H), 1.90–1.75 (m, 4H), 1.62 (m, 2H), 1.15 (s, 12H). 
13C {1H} NMR (CDCl3, 100 MHz) δ 136.2, 131.9, 128.3, 126.4, 
83.8, 36.4, 29.6, 24.8, 24.5. 11B NMR (CDCl3, 128.3 MHz) δ 33.8. 
HRMS (EI) for C17H25BO2S [M]+: calculated: 304.1668, found: 304.1667.  
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8.3. Experimental procedures and spectral data of Chapter 4 
8.3.1 General procedure for the protection of amines with sulphonyl 
chloride derivatives[2] 
N,N-diisopropyletilamina (DIPEA, 2 equiv, 20 mmol) and the arenesulphonyl 
chloride derivative (1 equiv, 10 mmol) were added to a solution of methyl 
piperidine-4-carboxylate (1 equiv, 10 mmol) in dry dichlorometane (0.14 M) at room 
temperature. The mixture was stirred for 4-16 hours until complete consumption of 
the corresponding arenesulphonyl chloride. The organic phase was washed with 
10% of NaHCO3. The aqueous phase was extracted with ethyl acetate. The organic 
extracts were combined, washed with H2O and sat. NaCl, dried (MgSO4), filtered and 
the solvent was gently concentrated on a rotary evaporator. The crude product was 
purified by flash column chromatography. 
8.3.2 General procedure for the alkylation reaction with different alkyl 
bromides[3] 
To a 0 °C solution of iPr2NH (1.5 equiv, 15 mmol) in THF (15 mL), was added a hexane 
solution of nBuLi 2.0 M (1.1 equiv, 11 mmol) dropwise. The reaction mixture was 
stirred for 20 minutes and then cooled to -78 °C. The corresponding ester (1 equiv, 
10 mmol) was added dropwise and the reaction mixture was stirred for 1 h at -78 
°C. The corresponding alkyl halide (1.5 equiv, 15 mmol, for n=1, allyl bromide; n=2, 
4-bromobut-1-ene; n=3, 5-bromo-1-pentene) was then added dropwise into the 
reaction mixture. The reaction mixture was then warmed naturally to room 
temperature and stirred until consumption of the starting sulphonamide. The 
reaction mixture was quenched by addition of saturated NH4Cl aq. and extracted 
with Et2O three times. The combined organic layers were then dried (MgSO4) filtered 
and concentrated under reduced pressure. The crude product was purified by flash 
column chromatography. 
8.3.3 General procedure for the reduction of the ester to alcohols[4] 
To a slurry of LiAlH4 (1.5 equiv, 12 mmol) in Et2O (0.9 M) was added a solution of the 
methyl ester (1 equiv, 8 mmol) in Et2O (1 M) dropwise at 0 °C. The mixture was 
stirred for 2 h (or until consumption of the substrate). Reaction was then quenched 
by addition of EtOH dropwise after no observation of bubbles. Further water was 
added and the combination was stirred until a white solid was formed. The mixture 
was then filtered and extracted with EtOAc. The organic layer was separated, dried 
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(MgSO4), filtered and concentrated under reduced pressure to obtain the alcohol 
without need of further purification for the next reaction. 
8.3.4 General procedure for the bromination reaction of alcohols[5] 
In a nitrogen round-bottom flask, CBr4 (1.1 equiv, 7.7 mmol) and the homoallylic 
alcohol (1 equiv, 7 mmol) were dissolved in dry THF (4 M). The reaction mixture was 
cooled to 0 °C. PPh3 (1.1 equiv, 7.7 mmol) was then added portion wise and the 
reaction mixture was stirred for 16 h. The reaction mixture was quenched by 
addition of water and extracted three times with Et2O. The combined organic layers 
were dried (MgSO4), filtered and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography. 
8.3.5 General procedure for the iodination reaction of alcohols[6] 
To a solution of triphenylphosphine (1.05 equiv, 7.35 mmol) and imidazole (1.05 
equiv, 7.35 mmol) in toluene (0.1 M) was added iodine (1.05 equiv, 7.35 mmol) and 
stirred for 30 minutes at room temperature. The homoallylic alcohol (1 equiv, 7 
mmol) was then added, and the reaction mixture was heated to 80 °C and stirred 
for 16 h. The solution was then quenched with H2O, extracted with Et2O for three 
times and washed with sat. Na2S2O3. The organic extracts were then dried (MgSO4), 
filtered and concentrated. The crude product was purified by flash chromatography. 
8.3.6 General procedure for the borylative cyclization catalyzed by 
copper (I) complex 
Copper chloride (5 mol%, 0.01 mmol), bis(pinacolato)diboron (1.2 equiv, 0.24 mmol) 
and Xantphos (5 mol%, 0.01 mmol) were placed in an oven-dried resalable Teflon 
screw-cap Schlenk reaction tube. The Schlenk tube was connected to a 
vacuum/nitrogen manifold evacuated and backfilled with nitrogen. Then THF (0.24 
ml, 1 M). KOtBu (1.2 equiv, 0.24 mmol) in THF (0.24 ml, 1 M) were added in the vial 
through the rubber septum. Then alkenyl halide (1 equiv, 0.2 mmol) in THF (0.2 ml, 
1 M) was added dropwise at 30 °C. After the reaction was complete, the reaction 
mixture was filtered over celite. The organic extracts were then concentrated in 
vacuo. The crude product was purified by flash chromatography. 
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8.3.7 General procedure for the oxidation of the spiro-boronates 
products[7] 
The oxidation was performed in a reaction vial, NaBO3·H2O (10 equiv, 2 mmol) was 
dissolved in THF/H2O (3:2, 0.2 M) and the boronate (1 equiv, 0.2 mmol) was then 
added at room temperature. After stirred for 1.5 h, the reaction mixture was 
extracted three times with EtOAc, dried (MgSO4), filtered and concentrated in 
vacuo. The crude mixture was further purified by flash column chromatography. 
8.3.8 Procedure used of the selective oxidation of the spiro-cyclic 
alcohol to aldehyde[8] 
To a solution of alcohol (1 equiv, 5 mmol) in CH2Cl2 (0.3 M) was added DMP (2.120 
g, 1 equiv, 5 mmol) at 0 °C. After being stirred at room temperature for 1 h, the 
mixture was filtered through celite. The crude was evaporated in vacuo and was 
further purified by flash column chromatography. 
8.3.9 Procedure used fot the spiro-olefination by reaction with gem-
bis(boryl)silylmethane reagent[9] 
An oven dried resealable Schlenk tube equipped with a stirring bar was charged with 
(bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)trimethylsilane (1.2 equiv, 
3.72 mmol) and THF (0.9 M) under Argon. The mixture was then cooled to 0 °C and 
lithium 2,2,6,6-tetramethylpiperidide (1.4 equiv, in a 0.4 M solution in THF) was 
added dropwise. After 5 min., the aldehyde (1 equiv, 3.1 mmol) was added and the 
reaction was allowed to warm to r.t. Reaction mixture was analyzed by TLC. After 
substrate completion the crude was filtered through a small pad of silica gel 
followed by a copious washing and concentrated in vacuo. The crude mixture was 
further purified by flash column chromatography. 
8.3.10 Procedure used for the Suzuki-Miyaura coupling reaction[10] 
An oven-dried resealable Schlenk tube equipped with a stirring bar was charged 
with Pd(PPh3)4 (3 mol%) and 1,4-dioxane (0.7 mL). To this solution the gem-
bismetallated alkene (0.251 g, 1 equiv, 0.5 mmol), dissolved in 0.6 mL of 1,4-
dioxane, 1-iodo-4-methylbenzene (3 equiv, 1.5 mmol) and a 3 M KOH solution (6 
equiv, 3 mmol) were added in sequence and the reaction was heated up at 90 °C for 
16 h. After completion (by TLC), the mixture was cooled to room temperature and 
diluted with DCM. The mixture was filtered through a small pad of celite and 
anhydrous MgSO4. Afterwards the solvent was concentrated in vacuo. The resulting 
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crude product was purified by column chromatography to give a coupled 
compound. 
8.3.11 Procedure used for the oxidation of the alcohol to the carboxylic 
acid[11] 
The alcohol (1 equiv, 5 mmol) was subjected to the oxidation reaction using Jones 
reagent (2 M, 0.7 equiv) in acetone (0.2 M) and H2O (2.5 M) at 0 °C. After 1 h, the 
reaction was quenched by saturated aqueous NH4Cl, extracted three times with 
Et2O. The combined organic layers were washed with aqueous NaOH (0.1 M) and 
then aqueous layer was acidified with saturated aqueous NH4Cl, extracted six times 
with Et2O. The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to obtain the corresponding carboxylic acid as a white solid. 
8.3.12 Procedure used for the esterification of the spirocyclic acid to the 
ester[12] 
The carboxylic acid (1 equiv, 3.8 mmol) was treated with a solution of concentrated 
sulphuric acid (30 µL/mmol) in methanol (0.5 M) and refluxed for one hour. The 
solution was cooled to room temperature and concentrated in vacuo. Et2O was 
added and the organic layer was washed with NaHCO3 (5% aq.) followed by brine. 
The organic layer was separated, dried (MgSO4), filtered and concentrated in vacuo, 
without need of further purification (quantitative reaction). 
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8.3.13 Spectral data of Chapter 4 
Methyl 1-(phenylsulfonyl)piperidine-4-carboxylate  
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 
Hexane:EtOAc) yielded 57 (85% yield) as a white solid. 1H NMR (CDCl3, 
400 MHz) δ 7.75 (m, 2H), 7.59 (m, 1H), 7.53 (m, 2H), 3.65 (s, 3H), 3.63 
(m, 2H), 2.46 (m, 2H), 2.26 (m, 1H), 1.97 (m, 2H), 1.81 (m, 2H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 174.2, 136.0, 132.7, 129.0, 127.5, 51.8, 45.3, 
39.8, 27.3. HRMS (ESI) for C13H17NNaO4S [M+Na]+: calculated: 
306.0769, found: 306.0770. 
Ethyl 1-(phenylsulfonyl)piperidine-3-carboxylate 
Flash column chromatography (5:1 Hexane:EtOAc) yielded 58 (88% 
yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.59 (d, J = 8.3 Hz, 
2H), 7.28 (d, J = 8.3 Hz, 2H), 4.08 (q, J = 7.1 Hz, 2H), 3.79 (m, 1H), 3.55 
(apparent d, 1H), 2.56 (m, 1H), 2.47 (m, 1H), 2.38 (s, 3H), 2.38 (m, 1H), 
1.90 (m, 1H), 1.75 (m, 1H), 1.64 – 1.51 (m, 1H), 1.36 (m, 1H), 1.20 (t, J = 
7.1 Hz, 3H). 13C {1H} NMR (CDCl3, 100 MHz) δ 172.5, 143.4, 132.7, 129.5, 
127.4, 60.6, 47.5, 4.13, 40.8, 26.2, 23.7, 21.3, 13.9. HRMS (ESI) for C15H21NNaO4S 
[M+Na]+: calculated: 334.1081, found: 334.1083. 
Methyl 4-allyltetrahydro-2H-pyran-4-carboxylate 
Flash column chromatography (20:1 Hexane:EtOAc) yielded 61 
(90% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 5.63 
(ddt, J = 16.8, 10.2, 6.5 Hz, 1H), 5.08 – 4.94 (m, 2H), 3.74 
(apparent dt, 2H), 3.67 (s, 3H), 3.40 (m, 2H), 2.20 (dd, J = 7.4, 1.0 
Hz, 2H), 2.02 - 1.94 (m, 2H), 1.52 (m, 2H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 175.5, 132.5, 118.2, 65.2, 51.6, 45.1, 44.7, 33.7. 
HRMS (ESI) for C10H16O3 [M]+ : calculated: 184.1102, found: 
184.1099. 
Methyl 4-(but-3-en-1-yl)tetrahydro-2H-pyran-4-carboxylate 
Flash column chromatography (20:1 Hexane:EtOAc) yielded 
62 (75% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 
5.74 (ddt, J = 16.8, 10.2, 6.5 Hz, 1H), 4.97 – 4.80 (m, 2H), 3.82 
(apparent dt, 2H), 3.71 (s, 3H), 3.42 (m, 2H), 2.15 (m, , 2H), 
1.98 – 1.90 (m, 2H), 1.67 – 1.57 (m, 2H), 1.50 (m, 2H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 176.0, 137.8, 114.8, 65.4, 51.8, 44.8, 
39.9, 34.2, 28.0. HRMS (ESI) for C11H18O3 [M]+: calculated: 
198.1255, found: 198.1256. 
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Methyl 4-(pent-4-en-1-yl)tetrahydro-2H-pyran-4-carboxylate  
Flash column chromatography (20:1 Hexane:EtOAc) yielded 
63 (68% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 
5.76 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.02 – 4.91 (m, 2H), 3.81 
(apparent dt, 2H), 3.71 (s, 3H), 3.40 (m, , 2H), 2.10 (m, 2H), 
1.99 – 1.90 (m, 2H), 1.57 – 1.41 (m, 4H), 1.27 (m, 2H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 176.2, 138.2, 114.8, 65.4, 51.7, 44.9, 
40.2, 34.2, 33.8, 22.9. HRMS (ESI) for C12H20O3 [M]+ : 
calculated: 212.1410, found: 212.1412. 
 
Methyl 2-allyltetrahydrofuran-2-carboxylate  
Flash column chromatography (20:1 Hexane:EtOAc) yielded 64 
(60% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 5.79 
(ddt, J = 24.0, 10.5, 7.2 Hz, 1H), 5.12 – 5.08 (m, 2H), 3.95 (m, 2H), 
3.72 (s, 3H), 2.62 (m, 1H), 2.46 (m, 1H), 1.90 (m, 4H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 175.2, 137.8, 114.6, 85.9, 68.9, 52.1, 37.3, 
35.5, 28.6, 25.3. HRMS (ESI) for C9H14O3 [M]+ : calculated: 
170.0944, found: 170.0943. 
Methyl 2-(but-3-en-1-yl)tetrahydrofuran-2-carboxylate  
Flash column chromatography (20:1 Hexane:EtOAc) yielded 
65 (20% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 
5.76 (ddt, J = 24.0, 10.5, 7.2 Hz, 1H), 5.03 – 4.85 (m, 2H), 4.02 
– 3.85 (m, 2H), 3.72 – 3.67 (m, 3H), 2.29 – 2.20 (m, 1H), 2.20 – 
2.11 (m, 1H), 2.01 – 1.92 (m, 2H), 1.88 – 1.81 (m, 2H), 1.78 – 
1.62 (m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ175.2, 137.8, 
114.6, 85.9, 68.9, 52.1, 37.3, 35.5, 28.6, 25.3. HRMS (ESI) for C10H16O3 [M]+: 
calculated: 184.1099, found: 184.1012. 
Methyl 4-allyl-1-tosylpiperidine-4-carboxylate 
Flash column chromatography (100:0 to 60:40 pentane: EtOAc) 
yielded 66 (85% yield) as white solid. The 1H NMR chemical shift of 
product 66 is the same that the one reported in the literature.[13]  
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Methyl 4-(but-3-en-1-yl)-1-(phenylsulfonyl)piperidine-4-carboxylate  
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 
Hexane: EtOAc) yielded 67 (83% yield) as a white solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.73 (dd, J = 8.4, 1.3 Hz, 2H), 7.58 (t, 
J = 8.4 Hz, 1H), 7.56 – 7.49 (m, 2H), 5.70 (m, 1H), 5.02 – 4.90 
(m, 2H), 3.63 (m, 2H), 3.58 (s, 3H), 2.36 (m, 2H), 2.21 (apparent 
d, 2H), 1.89 (m, 2H), 1.57 (m, 4H). 13C {1H}MR (CDCl3, 100 MHz) 
δ 175.2, 137.4, 136.2, 132.7, 129.0, 127.5, 115.0, 51.8, 44.9, 
43.8, 39.5, 32.9, 28.2. HRMS (ESI) for C17H24NO4S [M+H]+: calculated:338.1420, 
found: 338.1421. 
Methyl 4-(pent-4-en-1-yl)-1-(phenylsulfonyl)piperidine-4-carboxylate 
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 
Hexane: EtOAc) yielded 68 (84% yield) as a white solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.77 – 7.69 (m, 2H), 7.63 – 7.56 (m, 
1H), 7.55 – 7.48 (m, 2H), 5.71 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 
5.00 – 4.91 (m, 2H), 3.61 (ddd, J = 9.7, 6.4, 3.2 Hz, 2H), 3.57 
(s, 3H), 2.36 (m, 2H), 2.19 (apparent d, 2H), 1.97 (m, 2H), 1.53 
(m, 1H), 1.47 (ddd, J = 9.6, 7.9, 4.2 Hz, 2H), 1.30 – 1.17 (m, 
3H). 13C {1H} NMR (CDCl3, 100 MHz) δ 175.4, 137.9, 136.2, 
132.7, 129.0, 127.5, 115.0, 51.8, 45.0, 43.9, 39.8, 33.7, 32.9, 23.1. HRMS (ESI) for 
C18H26NO4S [M+H]+: calculated:352.1576, found: 352.1577. 
Ethyl 3-allyl-1-(phenylsulfonyl)piperidine-3-carboxylate 
Flash column chromatography (5:1 Hexane:EtOAc) yielded 69 (35% 
yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.61 (d, J = 7.9, 
2H), 7.28 (d, J = 7.9 Hz, 2H), 5.62 (m, 1H), 5.01 (m, 2H), 4.11 (m, 
2H), 3.39 (d, J = 11.5 Hz, 1H), 3.02 (m, 1H), 2.65 (m, 2H), 2.39 (s, 
3H), 2.19 (m, 1H), 1.86 (m, 1H), 1.68 (m, 2H), 1.32 (m, 2H), 1.24 (t, 
J = 7.1 Hz, 3H). 13C {1H} NMR (CDCl3, 100 MHz) δ 173.5, 143.3, 
132.9, 132.0, 129.5, 127.4, 118.7, 60.7, 51.7, 46.4, 46.0, 40.0, 30.4, 
21.5, 21.4, 14.1. HRMS (ESI) for C18H25NNaO4S [M+Na]+: calculated: 374.1394, 
found: 374.1397. 
Ethyl 3-allyl-1-(phenylsulfonyl)pyrrolidine-3-carboxylate 
Flash column chromatography (5:1 Hexane:EtOAc) yielded 70 
(40% yield) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.79 
(m, 2H), 7.58 (m, 1H), 7.50 (m, 2H), 5.54 (m, 1H), 5.01 (m, 1H), 
4.94 (m, 1H), 3.95 (m, 2H), 3.59 (d, J = 10.4 Hz, 1H), 3.35 (m, 1H), 
3.20 (m, 2H), 2.24 (m, 3H), 1.74 (m, 1H), 1.11 (t, J = 7.1 Hz, 3H). 
13C {1H} NMR (CDCl3, 100 MHz) δ 173.3, 136.4, 132.6, 132.3, 
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128.9, 127.3, 118.8, 61.0, 54.3, 52.8, 46.6, 40.4, 33.2, 13.9. HRMS (ESI) for 
C16H21NNaO4S [M+Na]+: calculated: 346.1086, found: 346.1083. 
Methyl 2-allyl-4-benzylmorpholine-2-carboxylate 
Flash column chromatography (5:1 Hexane:EtOAc) yielded 71 
(22% yield) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.28 (m, 
5H), 5.77 (ddt, J = 17.3, 10.3, 7.3 Hz, 1H), 5.04 (m, 2H), 4.03 (m, 
1H), 3.80 (m, 1H), 3.73 (s, 3H), 3.53 (d, J =13.3 Hz, 1H), 3.42 (d, 
13.3 Hz, 1H), 3.15 (dd, J = 11.3, 1.6 Hz, 1H), 2.60 (m, 1H), 2.39 (qd, 
J = 14.1, 7.3 Hz, 2H), 2.25 (apparent td, 1H), 2.06 (d, J = 11.3 Hz, 
1H). 13C {1H} NMR (CDCl3, 100 MHz) δ 172.7, 137.5, 131.7, 128.8, 
128.1, 127.1, 118.5, 79.7, 63.8, 62.6, 58.9, 52.7, 51.8, 41.6. HRMS (ESI) for C16H22NO3 
[M+H]+: calculated: 276.1595, found: 276.1594. 
4-Allyl-4-(bromomethyl)tetrahydro-2H-pyran  
Flash column chromatography (20:1 Hexane:EtOAc) yielded 72 (85% 
yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 5.72 (ddt, J = 16.9, 
10.3, 7.6 Hz, 1H), 5.16 (m, 2H), 3.70 – 3.60 (m, 4H), 3.39 (s, 2H), 2.27 
(d, J = 7.6 Hz, 2H), 1.55 (m, 4H). 13C {1H} NMR (CDCl3, 100 MHz) δ 
132.4, 119.2, 63.4, 42.3, 39.2, 34.8, 34.0. 
 
4-(Bromomethyl)-4-(but-3-en-1-yl)tetrahydro-2H-pyran  
Flash column chromatography (20:1 Hexane:EtOAc) yielded 73 
(83% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 5.82 (ddt, 
J = 16.8, 10.1, 6.5 Hz, 1H), 5.06 – 4.96 (ddd, J = 13.7, 12.2, 2.0 Hz, 
2H), 3.66 (m, 4H), 3.27 (s, 2H), 2.01 – 1.97 (m, 2H), 1.64 – 1.48 (m, 
6H). 13C {1H} NMR (CDCl3, 100 MHz) δ 138.2, 114.8, 63.7, 36.4, 35.2, 
33.2, 26.8, 19.8. 
4-(But-3-en-1-yl)-4-(iodomethyl)tetrahydro-2H-pyran 
Flash column chromatography (20:1 Hexane:EtOAc) yielded 74 
(89% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 5.82 (ddt, 
J = 16.8, 10.1, 6.5 Hz, 1H), 5.01 (ddd, J = 13.6, 11.5, 1.6 Hz, 2H), 3.63 
(m, 4H), 3.27 (s, 2H), 1.95 (m, 2H), 1.60 (m, 4H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 138.1, 114.8, 65.8, 63.6, 36.4, 35.2, 33.2, 26.8, 
19.7. HRMS (ESI) for C10H17IO [M+H]+: calculated: 281.0402, found: 
281.0395. 
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4-(Bromomethyl)-4-(pent-4-en-1-yl)-1-(phenylsulfonyl)piperidine  
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 
Hexane: EtOAc) yielded 75 (87% yield) as a colorless oil. 1H 
NMR (CDCl3, 400 MHz) δ 7.81 – 7.72 (m, 2H), 7.61 (m, 1H), 
7.54 (ddd, J = 8.4, 2.3, 0.9 Hz, 2H), 5.71 (ddt, J = 16.9, 10.2, 6.6 
Hz, 1H), 4.99 – 4.87 (m, 2H), 3.22 (s, 2H), 3.07 – 2.91 (m, 4H), 
1.98 (m, 2H), 1.60 (m, 4H), 1.33 – 1.16 (m, 4H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 138.0, 135.9, 132.7, 128.9, 127.4, 114.8, 
53.4, 41.7, 41.0, 34.3, 33.7, 32.8, 32.5, 30.79, 21.4. HRMS (ESI) 
for C17H25BrNO2S [M+H]+: calculated: 386.0786, found: 386.0784. 
4-(Iodomethyl)-4-(pent-4-en-1-yl)tetrahydro-2H-pyran 
Flash column chromatography (20:1 Hexane:EtOAc) yielded 76 
(92% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 5.81 
(ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.00 (ddd, J = 13.6, 12.2, 2.0 Hz, 
2H). 3.67 – 3.56 (m, 4H), 3.26 (s, 2H), 2.14 – 2.00 (m, 2H), 1.62 – 
1.49 (m, 4H), 1.49 – 1.34 (m, 2H), 1.32 – 1.18 (m, 2H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 138.4, 114.9, 63.7, 36.5, 35.3, 34.0, 
33.2, 21.6, 20.2. HRMS (ESI) for C11H19IO [M+Na]+: calculated: 
317.0378, found: 317.0524. 
2-Allyl-2-(iodomethyl)tetrahydrofuran  
Flash column chromatography (20:1 Hexane:EtOAc) yielded 77 (90% 
yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 5.77 (ddt, J = 17.4, 
10.1, 7.3 Hz, 1H), 5.15 (ddd, J = 13.6, 12.2, 2.1 Hz, 2H), 3.95 – 3.84 (m, 
2H), 3.26 (s, 2H), 2.46 (d, J = 7.4 Hz, 2H), 2.03 – 1.83 (m, 4H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 133.4, 118.7, 82.6, 68.6, 42.9, 34.6, 26.4, 
16.1. HRMS (ESI) for C8H13IO [M+Na]+ : calculated: 252.0008, found: 
252.0011. 
2-(But-3-en-1-yl)-2-(iodomethyl)tetrahydrofuran  
Flash column chromatography (20:1 Hexane:EtOAc) yielded 78 
(87% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 5.92 – 
5.76 (m, 1H), 5.08 – 4.93 (m, 2H), 3.88 (m, 2H), 3.26 (s, 2H), 2.13 – 
2.04 (m, 2H), 1.96 (m, 4H), 1.8 (m, 2H). 13C {1H} NMR (CDCl3, 100 
MHz) δ 138.2, 114.6, 83.0, 68.5, 37.7, 35.0, 28.3, 26.4, 15.7. HRMS 
(ESI) for C9H15IO [M+Na]+: calculated: 266.0168, found: 266.0169. 
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4-Allyl-4-(bromomethyl)-1-(phenylsulfonyl)piperidine 
Flash column chromatography (5:1 Hexane:EtOAc) yielded 79 (87% 
yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 7.78 – 7.76 (m, 
2H), 7.65 – 7.59 (m, 1H), 7.57 – 7.51 (m, 2H), 5.63 (ddt, J = 16.9, 10.2, 
7.6 Hz, 1H), 5.08 – 5.04 (m, 2H), 3.21 (s, 2H), 3.11 – 2.92 (m, 4H), 2.07 
(d, J = 7.5 Hz, 2H), 1.72 – 1.54 (m, 4H). 13C {1H} NMR (CDCl3, 100 MHz) 
δ 136.1, 132.8, 131.9, 129.1, 127.5, 119.5, 41.8, 41.0, 39.0, 34.9, 32.7. 
HRMS (ESI) for C15H20BrNO2S [M]+ : calculated: 357.0408, found: 
357.0398. 
4-(Bromomethyl)-4-(but-3-en-1-yl)-1-(phenylsulfonyl)piperidine  
Flash column chromatography (5:1 Hexane:EtOAc) yielded 80 
(90% yield) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.81 – 
7.72 (m, 2H), 7.66 – 7.59 (m, 1H), 7.58 – 7.52 (m, 2H), 5.74 (ddt, J 
= 16.8, 10.2, 6.5 Hz, 1H), 4.99 (dd, J = 17.1, 1.6 Hz, 1H), 4.94 (dd, 
J = 10.1, 1.1 Hz, 1H), 3.24 (s, 2H), 3.12 – 3.02 (m, 2H), 3.02 – 2.91 
(m, 2H), 1.91 (m, 2H), 1.65 (m, 4H), 1.46 – 1.35 (m, 2H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 137.9, 136.1, 132.8, 129.1, 127.5, 114.9, 
41.8, 40.7, 34.5, 33.0, 26.8. HRMS (ESI) for C16H23BrNO2S [M+H]+: 
calculated:372.0626, found: 372.0627. 
4-(But-3-en-1-yl)-4-(iodomethyl)-1-(phenylsulfonyl)piperidine  
Flash column chromatography (5:1Hexane:EtOAc) yielded 81 
(85% yield) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.77 (m, 
2H), 7.65 – 7.59 (m, 1H), 7.58 – 7.52 (m, 2H), 5.74 (m, 1H), 5.00 
(m, 1H), 4.94 (m, 1H), 3.07 (overlapped signals, s, 3H + m, 2H), 
2.93 (m, 2H), 1.95 – 1.83 (m, 2H), 1.65 (m, 4H), 1.36 (m, 2H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 137.7, 136.1, 132.8, 129.1, 127.5, 
114.9, 41.9, 36.4, 33.7, 33.3, 26.7, 17.9. HRMS (ESI) for 
C16H23INO2S [M+H]+: calculated:420.0487, found: 420.0489. 
4-(Bromomethyl)-4-(pent-4-en-1-yl)-1-(phenylsulfonyl)piperidine  
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 
Hexane: EtOAc) yielded 82 (95% yield) as a colorless oil. 1H 
NMR (CDCl3, 400 MHz) δ 7.81 – 7.72 (m, 2H), 7.61 (m, 1H), 
7.54 (ddd, J = 8.4, 2.3, 0.9 Hz, 2H), 5.71 (ddt, J = 16.9, 10.2, 6.6 
Hz, 1H), 4.99 – 4.87 (m, 2H), 3.22 (s, 2H), 3.07 – 2.91 (m, 4H), 
1.98 (m, 2H), 1.60 (m, 4H), 1.33 – 1.16 (m, 4H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 138.0, 135.9, 132.7, 128.9, 127.4, 114.8, 
53.4, 41.7, 41.0, 34.3, 33.7, 32.8, 32.5, 30.79, 21.4. HRMS (ESI) 
for C17H25BrNO2S [M+H]+: calculated: 386.0786, found: 386.0784. 
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3-Allyl-3-(bromomethyl)-1-(phenylsulfonyl)piperidine 
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 Hexane: 
EtOAc) yielded 83 (46% yield) as colorless oil. 1H NMR (CDCl3, 400 
MHz) δ 7.60 (dd, J = 8.4, 1.7 Hz, 2H), 7.36 – 7.28 (m, 2H), 5.70 (ddt, J 
= 17.8, 10.2, 7.6 Hz, 1H), 5.21 – 5.10 (m, 2H), 3.43 (d, J = 10.5 Hz, 1H), 
3.37 (d, J = 10.6 Hz, 1H), 3.03 (m, 1H), 2.91 (d, J = 11.6 Hz, 1H), 2.87 
– 2.76 (m, 1H), 2.72 (d, J = 11.6 Hz, 1H), 2.42 (s, 3H), 2.24 – 2.17 (m, 
2H), 1.74 – 1.60 (m, 2H), 1.54 – 1.27 (m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 143.5, 
132.8, 131.8, 129.6, 127.4, 119.5, 53.0, 46.5, 39.5, 38.8, 37.1, 31.3, 21.4, 20.8. HRMS 
(ESI) for C16H23BrNO2S [M+H]+: calculated: 372.0627, found: 372.0627. 
3-Allyl-3-(bromomethyl)-1-(phenylsulfonyl)pyrrolidine 
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 
Hexane: EtOAc) yielded 84 (45% yield) as a white solid. 1H NMR 
(CDCl3, 400 MHz) δ 7.80 (m, 2H), 7.59 (m, 1H), 7.56 – 7.49 (m, 
2H), 5.63 – 5.49 (m, 1H), 5.10 – 4.99 (m, 2H), 3.31 – 3.25 (m, 2H), 
3.19 (d, J = 10.4 Hz, 1H), 3.14 (apparent s, 2H), 3.06 (d, J = 10.4 
Hz, 1H), 2.14-2.08 (m, 2H), 1.75 (m, 2H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 136.0, 132.7, 132.1, 129.0, 127.2, 119.5, 55.8, 46.4, 46.2, 39.2, 38.9, 
33.8. HRMS (ESI) for C14H19BrNO2S [M+H]+: calculated: 344.0315, found: 344.0314. 
2-Allyl-4-benzyl-2-(iodomethyl)morpholine 
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 
Hexane:EtOAc) yielded 85 (67% yield) as a white solid. 1H NMR 
(CDCl3, 400 MHz) δ 7.37 – 7.19 (m, 5H), 5.72 – 5.53 (m, 1H), 5.08 (m, 
2H), 3.67 (m, 3H), 3.41 (s, 2H), 3.29 (d, J = 10.6 Hz, 1H), 2.53 (d, J = 
11.5 Hz, 1H), 2.46– 2.38 (m, 3H), 2.26 (d, J = 11.5 Hz, 1H), 2.20 (m, 
1H). 13C {1H} NMR (CDCl3, 100 MHz) δ 137.8, 132.2, 128.8, 128.3, 
127.2, 119.1, 72.7, 62.9, 61.7, 58.3, 52.9, 41.1, 13.0. HRMS (ESI) for C15H21INO 
[M+H]+: calculated: 358.0664, found: 358.0662. 
2-((7-Oxaspiro[3.5]nonan-2-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
Flash column chromatography (40:1 Hexane:EtOAc) yielded 86a 
(93% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 3.61 (m, 
2H), 3.51 (m, 2H), 2.40 (sep, J = 8.0 Hz, 1H), 2.03 (m, 2H) 1.60 (m, 
2H), 1.48 (m, 2H), 1.39 (m, 2H), 1.22 (s, 12H), 0.95 (d, J = 7.8 Hz, 2H). 
13C {1H} NMR (CDCl3, 100 MHz) δ 82.8, 64.9, 64.7, 40.8, 40.6, 37.2, 
32.8, 25.1, 24.8. 11B NMR (CDCl3, 128.3 MHz) δ 34.2. HRMS (ESI) for 
C15H27BO3 [M+H]+: calculated: 267.2123, found: 267.2134. 
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2-((7-Oxaspiro[3.5]nonan-2-yl)methyl)-4,4,6-trimethyl-1,3,2-dioxaborinane  
Flash column chromatography (40:1 Hexane:EtOAc) yielded 86b 
(hex) (65% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 4.12 
(m, 1H), 3.58 (m, 2H), 3.50 (m, 2H), 2.34 (sep, J = 8.0 Hz, 1H), 1.98 
(m, 2H), 1.73 (apparent dd, 1H), 1.58 (m, 2H), 1.46 (m, 2H), 1.35 (m, 
3H), 1.24 (s, 6H), 1.21 (d, J = 6.2 Hz, 3H), 0.81 (d, J = 7.8 Hz, 2H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 70.3, 65.0, 64.7, 64.4, 45.9, 40.8, 40.7, 
37.3, 32.8, 31.2, 28.1, 25.4, 23.2. 11B NMR (CDCl3, 128.3 MHz) δ 
30.2. HRMS (ESI) for C15H27BO3 [M+H]+: calculated: 267.2123, 
found: 267.2134. 
 
2-((7-Oxaspiro[3.5]nonan-2-yl)methyl)-5,5-dimethyl-1,3,2-dioxaborinane  
Flash column chromatography (40:1 Hexane:EtOAc) yielded 86c 
(neop) (54% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 
3.65 (m, 2H), 3.56 (s, 4H), 3.51 (m, 2H), 2.36 (sep, J = 8.0 Hz, 1H), 
2.92 (m, 2H) 1.62 – 1.58 (m, 2H), 1.49 (m, 2H), 1.38 (m, 2H), 0.93 (s, 
6H), 0.88 (d, J = 7.8 Hz, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 71.9, 
65.0, 64.7, 63.9, 41.0, 40.7, 37.6, 37.3, 32.8, 31.6, 25.2, 21.8. 11B 
NMR (CDCl3, 128.3 MHz) δ 34.6. HRMS (ESI) for C14H25BO3 [M+H]+ 
: calculated: 253.1975, found: 253.1976. 
2-((7-Oxaspiro[3.5]nonan-2-yl)methyl)-5,5-dimethyl-1,3,2-dioxaborinane  
Flash column chromatography (40:1 Hexane:EtOAc) yielded 87 
(85% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 3.62 
(m, 4H), 2.09 (m, 1H), 1.82 (m, 2H), 1.51 (m, 2H), 1.43 (m, 4H), 
1.23 (s, 12H), 1.18 (m, 2H), 0.83 (m, 2H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 82.8, 65.7, 65.4, 47.9, 40.1, 39.8, 38.9, 37.9, 34.8, 
33.7, 24.8, 24.7. 11B NMR (CDCl3, 128.3 MHz) δ 34.7. HRMS 
(ESI) for C14H25BO3 [M+H]+: calculated: 298.2548, found: 
298.2557. 
2-((5-Oxaspiro[3.4]octan-2-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane  
Flash column chromatography (40:1 Hexane:EtOAc) yielded 89 
(45% yield) as a yellowish oil, as a mixture of diastereoisomers 1:1 
(a:a’). 1H NMR (CDCl3, 400 MHz) δ 3.75 (m, 2Ha + 2Ha'), 2.41 (m, 
1Ha + 1Ha'), 2.17 (m, 1Ha +1Ha'), 1.86 (m, 4Ha), 1.82 (m, 4Ha'), 1.70 
(m, 1Ha + 1Ha'), 1.25 (apparent s, 2Ha), 1.24 (apparent s, 2Ha'), 1.22 
(s, 12Ha), 1.22 (s, 12Ha'), 0.99 (d, J = 4.9 Hz, 2Ha), 0.96 (d, J = 4.9 Hz, 
2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 82.9, 81.9, 79.3, 67.0, 66.2, 
44.1, 42.2, 38.3, 36.4, 29.7, 25.0, 24.8, 23.2, 22.5, 1.2. 11B NMR 
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(CDCl3, 128.3 MHz) δ 34.5. HRMS (ESI) for C14H25BO3 [M+H]+: calculated: 253.1975, 
found: 253.1976. 
2-((1-Oxaspiro[4.4]nonan-7-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane  
Flash column chromatography (40:1 Hexane:EtOAc) yielded 90 
(54% yield) as a yellowish oil, as a mixture of diastereoisomers 
6:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 3.77 (m, 2Ha + 2Ha'), 
2.27 (m, 1Ha + 1Ha'), 2.00 (m, 1Ha + 1Ha'), 1.87 (m, 1Ha + 
1Ha'), 1.76 (m, , 4Ha + 4Ha'), 1.52 (m, 2Ha + 2Ha'), 1.37 (m, 2Ha 
+ 2Ha'), 1.23 (s, 12Ha + 12Ha'), 0.90 (d, J = 7.0 Hz, 2Ha), 0.83 
(d, J = 7.5 Hz, 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 90.6, 82.8, 66.5, 66.4, 47.5, 
47.2, 38.3, 37.6, 36.8, 34.7, 34.4, 33.7, 33.5, 29.7, 25.8, 25.7, 24.8. 11B NMR (CDCl3, 
128.3 MHz) δ 34.4. HRMS (ESI) for C17H27BO3 [M+H]+ : calculated: 267.2123, found: 
267.2134. 
7-(Phenylsulfonyl)-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-7-
azaspiro[3.5]nonane 
Flash column chromatography (20:1 Hexane:EtOAc) yielded 91 
(93% yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 7.72 
(apparent d, J = 8.0 Hz, 2H), 7.57 (m, 1H), 7.50 (m, 2H), 2.95 (t, J = 
5.7 Hz, 2H), 2.85 (t, J = 5.7 Hz, 2H), 2.40 – 2.25 (sep, J = 8.0 Hz, 1H), 
1.85 (m, 2H), 1.67 (t, J = 5.4 Hz, 2H), 1.54 (t, J = 5.4 Hz, 2H), 1.29 – 
1.21 (m, 4H), 1.18 (s, 12H), 0.88 (d, J = 7.8 Hz, 2H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 136.4, 132.5, 128.9, 127.5, 82.8, 43.3, 43.0, 
39.9, 38.9, 35.5, 32.9, 24.9, 24.7. 11B NMR (CDCl3, 128.3 MHz) δ 
34.2. HRMS (ESI) for C21H32BNO4S [M]+: calculated: 404.2181, 
found: 404.2179. 
8-(Phenylsulfonyl)-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-8-
azaspiro[4.5]decane 
Flash column chromatography (20:1 Hexane:EtOAc to 15:1 
Hexane: EtOAc) yielded 92 (60% yield) as a colorless oil. 1H 
NMR (CDCl3, 400 MHz) δ 7.72 (d, J = 7.0 Hz, 2H), 7.55 (m, 1H), 
7.53 – 7.46 (m, 2H), 3.00 – 2.83 (m, 4H), 2.06 – 1.90 (m, 1H), 
1.79 – 1.68 (m, 1H), 1.60 – 1.52 (m, 2H), 1.49 (m, 3H), 1.34 (m, 
1H), 1.24 (m, 2H), 1.16 (s, 12H), 1.13 – 0.95 (m, 2H), 0.77 – 0.72 
(m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 136.1, 132.5, 128.9, 
127.6, 82.9, 46.9, 44.0, 43.8, 40.1, 38.1, 37.4, 37.0, 34.7, 33.6, 
24.7. 11B {1H} NMR (CDCl3, 128.3 MHz) δ 35.2. HRMS (ESI) for C22H35BNO4S [M+H]+: 
calculated:420.2376, found: 420.2378. 
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3-(Phenylsulfonyl)-8-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3-
azaspiro[5.5]undecane 
Flash column chromatography (20:1 pentane:EtOAc) yielded 
93 (35% yield) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 
7.76 (dd, J = 8.3, 1.3 Hz, 2H), 7.61 (m, 1H), 7.54 (m, 2H), 3.00 
(m, 4H), 1.61 (m, 4H), 1.36 (m , 4H), 1.23 (s, 12H), 0.88 (m, 
4H), 0.72 (m, 3H). 13C {1H} NMR (CDCl3, 100 MHz) δ 136.2, 
132.8, 129.1, 127.5, 82.9, 41.8, 41.2, 35.1, 34.4, 32.9, 32.7, 
29.7, 29.3, 24.8, 23.8, 22.7, 22.0. 11B {1H} NMR (CDCl3, 128.3 MHz) δ 35.0. HRMS 
(ESI) for C23H37BNO4S [M]+: calculated: 434.2538, found: 434.2535. 
2-((4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-6-tosyl-6-
azaspiro[3.5]nonane  
Flash column chromatography (20:1 pentane:EtOAc) yielded 94 
(62% yield) as a white solid, as a mixture of diastereoisomers 1:1 
(a:a’). 1H NMR (CDCl3, 400 MHz) δ 7.60 (m, 2Ha + 2Ha'), 7.29 (m, 
2Ha + 2Ha'), 2.82 (m, 2Ha + 2Ha'), 2.45 (m, 1Ha), 2.41 (s, 3Ha), 2.40 
(s, 3Ha'), 2.36 (m, 1Ha'), 2.06 (m, 2Ha), 1.89 (m, 2Ha'), 1.60 (m, 2Ha), 
1.52 (m, 2Ha'), 1.37(m, 6Ha + 6Ha'), 1.21 (s, 12Ha + 12Ha'), 0.94 
(apparent t, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 143.1, 
133.3, 133.1, 129.5, 127.6, 82.9, 57.5, 55.1, 46.4, 39.0, 38.9, 37.5, 
34.2, 33.9, 29.6, 25.1, 25.0, 24.8, 21.8, 21.6, 21.5. 11B NMR (CDCl3, 128.3 MHz) δ 
35.4. HRMS (ESI) for C22H35BNO4S [M+H]+: calculated: 420.2379, found: 420.2378. 
6-(Phenylsulfonyl)-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-6-
azaspiro[3.4]octane 
Flash column chromatography (20:1 pentane:EtOAc) yielded 95 
(60% yield) as a white solid, as a mixture of diastereoisomers 1:1 
(a:a’). 1H NMR (CDCl3, 400 MHz) δ 7.79 (m, 2Ha + 2Ha'), 7.54 (m, 1Ha 
+ 1Ha'), 7.49 (m, 2Ha + 2Ha'), 3.25 (t, J = 6.8 Hz, 2Ha), 3.21 (s, 2Ha), 
3.19 (apparent t, 2Ha'), 3.09 (s, 2Ha'), 2.28 (m, 1Ha + 1Ha'), 1.83 (m, 
2Ha +2Ha'), 1.75 (t, J = 7.0 Hz, 2Ha), 1.65 (t, J = 7.0 Hz, 2Ha'), 1.41 (m, 
2Ha +2Ha'), 1.17 (s, 12Ha + 12Ha'), 0.85 (d, J = 7.7 Hz, 2Ha), 0.83 (d, 
J = 7.6 Hz, 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 136.9, 132.4, 
128.8, 127.3, 82.8, 59.2, 58.6, 46.8, 46.5, 41.2, 40.8, 39.4, 39.3, 38.5, 
37.0, 29.6, 26.0, 25.4, 24.7. 11B NMR (CDCl3, 128.3 MHz MHz) δ 33.8. HRMS (ESI) for 
C20H31BNO4S [M+H]+: calculated: 392.2064, found: 392.2065. 
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8-Benzyl-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-5-oxa-8-
azaspiro[3.5]nonane 
Flash column chromatography (20:1 pentane:EtOAc) yielded 96 (68% 
yield) as a white solid, as a pure isomer. The other isomer was 
isolated as a mixture of the two isomers in a ratio 4:6. 1H NMR (CDCl3, 
400 MHz) δ 7.39 – 7.21 (m, 5H), 3.65 – 3.55 (m, 2H), 3.49 (apparent 
s, 2H), 2.47 – 2.20 (m, 6H), 1.91 (sep, J = 7.9 Hz, 1H), 1.58 (m, 2H), 
1.24 – 1.19 (s, 12H), 0.98 (d, J = 7.7 Hz, 2H). 13C {1H} NMR (CDCl3, 100 
MHz) δ 138.3, 128.8, 128.2, 127.0, 82.9, 72.1, 62.9, 61.9, 60.2, 53.0, 
40.2, 29.7, 24.7, 22.8. 11B NMR (CDCl3, 128.3 MHz) δ 35.4. HRMS 
(ESI) for C21H33BNO3 [M+H]+: calculated: 358.2552, found: 358.2552. 
(7-(Phenylsulfonyl)-7-azaspiro[3.5]nonan-2-yl)methanol 
Flash column chromatography (6:1 pentane:DCM) yielded 97 (78% 
yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.74 (m, 2H), 7.58 
(m, 1H), 7.52 (m, 2H), 3.53 (d, J = 6.5 Hz, 2H), 2.96 (m, 2H), 2.88 (m, 2H), 
2.38 (sep, J = 7.4 Hz, 1H), 1.75 (m, 2H), 1.70 (m, 2H), 1.59 (m, 2H), 1.42 
(m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 136.2, 132.6, 128.9, 127.5, 
67.4, 43.1, 42.87, 38.3, 36.0, 33.8, 33.1, 30.2. HRMS (ESI) for C15H22NO3S 
[M + H]+: calculated: 296.1315, found: 296.1315. 
(7-Oxaspiro[3.5]nonan-2-yl)methanol  
Flash column chromatography (6:4 pentane:DCM) yielded 98 (83% 
yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 3.67 (m, 4H), 3.54 
(m, 2H), 2.26 (sep, J = 7.7 Hz, 1H), 1.81 (m, 2H), 1.51 (m, 4H), 1.34 (m, 
2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 67.8, 64.7, 64.4, 40.0, 37.7, 34.7, 
33.2, 30.4. HRMS (ESI) for C9H16O2 [M + Na]+: calculated: 179.1047, 
found: 179.1057. 
(8-(Phenylsulfonyl)-8-azaspiro[4.5]decan-2-yl)methanol 
Flash column chromatography (6:1 pentane:DCM) yielded 99 (65% 
yield) a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.73 (m, 2H), 7.60 
(m, 1H), 7.50 (m, 2H), 3.47 (m, 2H), 3.03 (m, 2H), 2.92 (m, 2H), 2.13 
(sep, J = 7.4 Hz, 1H), 1.70 (m, 1H), 1.55 (m, 5H), 1.35 (m, 1H), 1.28 (m, 
1H), 0.95 (m, 1H). 13C {1H} NMR (CDCl3, 100 MHz) δ 136.1, 132.6, 
128.9, 127.6, 67.2, 44.0, 43.7, 40.9, 40.5, 40.4, 37.6, 37.0, 36.3, 27.3. 
HRMS (ESI) for C16H24NO3S [M + H]+: calculated: 310.1472, found: 
310.1471. 
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(8-Oxaspiro[4.5]decan-2-yl)methanol  
Flash column chromatography (6:4 pentane:DCM) yielded 100 (86% 
yield) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 3.63 (m, 4H), 
3.55 (m, 2H), 2.47 (sep, J = 7.5 Hz, 1H), 1.92 (m, 2H), 1.63 (m, 2H), 
1.53 (m, 6H). 13C {1H} NMR (CDCl3, 100 MHz) δ 67.5, 65.6, 65.3, 41.0, 
40.3, 39.1, 38.0, 27.5. HRMS (ESI) for C10H18O2 [M + Na]+: calculated: 
193.1204, found: 193.1209. 
7-(Phenylsulfonyl)-7-azaspiro[3.5]nonane-2-carbaldehyde 
Flash column chromatography (3:1 Hexane:EtOAc) yielded 101 (62% 
yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 9.66 (d, J = 1.5 Hz, 
1H), 7.72 (m, 2H), 7.57 (m, 1H), 7.50 (m, 2H), 3.06 (sep, J = 7.6 Hz, 1H), 
2.94 (m, 2H), 2.87 (m, 2H), 1.89 (m, 4H), 1.70 (m, 2H), 1.55 (m, 2H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 202.2, 136.1, 132.7, 129.0, 127.5, 42.9, 
42.7, 39.0, 37.0, 36.1, 33.9, 31.3. HRMS (ESI) for C15H20NO3S [M + H]+: 
calculated: 294.1160, found: 294.1158. 
E-7-(Phenylsulfonyl)-2-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-
(trimethylsilyl)vinyl)-7-azaspiro[3.5]nonane 
Flash column chromatography (40:1 pentane:EtOAc) yielded 102 
(88% yielding in a mixture of diastereoisomers 85:15) as a 
colorless solid. Major isomer was possible to be isolated 
exclusively. 1H NMR (CDCl3, 400 MHz) δ 7.72 (m, 2H), 7.54 (m, 
1H), 7.49 (m, 2H), 6.34 (d, J = 8.3 Hz, 1H), 3.16 (m, 1H), 2.94 (m, 
2H), 2.85 (m, 2H), 1.94 – 1.79 (m, 2H), ), 1.66 (m, 2H), 1.56 (m, 
2H), 1.48 (m, 2H), 1.20 (s, 12H), 0.05 (s, 9H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 164.9, 160.8, 136.1, 132.5, 128.9, 128.9, 127.5, 82.9, 
43.1, 42.9, 38.4, 38.2, 35.5, 33.7, 33.3, 24.7, 1.0. 11B NMR (129 MHz, cdcl3) δ 32.8. 
29Si NMR (80 MHz, cdcl3) δ -4.01. HRMS (ESI) for C25H41BNO4SSi [M + H]+: calculated: 
490.2618, found: 490.2618. 
E-7-(phenylsulfonyl)-2-(2-(p-tolyl)-2-(trimethylsilyl)vinyl)-7-azaspiro[3.5]nonane 
Flash column chromatography (30:1 pentane:EtOAc) yielded 
103 (81% yielding in a mixture of diastereoisomers 85:15) as a 
white solid. 1H NMR (CDCl3, 400 MHz) δ 7.71 (m, 2H), 7.59 (m, 
1H), 7.50 (m, 2H), 7.04 (m, 2H), 6.75 (m, 2H), 5.90 (d, J = 8.8 Hz, 
1H), 2.88 (m, 4H), 2.75 (m, 1H), 2.30 (s, 3H), 1.75 (m, 2H), 
1.58(m, 4H), 1.45 (m, 2H), 0.03 (m, 9H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 150.9, 145.9, 143.4, 139.1, 136.3, 134.6, 132.6, 
128.9, 128.6, 128.4, 127.5, 127.2, 43.1, 43.0, 38.8, 38.6, 35.3, 
33.3, 28.5, 21.1, -1.5. 29Si NMR (80 MHz, CDCl3) δ -5.13. HRMS (ESI) for C26H36NO2SSi 
[M+H]+: calculated: 454.2231, found: 454.2231. 
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8-(Phenylsulfonyl)-8-azaspiro[4.5]decane-2-carboxylic acid 
Work up purification mentioned previously yielded 104 (73% yield) 
as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.74 (d, J = 7.3 Hz, 2H), 
7.60 (m, 1H), 7.53 (m, 2H), 3.02 (m, 2H), 2.91 (m, 2H), 2.80 (m, 1H), 
1.90 (m, 2H), 1.86 (m, 7H), 0.90 – 0.81 (m, 1H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 182.2, 136.0, 132.7, 129.0, 127.6, 44.0, 43.7, 42.5, 40.8, 
40.2, 37.1, 36.7, 36.1, 28.0. HRMS (ESI) for C16H22NO4S [M+H]+: 
calculated 324.1264, found: 324.1264. 
Methyl 8-(phenylsulfonyl)-8-azaspiro[4.5]decane-2-carboxylate 
After work up, without purification it was recovered 105 (61% yield) 
as a colorless oil. It was only checked by 1H NMR to see if the 
esterification process occurred.1H NMR (CDCl3, 400 MHz) δ 7.73 (m, 
2H), 7.58 (m, 1H), 7.53 (m, 2H), 3.61 (s, 3H), 3.04 (m, 2H), 2.90 (m, 
2H), 2.77 (m, 1H), 1.83 (m, 2H), 1.49 (m, 8H). 
 
Methyl 2-allyl-8-(phenylsulfonyl)-8-azaspiro[4.5]decane-2-carboxylate 
Flash column chromatography (5:1 Hexane:EtOAc) yielded 106 
(51% yield) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.68 (dd, 
J = 8.1, 1.0 Hz, 2H), 7.52 (m, 1H), 7.46 (m, 2H), 5.53 (m, 1H), 4.91 
(m, 2H), 3.54 (s, 3H), 2.98 (m, 2H), 2.81 (m, 2H), 2.23 (m, 2H), 2.04 
(m, 1H), 1.96 (d, J = 13.7 Hz, 1H), 1.49 (m, 5H), 1.35 (m, 2H), 1.15 
(d, J = 13.9 Hz, 1H). 13C {1H} NMR (CDCl3, 100 MHz) δ 177.4, 136.0, 
134.1, 132.6, 128.9, 127.5, 117.7, 53.6, 51.8, 45.6, 44.1, 43.9, 43.7, 
40.4, 37.7, 36.7, 36.5, 33.8. HRMS (ESI) for C20H28NO4S [M+H]+: 
calculated: 378.1733, found: 378.1734. 
2-Allyl-2-(iodomethyl)-8-(phenylsulfonyl)-8-azaspiro[4.5]decane 
Flash column chromatography (5:1 Hexane:EtOAc to 3:1 
Hexane:EtOAc) yielded 107 (70% yield) as a colorless oil. 1H NMR 
(CDCl3, 400 MHz) δ 7.72 (m, 2H), 7.57 (m, 1H), 7.51 (m, 2H), 5.60 (m, 
1H), 5.07 (m, 2H), 3.16 (d, J = 9.8 Hz, 1H), 3.13 (d, J = 9.8 Hz, 1H), 2.99 
(m, 2H), 2.89 (m, 2H), 1.61 – 1.49 (m, 6H), 1.44 (dd, J = 10.7, 3.7 Hz, 
2H), 1.37 (dd, J = 14.2 Hz, 1H), 1.21 (t, J = 7.1 Hz, 1H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 136.1, 133.9, 132.7, 129.0, 127.5, 118.6, 48.0, 
45.6, 44.4, 43.7, 43.7, 40.7, 37.8, 37.7, 36.6, 35.5, 22.6. HRMS (ESI) 
for C19H27INO2S [M+H]+: calculated: 460.0806, found: 460.0802. 
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9-(Phenylsulfonyl)-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-9-
azadispiro[3.1.56.24]tridecane 
Flash column chromatography (20:1 Hexane:EtOAc) yielded 
108 (64% yield) as a yellowish oil, as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 
7.76 (m, 2Ha + 2Ha'), 7.66 – 7.57 (m, 1Ha + 1Ha'), 7.57 – 
7.51 (m, 2Ha + 2Ha'), 3.02 (m, 2Ha + 2Ha'), 2.97 – 2.82 (m, 
2Ha + 2Ha'), 2.31 (sep, J = 8.5 Hz, 1Ha + 1Ha'), 1.98 (m, 2Ha 
+ 2Ha'), 1.65 (apparent t, 2Ha), 1.60 (s, 2Ha + 2Ha'), 1.52 (m, 
6Ha + 6Ha'), 1.35 (apparent t, 2Ha'), 1.30 (m, 2Ha + 2Ha'), 
1.22 (s, 12Ha + 12Ha'), 0.88 (apparent t, 2Ha + 2Ha'). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 136.1, 132.5, 128.9, 127.6, 82.8, 52.3, 51.0, 43.9, 43.4, 
43.2, 39.8, 39.6, 37.7, 37.7, 36.7, 29.6, 26.4, 24.7. 11B NMR (CDCl3, 128.3 MHz) δ 
34.7. HRMS (ESI) for C25H39BNO4S [M+H]+ : calculated: 460.2693, found: 460.2692. 
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8.4. Experimental procedures and spectral data of Chapter 5 
8.4.1 Specific procedure for the synthesis of central core 112 
To a solution of the pyrrolidine methyl ester 117 (103 mmol, 1 equiv) in DCM (171 
mL), followed by the addition of Et3N (309 mmol, 3 equiv) and di-tert-butyl 
dicarbonate (103 mmol, 1 equiv,) at 0°C. Then the mixture was stirred at room 
temperature for 72 h. The mixture was diluted in DCM and treated with water. The 
suspension was filtered over a celite pad and washed with DCM. The organic layers 
were separated, dried (MgSO4), filtered and evaporated in vacuo. The crude product 
was purified by flash column chromatography.[14] 
To the corresponding solution of the protected methyl ester 118 (10 g, 1 equiv, 44 
mmol) in 2-Me-THF (200 mL), LiHMDS 1 M in hexane (66 mL, 66 mmol,1.5 equiv) 
was added dropwise at -78 °C and stirred for 10 minutes. Then allyl bromide (7.6 
mL, 87 mmol, 2 equiv) was added at -78 °C and sitirred for 30 min. at the same 
temperature. Then the mixture was warmed up to room temperature. After 
completion, the reaction was quenched with NH4Cl sat. at 0 °C and diluted with 
EtOAc. The organic layers were separated, dried (MgSO4), filtered and the solvents 
evaporated in vacuo. The crude was purified by flash column chromatography.[15] 
The alkylated intermediate 119 (6 g, 1 equiv, 22 mmol) in THF (103 mL), LiBH4 (11 
mmol, 3 equiv) was added dropwise at 0 °C. The mixture was stirred for 2 h at room 
temperature. Then more LiBH4 was added (11 mmol, 3 equiv) and stirred for 16 h. 
The mixture was treated with water and extracted with EtOAc. The organic layers 
were separated, dried (MgSO4), filtered and the solvents evaporated in vacuo to 
yield the product 120 as a clear oil.[16] 
To a solution of triphenylphosphine (122 mmol, 1.1 equiv) and imidazole (122 mmol, 
1.1 equiv) in toluene (160 mL) iodine (122 mmol, 1.1 equiv) was added and stirred 
for 30 min. at room temperature. Then intermediate 120 (9.9 g, 1 equiv, 41 mmol) 
was added, and the reaction mixture was heated to 80 °C and stirred for 16 h. The 
solution was quenched with H2O, extracted with EtOAc for three times and washed 
with Na2S2O3 sat. The organic extracts were then dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography to 
deliver product 121 in 60% isolated yield.[6] 
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Copper chloride (5 mol%, 0.147 mmol), bis(pinacolato)diboron (3.5 mmol, 1.2 equiv) 
and Xantphos (5 mol%, 0.147 mmol) were placed in an oven-dried reaction vial. The 
vial was sealed with a screw cap containing a teflon-coated rubber septum. The vial 
was connected to a vacuum/nitrogen manifold through a needle, evacuated and 
backfilled with nitrogen and THF (3.5 mL, 1 M). KOtBu (3.5 mmol, 1.2 equiv, 1M in 
THF) was added to the vial through the rubber septum. Then, the alkenyl halide 121 
(2.9 mmol, 1 equiv) in THF (3.5 mL, 1 M) was added dropwise at 30 °C. After the 
reaction was complete (around 16 h), the reaction mixture was filtered over celite. 
The organic extracts were then concentrated in vacuo. The crude product was 
purified by flash column chromatography to produce 112 in 60% isolated yield in a 
diastereomeric ratio of 45 to 55.[17] 
8.4.2 Specific procedure for the synthesis of central core 113 
To a solution of the pyrrolidin-2-one (122) (73 mmol, 1 equiv) in ACN (139 mL) was 
added di-tert-butyl dicarbonate (88 mmol, 1.2 equiv) at 0°C. Then the mixture was 
stirred at room temperature for 16 h. The reaction mixture was diluted in EtOAc and 
treated with water. The suspension was filtered over a celite pad and washed with 
EtOAc. The organic layers were separated, dried (MgSO4), filtered and evaporated 
in vacuo. The crude product was purified by flash column chromatography to yield 
123 in 75%.[14] 
To a solution of LHMDS (115 mmol, 2.1 equiv) 1 M in hexane in THF (40 mL) at -78°C 
was added dropwise intermediate 123 (55 mmol, 1 equiv) in THF (40 mL), followed 
immediately by the addition of methyl chloroformate (55 mmol, 1 equiv) dropwise 
in THF (40 mL) and stirred for 5 min. at -78°C. After full conversion of compound 
123, HCl 1 M was added, until reach pH=1 and allowed to warm to room 
temperature. The biphasic mixture was extracted with EtOAc. The organic layers 
were separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The 
crude product was purified by flash column chromatography yielding 124 in 85%.[18] 
Then a solution of 1-(tert-butyl) 3-methyl 2-oxopyrrolidine-1,3-dicarboxylate (124) 
(47 mmol, 1 equiv) in acetone (300 mL) was added 4-bromo-1-butene (70 mmol, 1.5 
equiv), K2CO3 (169 mmol, 3.6 equiv), tetrabutylamonium bromide (10mmol, 2 equiv) 
at room temperature. Then the mixture was warmed up to 60 °C to reflux. After 2 h 
an extra amount of 4-bromo-1-butene (70 mmol, 1.5 equiv) was added and stirred 
at 60 °C for 2 h more. Then an extra amount of 4-bromo-1-butene (140 mmol, 3 
equiv) was added and refluxed for 16 h (the extra addition of 4-bromo-1-butene 
should be added at room temperature). After full conversion of the substrate, the 
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volatiles were evaporated and the residue purified by flash column chromatography 
providing 125 in 90% isolated yield.[19] 
To a solution of the alkylated product 125 (20 mmol, 1 equiv) in dioxane (24 mL) was 
added HCl 4 N in dioxane (120 mmol, 6 equiv) and stirred for 2 h at room 
temperature. After complete deprotection the solvent was evaporated in vacuo, the 
residue was dissolved in EtOAc and water and extracted with EtOAc many times. 
The organic layers were separated, dried (MgSO4), filtered and the solvents 
evaporated in vacuo to yield 126 in a 87%.[20] 
To a solution of 126 (22 mmol, 1 equiv) in ACN (124 mL), was added Cs2CO3 (56 
mmol, 2.5 equiv) followed by bromomethylbenzene (33 mmol, 1.5 equiv), then the 
mixture was stirred at 90 °C in a sealed tube for 1h. The mixture was cool down and 
EtOAc was added, then the solid was filtered off through a celite pad. The solvent 
was evaporated in vacuo and the residue was purified by flash column 
chromatography to yield 127 in 79%.[21] 
To a stirred solution of methyl 1-benzyl-3-(but-3-en-1-yl)-2-oxopyrrolidine-3-
carboxylate (127) (12 mmol, 1 equiv) in THF (55 mL), was added LiAlH4 (18 mmol, 1.5 
equiv) at 0 °C and stirred for 2 h at room temperature. Then more LiAlH4 (18 mmol, 
1.5 equiv) was added at room temperature and stirred for 16 h more at the same 
temperature. The mixture was treated with water and then diluted with EtOAc. 
Then a solution of H2SO4 (10% aq.) was added (in order to dissolve the aluminum 
salts). Then, it was extracted many times with EtOAc. The organic layers were 
separated. The aqueous phase was saturated with NaCl and extracted with EtOAc 
(until no observation of the product in the aqueous phase). The organic layers were 
combined and washed with NaHCO3 sat., then the organic layers were separated, 
dried (MgSO4), filtered and the organic solvents removed in vacuo and the residue 
was purified by flash column chromatography.[4] 
Then to a solution of triphenylphosphine (22 mmol, 1.1 equiv) and imidazole (22 
mmol, 1.1 equiv) in toluene (32 mL) was added iodine (22 mmol, 1.1 equiv) and 
stirred for 30 minutes at room temperature. Then intermediate 128 (20 mmol, 1 
equiv) was added, and the reaction mixture was heated to 80 °C and stirred for 16 
h. The solution was quenched with H2O, extracted with EtOAc for three times and 
washed with Na2S2O3 sat. The organic extracts were dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography to 
yield 129 in 45%.[6] 
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Copper chloride (5 mol%, 0.1 mmol), bis(pinacolato)diboron (2.4 mmol, 1.2 equiv) 
and Xantphos (5 mol%, 0.1 mmol) were placed in an oven-dried reaction vial. The 
vial was sealed with a screw cap containing a teflon-coated rubber septum. The vial 
was connected to a vacuum/nitrogen manifold through a needle, evacuated and 
backfilled with nitrogen and THF (2.4 mL, 1 M). KOtBu (2.4 mmol, 1.2 equiv, 1 M in 
THF) was added to the vial through the rubber septum. Then alkenyl halide 129 (2 
mmol, 1 equiv) in THF (2.4 mL, 1 M) was added dropwise at 30 °C. After the reaction 
was complete (around 16 h), the reaction mixture was filtered over celite pad. The 
organic extracts were then concentrated in vacuo. The crude product was purified 
by flash column chromatography yielding 113 in 72%.[17] 
8.4.3 Specific procedure for the synthesis of central core 114 
To the corresponding solution of the N-Boc protected carboxylic piperidine 130 (93 
mmol, 1 equiv) in THF (214 mL), LHMDS (121 mmol, 1.3 equiv, 1.06 M in hexane) 
was added dropwise at -78 °C and stirred for 10 min. Then allyl bromide (112 mmol, 
1.2 equiv) was added at -78 °C and stirred for 30 min. at the same temperature. 
Then the mixture was warmed up to room temperature. After full conversion was 
quenched with NH4Cl sat. at 0 °C and diluted with EtOAc. The organic layers were 
separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude 
was purified by flash column chromatography providing 131 in 94% yield.[15] 
The alkylated intermediate 131 (86 mmol, 1 equiv) in THF (402 mL), LiBH4 (258 
mmol, 3 equiv) was added dropwise at 0 º C. The mixture was stirred for 2 h at room 
temperature. Then more LiBH4 was added (258 mmol, 3 equiv) and stirred for 16 h. 
The mixture was treated with water and extracted with EtOAc. The organic layer 
was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo to yield 
the product 132 as a clear oil in 93% isolated yield.[16] 
Then to a solution of triphenylphosphine (85 mmol, 1.1 equiv) and imidazole (85 
mmol, 1.1 equiv) in toluene (113 mL) was added iodine (85 mmol, 1.1 equiv) and 
stirred for 30 min. at room temperature. Then intermediate 132 (78 mmol, 1 equiv) 
was added, and the reaction mixture was heated to 80 °C and stirred for 16 h. The 
solution was quenched with H2O, extracted with EtOAc for three times and washed 
with Na2S2O3 sat. The organic extracts were dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography to 
yield 133 in 69%.[6]  
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Copper chloride (5 mol%, 3.1 mmol), bis(pinacolato)diboron (74 mmol, 1.2 equiv) 
and Xantphos (5 mol%, 3.1 mmol) were placed in an oven-dried reaction vial. The 
vial was sealed with a screw cap containing a teflon-coated rubber septum. The vial 
was connected to a vacuum/nitrogen manifold through a needle, evacuated and 
backfilled with nitrogen and THF (74 mL, 1 M). KOtBu (74 mmol, 1.2 equiv, 1 M in 
THF) was added to the vial through the rubber septum. Then alkenyl halide 133 (62 
mmol, 1 equiv) in THF (74 mL, 1 M) was added dropwise at 30 °C. After the reaction 
was complete (around 16 h), the reaction mixture was filtered over celite pad. The 
organic extracts were then concentrated in vacuo. The crude product was purified 
by flash column chromatography yielding 114 in 55%.[17] 
8.4.4 General procedure for the synthesis of central core 115 and 116[22] 
Zinc dust (54 mmol, 2 equiv) was slowly added under vigorous stirring to a mixture 
of cyclopentanone (27 mmol, 1 equiv), allyl bromide (54 mmol, 2 equiv) in THF (8 
mL, 16 M) and NH4Cl sat. (27 mL, 5M) was added in such a way that the temperature 
did not exceed 40 °C. The mixture was then stirred for 10 h at room temperature. 
Then H2SO4 (10% aq., 13 mL, 10M) was added, the mixture was filtered, the organic 
phase was separated, and the aqueous phase was saturated with NaCl and extracted 
with Et2O. The extracts were combined, dried over anhydrous magnesium sulphate, 
then filtered and the volatiles evaporated under reduced pressure to yield a viscous 
black oil (for the synthesis of the central core 115 was not purified, however for the 
synthesis of the central core 116 was purified the intermediate 136 by flash 
chromatography. 
Then was added Na2S2O5 (27 mmol, 1 equiv) in water (21 mL, 1.2 M) dropwise over 
a period of 2 h to a mixture of the viscous black oil, NaIO4 (1 equiv, 27 mmol), tert-
butyl alcohol (40.5 mL), and water (35 mL) under stirring at 50 °C. The mixture was 
stirred for 10 h at 50 °C and for 10 h at room temperature, the dark brown organic 
layer was separated, and the aqueous phase was saturated with sodium chloride 
and extracted with ethyl acetate. The extracts were combined with the organic 
phase and washed with a saturated aqueous solution of sodium thiosulfate, the 
resulting colorless solution was dried (MgSO4) and the volatiles were removed under 
reduced pressure. The oily residue was purified by flash column chromatography. 
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8.4.5 General procedure for the Suzuki-Miyaura coupling of methylene 
boronates with heteroaryl bromides catalysed by palladium[10] 
On a microwave vial tube equipped with a stirring bar was charged with Pd(PPh3)4 
(3 mol%, 0.0159 mmol) and 1,4-dioxane (0.7 mL). To this solution the corresponding 
spiro-methylene boronate compound (0.53 mmol, 1 equiv), dissolved in 0.6 mL of 
1,4-dioxane, 4-bromo-2,6-dimethylpyridine (1.58 mmol, 3 equiv) and a 3 M KOH 
solution (3 mmol, 6 equiv) were added in sequence and heated up at 90 °C for 16 h. 
After consumption of the substrate the mixture was cooled to room temperature 
and diluted in DCM. The reaction mixture was filtered through a small pad of celite 
and anhydrous MgSO4. Then the organic solvents were evaporated in vacuo. The 
crude was purified by flash column chromatography to yield the arylated spiro-
compound. 
8.4.6 General procedure for the Suzuki-Miyaura coupling of secondary 
iodides and heteroaryl boronates catalyzed by nickel[23] 
To a mixture of NiI2 (6 mol%, 0.006 mmol), (1R,2R)-2-aminocyclohexanol 
hydrochloride (0.006 mmol, 0.06 equiv), the pyridine boronate derivative (0.229 
mmol, 2 equiv,) NaHMDS (0.229 mmol, 2 equiv) in iPrOH (2 mL) under N2 
atmosphere and stirred for 10 min. at room temperature. Then the spiro-iodinated 
compound was added (0.114 mmol, 1 equiv) and irradiated under microwave at       
80 °C for 1.5 – 3 h. After consumption of the substrate de mixture was cooled down 
and diluted in EtOH, filtered through a celite pad and the volatiles removed in vacuo. 
The crude was purified by flash column chromatography. 
8.4.7 General procedure of the arylation of ketones by lithiation[24] 
To a solution of a commercially available bromo pyridine derivative (5.95 mmol, 1.5 
equiv) in THF (10 mL) at -78 °C under N2 atmosphere was added dropwise nBuLi 
(7.14 mmol, 1.8 equiv, 1.6 M in hexane) and stirred for 20 minutes at -78°C. Then 
the commercially available spiro-cyclic ketone (3.97 mmol, 1 equiv) in THF (10 mL) 
was added and stirred for 2 h at -78 °C. Then the reaction mixture was warmed up 
to room temperature and stirred for 20 minutes more. After consumption of the 
limiting reagent, NH4Cl sat. was added, followed by water and extracted with DCM. 
The organic layers were separated, dried (MgSO4), filtered and the solvent removed 
in vacuo. The crude was purified by flash column chromatography. 
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8.4.8 General procedure for the O-arylation of alcohols with KOtBu[25] 
To a mixture of the spiro-cyclic alcohol (0.63 mmol, 1 equiv), KOtBu (1.26 mmol, 2 
equiv) in DMSO (1.26 mL) was added chloro pyridine derivative (1 mmol, 1.6 equiv) 
and stirred at 70 °C for 5 h. The mixture was cooled to room temperature and then 
water followed by EtOAc were added. The organic layer was separated, dried 
(MgSO4) and the volaties evaporated in vacuo. The residue obtained was purified by 
flash column chromatography.  
8.4.9 General procedure for the O-arylation of alcohols with NaH[26] 
To the corresponding solution spiro-cyclic alcohol (0.264 mmol, 1 equiv) in THF (1 
mL) was added NaH 60% dispersion in oil (0.37 mmol, 1.4 equiv) at room 
temperature. The mixture was stirred during 40 min. Then chloro pyridine or 
pyrimidine derivative (0.31 mmol, 1.2 equiv) was added dropwise at 0 °C, and was 
stirred for 16 h at 40 °C. The mixture was treated with water and extracted many 
times with EtOAc. The organic layer was separated, dried (MgSO4), filtered and the 
solvents evaporated in vacuo. The crude was purified by flash column 
chromatography. 
8.4.10 General procedure for the deprotection of N-Boc amines with 
HCl[20] 
The N-Boc protected spiro-compound (0.76 mmol, 1 equiv) in 1,4-dioxane (0.89 mL) 
at 0°C, was added HCl 4 M in 1,4-dioxane (4.61 mmol, 6 equiv) dropwise and stirred 
at room temperature for 2 h. After consumption of the substrate the mixture was 
evaporated in vacuo to give the corresponding N-deprotected amine spiro-cycle 
which was used for the next step reaction without purification. 
8.4.11 General procedure for the deprotection of N-Boc amines with 
Amberlyst-15[27] 
The N-Boc protected spiro-compound (1.8 mmol, 1 equiv) was dissolved in MeOH 
(89 mL), the solution was introduced into a extraction funnel equipped with filter 
plate. Then resin Amberlyst-15 (PS-SO3 (4.11 mmol/g) 1 equiv) was added and it was 
left shaken over 24 h. Then the solvent was removed and discarded. The resin 
(Amberlyst-15) was washed a three times with MeOH which was discarded. Then 7 
N NH3 in MeOH solution was added to the resin and left shaken over 2 h. The solvent 
was removed and the resin was washed two times more with 7 N NH3 in MeOH. The 
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organic solvent (7 N NH3 in MeOH) was evaporated to yield the N-deprotected 
amine spiro-cycle, which was used for the next step reaction without purification. 
8.4.12 General procedure for the deprotection of benzylic amines with 
H-cube technology 
The N-benzylic protected spiro-compound was deprotected using H-cube reactor 
technology. A solution of the benzylic spiro-cycle (0.26 mmol, 1 equiv) 0.05 M in 
MeOH (5.2 mL) was passed through a Pd(OH)2/C 20% (30mm) cartridge in full H2 
mode at 80 °C (3 cycles) affording full conversion towards the desired product. Then 
if some impurities were present, the mixture was purified by flash column 
chromatography. 
8.4.13 General procedure for the reduction of the commercially 
available spiro-cyclic ketones to alcohols[28] 
To a solution of a commercially available spiro-cyclic ketones (2.75 mmol, 1 equiv) 
in MeOH (6.2 mL) at 0 °C was added NaBH4 (4.1 mmol, 1.5 equiv,). Then the mixture 
was warmed naturally to room temperature and stirred for 2 h. If the reaction does 
not complete, an extra amount of NaBH4 (4.1 mmol, 1.5 equiv) should be added to 
get full conversion toward the reduced spiro-cyclic alcohol. After full conversion, to 
the mixture reaction was added water and extracted with EtOAc. The organic layer 
was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo to yield 
the spiro-cyclic alcohol, which was used for the next step without need of 
purification (quantitative reaction). 
8.4.14 General procedure for the iodination of secondary alcohols[6] 
To a solution of triphenylphosphine (8.8 mmol, 1.1 equiv) and imidazole (8.8 mmol, 
1.1 equiv) in toluene (11 mL) was added iodine (8.8 mmol, 1.1 equiv) and stirred for 
30 min. at room temperature. Then spiro-cyclic alcohol (8 mmol, 1 equiv) was 
added, and the reaction mixture was heated to 80 °C and stirred for 16 h. The 
solution was quenched with H2O, extracted with EtOAc for three times and washed 
with Na2S2O3 sat. The organic extracts were then dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography.  
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8.4.15 General procedure for the fluorination of tertiary alcohols[29] 
Then to a solution of the arylated spiro-cyclic alcohols (2.02 mmol, 1 equiv) in DCM 
(15 mL) was added DAST (4 mmol, 2 equiv) at 0 °C under N2 atmosphere and stirred 
at this temperature for 1 h, then it was let to warm up and stirred for 1 h more. The 
mixture was treated with water and NaHCO3 sat. solution and extracted with DCM. 
The organic layer was separated, dried (MgSO4), filtered and the solvents 
evaporated in vacuo. The crude product was purified by flash chromatography.  
8.4.16 General procedure for the reduction of double bonds and 
defluorination by hydrogenation 
The mixture of compounds or the fluorinated spiro-cycle (1.8 mmol, 1 equiv) were 
disolved in MeOH (24.5 mL, 305 equiv, 606 mmol), followed by addition of Pd/C 10% 
(0.09 mmol, 0.05 equiv) at room temperature and hydrogenated with a balloon 
filled of hydrogen at atmospheric pressure. The mixture was stirred for 16 h at room 
temperature. Then, the reaction mixture was filtered through celite pad and 
evaporated in vacuo. The crude product was purified by flash chromatography.  
8.4.17 General procedure for the oxidation of secondary alcohols to 
ketones in the intermediates for the preparation of final targets[30] 
To a solution of the spiro-cyclic alcohols (5 mmol, 1 equiv) in DCM (4 mL) was added 
DMP (10 mmol, 2 equiv) and stirred at room temperature for 16 h. Then NaHCO3 
sat. solution was added and extracted few times with DCM. The organic layer was 
separated, dried (MgSO4), filtered and the solvent removed in vacuo. The crude was 
purified by flash column chromatography. 
8.4.18 Procedure for the synthesis of the amino linker and the arylation 
protocol 
To a solution of compound 161 (3.1 mmol, 1 equiv), N,N-diisopropylethylamine ( 6.3 
mmol, 2 equiv) in DCM (9 mL) was added methanesulfonyl chloride (3.4 mmol, 1.1 
equiv) at 0 °C and stirred for 1 h at room temperature. After consumption of the 
substrate (reaction monitored by TLC with eluting solution of EtOAc in Heptane 1:1) 
the mixture was diluted with NaHCO3 sat. solution and extracted three times with 
DCM. The organic layer was separated and washed with water. Then the organic 
layer was separated from the aqueous phase, dried (MgSO4), filtered and the 
solvents removed in vacuo to provide the protected alcohol as an orange oil. The 
crude was used for the next step reaction without purification.[31] 
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To a solution of the protected alcohol (3.35 mmol, 1 equiv) in DMF (9.5 mL) was 
added sodium azide (10 mmol, 3 equiv) at 0 °C. Then was heat it up at 70 °C and 
stirred for 16 h. The reaction mixture was then cooled to room temperature, diluted 
with EtOAc and water. The organic layer was separated and washed with an extra 
amount of water (3 x 30 mL). The organic layers were separated from the aqueous 
phase, dried (MgSO4), filtered and the volatiles removed in vacuo. The crude was 
purified by flash column chromatography.[32] 
A solution of compound 164 (0.5 mmol, 1 equiv) in EtOH (0.9 mL) was hydrogenated 
using H-cube technology with Pd/C 10% cartridge in full H2 mode for 1 cycle. Then, 
the solvent was evaporated to yield compound 165.[33] 
In a microwave vial a mixture of Pd2(dba)3 (5 mol%, 0.018 mmol), Davephos (7 mol%, 
0.025 mmol), NaOtBu (0.55 mmol, 1.5 equiv) in 1,4-dioxane (1 mL) was added the 
spiro-compound 165 (0.37 mmol, 1 equiv) and 4-chloro-2,6-dimethylpyridine (0.74 
mmol, 2 equiv), the vial was sealed and heated at 100 °C for 16 h. The mixture was 
cooled and filtered over a celite pad and rinsed with DCM. The filtrate was 
concentrated and the residue was purified by flash column chromatography. 
Then to the N-Boc protected spiro-compound 166 (0.18 mmol, 1 equiv) in 1,4-
dioxane (0.22 mL) at 0 °C, was added HCl 4 M in 1,4-dioxane (1.1 mmol, 6 equiv) 
dropwise and stirred at room temperature for 2 h. After consumption of the 
protected amine, the mixture was evaporated in vacuo to give the corresponding 
deprotected pyrrolidine spiro-compound.[20] 
To a solution of the N-deprotected amine (0.18 mmol, 1 equiv) in DCM (2.8 mL) 
under N2 atmosphere, was added TEA (0.75 mmol, 4 equiv) and stirred for 10 
minutes at room temperature. Then N-(5-formylthiazol-2-yl)acetamide (0.22 mmol, 
1.2 equiv) was added and stirred at room temperature for 30 min. Then sodium 
triacetoxyborohydride (0.56 mmol, 3 equiv) was added and stirred at room 
temperature for 16 h. The mixture was treated with NaHCO3 sat. and extracted with 
DCM. The organic layer was separated, dried (MgSO4), filtered and the solvents 
evaporated in vacuo. The crude was purified by revers phase HPLC 
chromatography.[34] 
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8.4.19 General procedure for the reductive amination reaction with 
aldehydes[34] 
To a solution of the deprotected spiro-cyclic amine (0.451 mmol, 1 equiv,) in DCM 
(6.8 mL) under N2 atmosphere, was added TEA (1.8 mmol, 4 equiv) and stirred for 
10 min. at room temperature (TEA was only added when the deprotection of the 
amine has been performed with 4 N HCl in 1,4-dioxane). Then N-(5-formylthiazol-2-
yl)acetamide (0.541 mmol, 1.2 equiv) was added and stirred at room temperature 
for 30 min. Then sodium triacetoxyborohydride (1.352 mmol, 3 equiv) was added 
and stirred at room temperature for 16 h. The mixture was treated with NaHCO3 
sat. and extracted with DCM. The organic layers were separated, dried (MgSO4), 
filtered and the solvents evaporated in vacuo. The crude was purified by flash 
chromatography. 
8.4.20 General procedure for the reductive amination reaction with 
ketones[35] 
To a solution of the deprotected spiro-cyclic amine (0.48 mmol, 1 equiv), 1-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)ethan-1-one (0.58 mmol, 1.2 equiv), Titanium (IV) 
isopropoxide (0.72 mmol, 1.5 equiv) in DCE (3.28 mL) at room temperature was 
added sodium cyanoborohydride (0.72 mmol, 1.5 equiv) and stirred at 80 °C for 16 
h. Then the crude was cooled and filtered through a celite pad, the organic layer 
was separated and the aqueous phase extracted many times with EtOAc. The 
organic extracts were collected together, dried (MgSO4), filtered and the volatiles 
removed in vacuo. The crude was purified by flash column chromatography. 
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8.4.21 Spectral data of Chapter 5 from central cores and their 
intermediates 
Tert-butyl2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-6-
azaspiro[3.4]octane-6-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 10/90) 
yielded 112 (60% yield) as a colorless oil, as a mixture of 
diastereoisomers 45:55 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 3.33 (t, 
J = 6.7 Hz, 2Ha), 3.27 (t, J = 6.6 Hz, 2Ha'), 3.18 (s, 2Ha), 3.13 (s, 
2Ha'), 2.40 (m, 1Ha + 1Ha'), 2.07 (d, J = 10.8 Hz, 2Ha), 2.03 (d, J = 
8.5 Hz, 2Ha'), 1.85 (d, J = 6.8 Hz, 2Ha), 1.83 (d, J = 6.8 Hz, 2Ha'), 
1.62 (m, 2Ha + 2Ha'), 1.44 (s, 9Ha + 9Ha'), 1.22 (s, 12Ha + 12Ha'), 
0.94 (d, J = 7.7 Hz, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 
154.6, 82.9, 78.8, 58.2, 57.5, 44.8, 44.3, 40.7, 40.0, 39.9, 39.8, 37.2, 
36.6, 29.6, 28.5, 25.7, 25.6, 24.9 (2xC), 24.8 (5xC), 24.7 (4xC), 24.6 
(2xC), 19.6.11B NMR (160 MHz, CDCl3) δ 33.4. HRMS (ESI) for 
C38H69B2N2O8 [MM+H]+: calculated: 703.1468, found: 703.5247. 
2-Benzyl-7-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-2-
azaspiro[4.4]nonane 
Flash column chromatography (EtOAc in Heptane 0/100 to 
30/70) yielded 113 (72% yield) as a clear oil, as a mixture of 
diastereoisomers 1:1 (a:a’).Product 113 (60 mg) was sent to SFC 
separation (Stationary phase: Chiralpak IC 5μm 250*21.2 mm, 
Mobile phase: 90% CO2, 10% iPOH(0.3% iPrNH2)) yielding 28 mg 
113a and 38mg 113a’.  
1H NMR (CDCl3, 400 MHz) δ 7.31 (m, 4H), 7.25 – 7.20 (m, 1H), 
3.61 (s, 2H), 2.60 (t, J = 7.0 Hz, 2H), 2.39 (d, J = 9.0 Hz, 1H), 2.36 
(d, J = 9.0 Hz, 1H), 2.01 (m, 1H), 1.89 (m, 1H), 1.81 (m, 1H), 1.77 
(t, J = 7.0 Hz, 1H), 1.61 (t, J = 7.0 Hz), 1.23 (s, 12H), 1.15 (m, 1H), 
0.85 (m, 1H). 13C {1H} NMR (CDCl3, 100 MHz) δ 128.7, 128.1, 
126.7, 82.8, 67.6, 60.7, 54.1, 49.8, 49.3, 40.1, 39.2, 35.1, 33.9, 
24.8, 24.6, 18.5. 11B NMR (160 MHz, CDCl3) δ 33.3. HRMS (ESI) 
for C22H35BNO2 [M+H]+: calculated: 356.2761, found: 356.2764. 
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1H NMR (CDCl3, 400 MHz) δ 7.31 (dt, J = 14.9, 7.3 Hz, 4H), 7.22 
(t, J = 7.0 Hz, 1H), 3.61 (s, 1H), 2.65 (td, J = 9.3, 5.0 Hz, 1H), 2.61 
– 2.54 (td, J = 9.3, 5.0 Hz, 1H), 2.50 (d, J = 9.2 Hz, 1H), 2.45 (d, J 
= 9.2 Hz, 1H), 2.09 (m, 1H), 1.83 (m, 2H), 1.69 (m, 2H), 1.54 (dt, 
J = 12.7, 7.7 Hz, 1H), 1.24 (s, 12H), 1.17 (m, 2H), 1.11 (m, 1H), 
0.83 (m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 128.8, 128.7, 
128.1, 126.7, 82.8, 77.2, 77.0, 76.7, 67.1, 60.7, 54.1, 49.5, 49.1, 
40.3, 39.8, 34.8, 34.0, 24.8, 24.7, 24.6, 18.4. 11B NMR (160 MHz, 
CDCl3) δ 34.0. HRMS (ESI) for C22H35BNO2 [M+H]+: calculated: 356.2761, found: 
356.2764. 
Tert-butyl-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-6-
azaspiro[3.5]nonane-6-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 
to 20/80) yielded 114 (55% yield) as a clear transparent 
oil, as a mixture of diastereoisomers 1:1 (a:a’). 1H NMR 
(CDCl3, 400 MHz) δ 3.29 (s, 2Ha), 3.27 (s, 2Ha + 2Ha'), 3.18 
(s, 2Ha'), 2.36 (m, 1Ha + 1Ha'), 1.97 (m, 2Ha), 1.87 (m, 
2Ha'), 1.45 (s, 9Ha), 1.44 (s, 9Ha'), 1.40 (broad s, 2Ha + 
2Ha'), 1.32 – 1.23 (broad s, 4Ha + 4Ha'), 1.21 (s, 12Ha + 
12Ha'), 0.94 (m, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 
MHz) δ 155.1, 82.8, 78.9, 56.0, 53.1, 43.5, 38.6, 35.7, 34.5, 28.4, 24.7 (3xC), 22.0, 
20.1. 11B NMR (160 MHz, CDCl3) δ 33.4. HRMS (ESI) for C20H36BNNaO4 [M+Na]+: 
calculated: 388.2635, found: 388.2635. 
Tert-butyl 3-hydroxy-1-oxa-7-azaspiro[4.4]nonane-7-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 66/34) 
yielded 115 (28% yield) as a sticky brown oil, as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 4.50 (s, 
1Ha + 1Ha’), 3.93 (m, 1Ha + 1Ha’), 3.81 (m, 2Ha), 3.61 (m, 2Ha’), 
3.53 – 3.36 (m, 3Ha+ 3Ha’), 3.33 (d, J = 11.7 Hz, 1Ha), 3.20 (d, J = 
11.5 Hz, 1Ha’),2.25 (m, 2Ha), 2.16 (m, 2Ha’), 1.95(m, 2Ha), 1.82(m, 
2Ha’), 1.44 (s, 9Ha + 9Ha’). 13C {1H} NMR (CDCl3, 100 MHz) δ 164.0, 
162.4, 159.4, 154.4, 107.2, 107.2, 88.2, 88.1, 87.4, 87.3, 79.3, 72.1, 
72.0, 56.2, 55.7, 55.6, 55.2, 45.2, 44.8, 44.6, 44.3, 40.0, 39.9, 39.5, 37.0, 36.5, 36.4, 
36.3, 35.9, 31.3, 28.4, 24.6. HRMS (ESI) for C12H20NO4 [M-H]-: calculated: 242.1398, 
found: 242.1390. 
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Tert-butyl 3-hydroxy-1-oxa-8-azaspiro[4.5]decane-8-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 66/34) 
yielded 116 (29% yield) as a transparent oil. 1H NMR (CDCl3, 400 MHz) 
δ 4.48 (s, 1H), 3.90 (dd, J = 9.9, 4.4 Hz, 1H), 3.79 (m, 1H), 3.57 (broad s, 
2H), 3.32 (m, 2H), 2.16 (d, J = 4.4 Hz, 1H), 1.94 (dd, J = 13.6, 6.3 Hz, 1H), 
1.82 (m, 2H), 1.65 (m, 1H), 1.52 (m, 2H), 1.44 (s, 9H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 154.8, 80.2, 79.4, 73.9, 72.6, 46.4, 37.1, 36.2, 28.4. 
HRMS (ESI) for C13H22NO4 [M-H]-: calculated: 256.1554 found: 
256.1550. 
1-(Tert-butyl) 3-methyl pyrrolidine-1,3-dicarboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 15/85) 
yielded 118 (89% yield) as a colorless oil. 1H NMR (CDCl3, 400 
MHz) δ 3.69 (s, 3H), 3.64 – 3.38 (m, 3H), 3.38 – 2.92 (m, 2H), 2.10 
(s, 2H), 1.43 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 173.4, 154.2, 
79.3, 51.9, 47.9, 45.0, 43.1, 42.2, 28.4. HRMS (ESI) for 
C11H19NNaO4 [M+Na]+: calculated: 252.1211, found: 252.1210. 
1-(Tert-butyl) 3-methyl 3-allylpyrrolidine-1,3-dicarboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 
15/85) yielded 119 (50% yield) as a yellow oil. 1H NMR (CDCl3, 
400 MHz) δ 5.68 (m, 1H), 5.06 (m, 2H), 3.74 (dd, J = 32.6, 11.0 
Hz, 1H), 3.69 (s, 3H), 3.46 – 3.32 (m, 2H), 3.25 (dd, J = 16.5, 11.3 
Hz, 1H), 2.40 (d, J = 7.1 Hz, 2H), 2.35 – 1.83 (m, 2H), 1.44 (s, 9H). 
13C {1H} NMR (CDCl3, 100 MHz) δ 174.8, 154.4, 133.1, 118.6, 
79.4, 79.3, 53.0, 52.1, 44.8, 44.3, 40.4, 33.4, 32.8, 31.8, 28.4, 
22.6, 14.0. HRMS (ESI) for C14H23NNaO4 [M+Na]+: calculated: 292.1524, found: 
292.1527. 
1-(Tert-butyl) 3-methyl 3-allylpyrrolidine-1,3-dicarboxylate 
After evaporation of the volatiles yielded 120 (98% yield) as a 
yellow oil. 1H NMR (CDCl3, 400 MHz) δ 5.89 – 5.70 (m, 1H), 5.18 
– 5.02 (m, 2H), 3.54 – 3.43 (s, 2H), 3.36 (m, 2H), 3.30 – 3.17 (m, 
1H), 3.10 (m, 1H), 2.31 – 2.01 (m, 3H), 1.77 (m, 1H), 1.66 (m, 
1H), 1.44 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 154.7, 134.3, 
118.1, 79.2, 65.9, 52.9, 52.5, 44.7, 44.3, 39.16, 32.0, 31.3, 28.5. 
HRMS (ESI) for C13H22NO3 [M-H]-: calculated: 240.1599, found: 
240.1599. 
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Tert-butyl 3-allyl-3-(iodomethyl)pyrrolidine-1-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 
15/85) yielded 121 (60% yield) as a colorless oil. 1H NMR (CDCl3, 
400 MHz) δ 5.69 (m, 1H), 5.25 – 5.07 (m, 2H), 3.41 (m, 2H), 3.30 
(s, 1H), 3.25 – 3.19 (s, 3H), 2.34 – 2.21 (m, 2H), 1.89 – 1.80 (m, 
2H), 1.45 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 154.5, 132.8, 
119.2, 79.4, 79.4, 55.3, 54.6, 45.1, 44.6, 44.41, 44.3, 40.8, 40.7, 
35.4, 34.3, 28.4, 15.9. HRMS (ESI) for C26H45I2N2O4 [MM+H]+: 
calculated:703.1469, found: 703.0930. 
Tert-butyl 2-oxopyrrolidine-1-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 15/85) 
yielded 123 (75% yield) as a clear transparent oil. 1H NMR (CDCl3, 
400 MHz) δ 3.74 – 3.68 (t, 2H, J= 8.1 Hz), 2.47 (t, J = 8.1 Hz, 2H), 1.97 
(tt, J = 15.2, 7.7 Hz, 2H), 1.49 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) 
δ 174.2, 150.1, 82.6, 46.3, 32.8, 27.9, 17.3. HRMS (ESI) for 
C9H15NNaO3 [M+Na]+: calculated: 208.0950, found: 208.0945. 
1-(Tert-butyl) 3-methyl 2-oxopyrrolidine-1,3-dicarboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 60/40) 
yielded 124 (85% yield) as a viscous transparent oil that 
precipitates upon standing as white solid. 1H NMR (CDCl3, 400 
MHz) δ 3.86 (ddd, J = 10.8, 8.5, 5.4 Hz, 1H), 3.76 (s, 3H), 3.68 (ddd, 
J = 10.8, 8.1, 6.6 Hz, 1H), 3.53 (dd, J = 9.1, 7.4 Hz, 1H), 2.37 (dddd, J 
= 13.2, 8.4, 7.4, 6.7 Hz, 1H), 2.21 (dddd, J = 13.2, 9.1, 8.1, 5.4 Hz, 
1H), 1.50 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 169.0, 168.5, 
149.8, 83.3, 52.7, 50.0, 44.8, 27.8, 21.3. HRMS (ESI) for 
C11H17NNaO5 [M+Na]+: calculated: 266.1004, found: 266.1008. 
1-(Tert-butyl) 3-methyl 3-(but-3-en-1-yl)-2-oxopyrrolidine-1,3-dicarboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 
14/86) yielded 125 (90% yield) as a viscous colourless oil. 1H 
NMR (CDCl3, 400 MHz) δ 5.77 (ddt, J = 16.8, 10.2, 6.5 Hz, 
1H), 5.03 (dd, J = 17.1, 1.6 Hz, 1H), 4.97 (dd, J = 10.2, 1.4 Hz, 
1H), 3.74 (s, 3H), 3.71 (dt, J = 8.4, 2.3 Hz, 2H), 2.54 (ddd, J = 
13.1, 6.4, 4.2 Hz, 1H), 2.23 (ddd, J = 13.5, 11.1, 5.4 Hz, 1H), 
2.15 – 1.97 (m, 2H), 1.92 (dt, J = 13.1, 8.8 Hz, 1H), 1.79 (ddd, 
J = 13.6, 10.8, 5.3 Hz, 1H), 1.52 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 170.9, 170.6, 
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150.0, 137.1, 115.3, 83.3, 57.3, 52.9, 43.8, 33.5, 31.8, 28.8, 27.9, 27.2, 22.6, 14.0. 
HRMS (ESI) for C15H22NO5 [M-H]-: calculated: 296.1503, found: 296.1170. 
Methyl 3-(but-3-en-1-yl)-2-oxopyrrolidine-3-carboxylate 
After work up yielded 126 (87% yield) as colourless oil. 1H NMR 
(CDCl3, 400 MHz) δ 5.78 (ddt, J = 16.5, 10.2, 6.4 Hz, 1H), 5.02 (dd, 
J = 17.2, 1.7 Hz, 1H), 4.95 (dd, J = 10.3, 1.7 Hz, 1H), 3.73 (s, 3H), 
3.43 (dt, J = 9.3, 7.6 Hz, 1H), 3.31 (tdd, J = 9.7, 3.4, 1.1 Hz, 1H), 
2.64 (ddd, J = 13.0, 7.8, 3.4 Hz, 1H), 2.20 – 2.11 (m, 1H), 2.10 – 
2.00 (m, 4H), 1.83 – 1.69 (m, 1H). 13C {1H} NMR (CDCl3, 100 MHz) δ 175.7, 171.7, 
137.4, 115.0, 54.7, 52.6, 39.7, 33.2, 30.4, 28.9. HRMS (ESI) for C10H15NNaO3 
[M+Na]+: calculated:220.0950, found: 220.0948. 
Methyl 1-benzyl-3-(but-3-en-1-yl)-2-oxopyrrolidine-3-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 
50/50) yielded 127 (79% yield) as a transparent oil. 1H NMR 
(CDCl3, 400 MHz) δ 7.41 – 7.24 (m, 3H), 7.24 – 7.17 (m, 2H), 
5.88 – 5.73 (m, 1H), 5.03 (dd, J = 17.2, 1.7 Hz, 1H), 4.96 (dd, 
J = 10.2, 1.7 Hz, 1H), 4.50 (d, J = 14.7 Hz, 1H), 4.44 (d, J = 
14.7 Hz, 1H), 3.73 (s, 3H), 3.32 (dt, J = 9.5, 7.8 Hz, 1H), 3.15 
(td, J = 9.2, 3.2 Hz, 1H), 2.57 – 2.41 (m, 1H), 2.23 – 2.13 (m, 1H), 2.13 – 2.00 (m, 2H), 
1.95 (ddd, J = 13.2, 8.9, 7.6 Hz, 1H), 1.90 – 1.81 (m, 1H). 13C {1H} NMR (CDCl3, 100 
MHz) δ 172.0, 171.8, 137.5, 136.0, 128.6, 128.4, 128.0, 127.6, 127.5, 126.9, 115.0, 
65.2, 55.6, 52.5, 47.0, 44.0, 33.2, 28.8, 27.9. HRMS (ESI) for C17H22NO3 [M+H]+: 
calculated: 288.1594, found: 288.1600. 
(1-Benzyl-3-(but-3-en-1-yl)pyrrolidin-3-yl)methanol 
After work up yielded 128 (80% yield) as a brown oil. 1H 
NMR (CDCl3, 400 MHz) δ 7.21 (m, 5H), 5.71 (ddt, J = 16.8, 
10.2, 6.5 Hz, 1H), 4.93 (dd, J = 17.1, 1.7 Hz, 1H), 4.86 (dd, J 
= 10.2, 1.8 Hz, 1H), 3.53 (d, J = 9.6 Hz, 1H), 3.49 (d, J = 2.5 
Hz, 2H), 3.35 (dd, J = 9.6, 1.8 Hz, 1H), 2.95 (td, J = 9.0, 2.9 
Hz, 1H), 2.79 (d, J = 9.0 Hz, 1H), 2.17 (dd, J = 17.6, 9.4 Hz, 
1H), 2.08 (dd, J = 9.1, 1.7 Hz, 1H), 1.92 (m, 3H), 1.61 (ddd, J = 12.8, 9.7, 3.0 Hz, 1H), 
1.38 (m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 138.7, 138.2, 128.5, 128.4, 127.1, 
114.4, 71.8, 64.3, 59.9, 53.9, 45.3, 36.2, 32.8, 29.3.HRMS (ESI) for C16H24NO [M+H]+: 
calculated: 246.1858, found: 246.1863. 
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1-Benzyl-3-(but-3-en-1-yl)-3-(iodomethyl)pyrrolidine 
Flash column chromatography (EtOAc in Heptane 0/100 to 
15/85) yielded 129 (45% yield) as a colorless oil. 1H NMR 
(CDCl3, 400 MHz) δ 7.33 – 7.19 (m, 5H), 5.83 (ddt, J = 16.8, 
10.2, 6.5 Hz, 1H), 5.04 (dd, J = 17.1, 1.8 Hz, 1H), 4.96 (dd, J 
= 10.2, 1.9 Hz, 1H), 3.57 (s, 2H), 3.41 (d, J = 9.7 Hz, 1H), 3.32 
(d, J = 9.7 Hz, 1H), 2.77 – 2.64 (m, 1H), 2.57 (d, J = 9.6 Hz, 
1H), 2.50 (m, 1H), 2.35 (d, J = 9.6 Hz, 1H), 2.03 – 1.91 (m, 2H), 1.82 – 1.69 (m, 2H), 
1.68 – 1.53 (m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 139.1, 138.4, 128.4, 128.2, 
126.8, 114.5, 64.9, 60.0, 53.8, 44.8, 39.1, 36.2, 28.8, 21.3. HRMS (ESI) for C16H23IN 
[M+H]+: calculated: 353.0870, found: 356.0916. 
1-(Tert-butyl) 3-ethyl piperidine-1,3-dicarboxylatee 
Flash column chromatography (pentane: EtOAc 100:0 to 60:40) 
yielded 130 (86% yield) as a colorless oil. 1H NMR (CDCl3, 400 MHz) 
δ 4.07 (q, J = 8 Hz, 2H), 3.84 (apparent d, 1H), 2.75 (ddd, J = 13.3, 
11.4, 3.0 Hz, 1H), 2.36 (m, 1H), 1.97 (m, 1H), 1.59 (m, 2H), 1.44(m, 
3H), 1.39 (s, 9H), 1.19 (t, J = 7.1 Hz, 3H). 13C {1H} NMR (CDCl3, 100 
MHz) δ 173.3, 154.5, 146.7, 85.0, 79.5, 60.3, 41.3, 28.3, 27.3, 27.2, 
14.1. HRMS (ESI) for C13H23NNaO4 [M + Na]+: calculated:280.1519, 
found: 280.1523. 
1-(Tert-butyl) 3-ethyl 3-allylpiperidine-1,3-dicarboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 
15/85) yielded 131 (94% yield) as a brown oil. 1H NMR (CDCl3, 
400 MHz) δ 5.89 – 5.55 (m, 1H), 5.23 – 4.93 (m, 2H), 4.11 (s, 2H), 
3.77 (broad s, 1H), 3.41 (broad s, 1H), 3.22 (broad s, 2H), 2.34 
(dd, J = 13.8, 7.1 Hz, 1H), 2.19 (dd, J = 13.8, 7.7 Hz, 1H), 1.99 
(broad s, 1H), 1.55 (m, 3H), 1.43 (m, 9H), 1.24 (t, J = 7.0 Hz, 3H). 
13C {1H} NMR (CDCl3, 100 MHz) δ 174.4, 154.7, 132.8, 118.3, 79.4, 
60.4, 49.7, 46.3, 43.3, 39.8, 31.6, 28.3, 27.7, 21.7, 14.2. HRMS 
(ESI) for C16H27NO4 [M+Na]+: calculated: 320.1837, found: 
320.1838. 
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Tert-butyl 3-allyl-3-(hydroxymethyl)piperidine-1-carboxylate 
 After evaporation of the volatiles yielded 132 (93% yield) as a clear 
transparent oil. 1H NMR (CDCl3, 400 MHz) δ 5.81 (m, 1H), 5.03 (m, 
2H), 3.77 (broad s, 1H), 3.47 (broad s, 1H), 3.21 (broad s, 1H), 2.94 
(broad s, 2H), 2.56 (s, 1H), 2.16 (m, 1H), 1.99 (m, 1H), 1.48 (m, 1H), 
1.43 (m, 9H), 1.33 (broad s, 4H). 13C {1H} NMR (CDCl3, 100 MHz) δ 
155.0, 132.6, 116.8, 78.7, 62.1, 48.1, 44.4, 38.9, 37.5, 29.2, 27.2, 
20.3. HRMS (ESI) for C14H25NNaO3 [M+Na]+: calculated: 278.1732, 
found: 278.1735. 
Tert-butyl 3-allyl-3-(iodomethyl)piperidine-1-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 15/85) 
yielded 133 (69% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ 5.70 
(m, 1H), 5.15 (m, 2H), 3.44 (m, 1H), 3.32 (m, 1H), 3.20 (m, 4H), 2.09 
(s, 2H), 1.56 (t, J = 14.9 Hz, 4H), 1.45 (s, 10H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 154.8, 132.3, 119.1, 79.7, 51.9, 43.5, 40.2, 36.1, 33.5, 
31.8, 29.0, 28.4, 22.7, 21.1, 16.9, 14.1. HRMS (ESI) for C14H25INO2 
[M+H]+: calculated: 366.09301, found: 366.0917. 
Tert-butyl 4-allyl-4-hydroxypiperidine-1-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 20/80) 
yielded 136 (97% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 
5.84 (ddt, J = 17.7, 10.2, 7.5 Hz, 1H), 5.16 (dd, J = 10.2, 2.1 Hz, 1H), 5.11 
(dd, J = 10.2, 2.1 Hz, 1H), 3.71 (broad s, 2H), 3.14 (broad s, 2H), 2.20 (d, 
J = 7.5 Hz, 2H), 1.53 – 1.47 (m, 4H), 1.42 (s, 9H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 154.8, 132.6, 119.5, 79.3, 69.1, 47.2, 36.5, 28.4. HRMS 
(ESI) for C13H23NNaO3 [M+Na]+: calculated: 264.1575, found: 
264.1582. 
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8.4.22 Spectral data of Chapter 5 from final targets and their 
intermediates  
Tert-butyl 2-((2,6-dimethylpyridin-4-yl)methyl)-6-azaspiro[3.4]octane-6-
carboxylate 
Flash column chromatography (MeOH in DCM 0/100 to 5/95) 
yielded 137 (54% yield) as a clear transparent oil. 1H NMR (CDCl3, 
400 MHz) δ 6.73 (s, 2Ha + 2Ha'), 3.32 (m, 4Ha + 4Ha'), 2.62 (t, J = 
6.4 Hz, 2Ha + 2Ha'), 2.54 (m, 1Ha + 1Ha'), 2.48 (s, 6Ha + 6Ha'), 2.06 
(m, 2Ha + 2Ha'), 1.70 (m, 4Ha + 4Ha'), 1.45 (s, 9Ha + 9Ha'). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 157.4, 154.7, 154.5, 150.0, 121.3, 120.4, 
118.2, 78.9, 57.3, 56.6, 44.6, 44.3, 44.2, 42.4, 42.3, 41.9, 41.3, 38.8, 
38.1, 37.6, 37.4, 37.4, 37.2, 36.5, 30.4, 30.2, 30.0, 28.5, 24.4, 24.3. 
HRMS (ESI) for C20H31N2O2 [M+H]+: calculated: 331.2386, found: 
331.2385. 
N-(5-((2-((2,6-dimethylpyridin-4-yl)methyl)-6-azaspiro[3.4]octan-6-
yl)methyl)thiazol-2-yl)acetamide 
Purified by by RP HPLC (Stationary phase: XBridge C18 50 x 
100mm, 5 μm), Mobile phase: Gradient from 73% NH4HCO3 
0.25% solution in Water, 27% CH3CN to 56% NH4HCO3 
0.25% solution in Water, 44% CH3CN), yielded the two 
diastereoisomers separated. 138a (13.5% yield) and 138a’ 
(13.2% yield) as a transparent oil. 
 
1H NMR (CDCl3, 400 MHz) δ 12.43 (s, 1H), 7.19 (s, 1H), 6.69 
(s, 2H), 3.74 (s, 2H), 2.62 (t, J = 6.8 Hz, 2H), 2.58 – 2.53 (m, 
4H), 2.46 (s, 6H), 2.45 – 2.38 (m, 1H), 2.30 (s, 3H), 2.04 (m, 
2H), 1.91 (t, J = 6.8 Hz, 2H), 1.77 – 1.68 (m, 2H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 167.9, 159.8, 157.4, 150.3, 133.4, 
130.5, 120.4, 67.1, 53.2, 51.6, 42.2, 41.0, 40.8, 39.3, 30.2, 
24.3, 23.1. HRMS (ESI) for C21H28N4OS [M]+: calculated: 
384.1984 found: 384.1983. 
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1H NMR (CDCl3, 400 MHz) δ 12.51 (s, 1H), 7.19 (s, 1H), 6.69 (s, 
2H), 3.74 (s, 2H), 2.60 (s, 2H), 2.56 (dd, J = 7.4, 2.7 Hz, 4H), 
2.46 (s, 6H), 2.34 (m, 1H), 2.30 (s, 3H), 2.10 (m, 2H), 1.82 (t, J 
= 7.1 Hz, 2H), 1.69 (m, 2H).13C {1H} NMR (CDCl3, 100 MHz) δ 
167.9, 159.8, 157.3, 150.3, 133.3, 130.7, 120.4, 66.5, 53.3, 
51.6, 42.3, 41.1, 41.0, 39.4, 31.0, 24.3, 23.1.HRMS (ESI) for 
C21H28N4OS [M]+: calculated: 384.1984, found: 384.1983. 
 
Tert-butyl 2-(hydroxymethyl)-6-azaspiro[3.4]octane-6-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100; 20/80; 
40/60; 100/0) yielded 139 (91% yield) as a transparent oil as a 
mixture of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 
3.59 – 3.48 (m, 2Ha + 2Ha'), 3.34 – 3.10 (m, 4Ha + 4Ha'), 2.59 (broad 
s, 1Ha + 1Ha'), 2.45 – 2.34 (m, 1Ha + 1Ha'), 2.03 – 1.96 (m, 2Ha), 
1.95 – 1.89 (m, 2Ha'), 1.83 (m, 2Ha), 1.77 – 1.70 (m, 2Ha + 2Ha'), 
1.70 – 1.65 (m, 2Ha'), 1.39 (s, 9Ha + 9Ha'). 13C {1H} NMR (CDCl3, 100 
MHz) δ 154.8, 79.0, 66.9, 66.8, 63.0, 44.8, 44.7, 44.6, 44.5, 44.2, 
44.2, 38.7, 38.0, 37.7, 37.7, 37.0, 35.6, 33.8, 33.5, 33.5, 31.8, 31.1, 
30.9, 28.9, 28.4, 28.2, 24.7, 23.2, 23.1, 22.6, 14.0. HRMS (ESI) for C13H23NNaO3 
[M+Na]+: calculated: 264.1575, found: 264.1574. 
Tert-butyl-2-(((2,6-dimethylpyridin-4-yl)oxy)methyl)-6-azaspiro[3.4]octane-6-
carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 100/0) 
yielded 140 (70% yield) as a colourless oil. 1H NMR (CDCl3, 400 
MHz) δ 6.48 (s, 2Ha + 2Ha'), 3.94 (m, 2Ha + 2Ha'), 3.69 (s, 2Ha), 3.37 
(m, 2Ha + 2Ha'), 3.25 (m, 2Ha'), 2.72 (m, 1Ha + 1Ha'), 2.46 (s, 6Ha + 
6Ha'), 2.13 (m, 2Ha), 2.08 (t, J = 10.3 Hz, 2Ha'), 1.92 (m, 2Ha), 1.87 
(m, 2Ha'), 1.80 (m, 2Ha + 2Ha'), 1.49 (s, 9Ha + 9Ha'). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 165.7, 159.0, 154.6, 106.6, 78.9, 71.2, 71.2, 
70.5, 67.7, 44.6, 44.5, 44.4, 44.2, 44.1, 38.6, 37.9, 37.6, 36.9, 34.0, 
33.9, 33.8, 33.6, 28.4, 24.4. HRMS (ESI) for C20H31N2O3 [M+H]+: 
calculated: 347.2334, found: 347.2335.  
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N-(5-((2-(((2,6-dimethylpyridin-4-yl)oxy)methyl)-6-azaspiro[3.4]octan-6-
yl)methyl)thiazol-2-yl)acetamide 
 Purified by RP HPLC (Stationary phase: C18 XBridge 30 x 100 
mm 5 um), Mobile phase: Gradient from 81% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 19% CH3CN to 
64% 0.1% NH4CO3H/NH4OH pH 9 solution in Water, 36% 
CH3CN), and via chiral SFC (Stationary phase: CHIRALPAK 
AD-H 5μm 250*30mm, Mobile phase: 60% CO2, 40% 
EtOH(0.3% iPrNH2)) yielded the two diastereoisomers 
separatelly 141a (10% yield) and 141a’ (13% yield) both as 
sticky oils. 
1H NMR (CDCl3, 400 MHz) δ 12.43 (s, 1Ha), 7.19 (s, 1Ha), 
6.45 (s, 2Ha), 3.87 (d, J = 6.4 Hz, 2Ha), 3.74 (s, 2Ha), 2.66 
(dt, J = 10.1, 6.7 Hz, 1Ha + 2Ha), 2.60 (s, 2Ha), 2.44 (s, 6Ha), 
2.30 (s, 3Ha), 2.10 (m, 2Ha), 1.98 (t, J = 6.9 Hz, 2Ha), 1.89 
(m, 2Ha).13C {1H} NMR (CDCl3, 100 MHz) δ 167.8, 165.8, 
159.8, 159.0, 133.5, 130.4, 106.7, 71.5, 67.18, 53.2, 51.6, 
41.0, 39.6, 37.6, 28.3, 24.4, 23.0.HRMS (ESI) for 
C21H29N4O2S [M+H]+: calculated: 401.2011, found: 
401.2010. 
 
1H NMR (CDCl3, 400 MHz) δ 12.62 (s, 1Ha'), 7.22 (s, 1Ha'), 
6.47 (s, 2Ha'), 3.90 (d, J = 6.4 Hz, 2Ha'), 3.78 (s, 2Ha'), 2.67 
(s, 2Ha'), 2.62 (t, J = 7.1 Hz, 2Ha'), 2.56 (m, 1Ha'), 2.46 (s, 
6Ha'), 2.33 (s, 3Ha'), 2.25 – 2.10 (m, 2Ha'), 1.86 (m, 
4Ha').13C {1H} NMR (CDCl3, 100 MHz) δ 168.0, 165.8, 159.9, 
159.0, 133.3, 130.6, 106.7, 71.6, 66.6, 53.3, 51.5, 41.3, 
39.5, 37.5, 28.9, 24.4, 23.0.HRMS (ESI) for C21H29N4O2S 
[M+H]+: calculated: 401.2011, found: 401.2010. 
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Tert-butyl 2-iodo-6-azaspiro[3.4]octane-6-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 15/85) 
yielded 143 (48% yield) as a clear trasnparent oil, as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 4.45 (p, J = 
8.2 Hz, 1Ha + 1Ha'), 3.31 (m, 4Ha + 4Ha'), 2.66 (m, 4Ha + 4Ha'), 1.96 
(m, 2Ha), 1.86 (m, 2Ha'), 1.44 (s, 9Ha + 9Ha').13C {1H} NMR (CDCl3, 
100 MHz) δ 154.6, 154.4, 79.3, 57.4, 56.9, 56.2, 55.6, 46.3, 45.9, 
45.8, 45.7, 45.5, 45.2, 44.5, 44.1, 35.5, 31.8, 28.5, 22.6, 14.1, 8.5, 
8.4, 8.3, 8.2. HRMS (ESI) for C24H41I2N2O4 [MM+H]+: calculated: 
675.1155, found: 675.1152. 
Tert-butyl 2-(2,6-dimethylpyridin-4-yl)-6-azaspiro[3.4]octane-6-carboxylate 
Flash column chromatography (MeOH in DCM 0/100 to 10/90) 
and repurified by HPLC (Stationary phase: C18 XBridge 30 x 100 
mm 5 um), Mobile phase: Gradient from 81% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 19% CH3CN to 64% 
0.1% NH4CO3H/NH4OH pH 9 solution in Water, 36% CH3CN) 
yielded 144 (9% yield) as a colourless oil, as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 6.76 (s, 
2Ha + 2Ha'), 3.44 (m, 2Ha + 2Ha'), 3.36 (m, 1Ha + 1Ha'), 3.28 (m, 
2Ha + 2Ha'), 2.48 (s, 6Ha + 6Ha'), 2.41 – 2.26 (m, 2Ha + 2Ha'), 
2.20 – 2.02 (m, 2Ha + 2Ha'), 1.99 (m, 2Ha), 1.80 (m, 2Ha'), 1.48 
– 1.44 (s, 9Ha + 9Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 157.6, 154.5, 118.2, 118.2, 
79.1, 57.7, 57.10, 57.0, 56.3, 44.8, 44.6, 44.4, 44.2, 41.0, 40.2, 38.4, 38.0, 37.9, 37.7, 
37.0, 36.2, 33.5, 33.1, 28.5, 24.4. HRMS (ESI) for C19H29N2O2 [M+H]+: calculated: 
317.2229, found: 317.2229. 
N-(5-((2-(2,6-dimethylpyridin-4-yl)-6-azaspiro[3.4]octan-6-yl)methyl)thiazol-2-
yl)acetamide 
Purified by RP HPLC (Stationary phase: XBridge C18 50 x 
100 mm, 5 μm), Mobile phase: Gradient from 73% 
NH4HCO3 0.25% solution in Water, 27% CH3CN to 56% 
NH4HCO3 0.25% solution in Water, 44% CH3CN)yielded 
145 (43% yield) as a colourless oil, as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 
12.42 (s, 1Ha + 1Ha'), 7.23 (s,1Ha), 7.20 (s, 1Ha'), 6.74 (s, 
2Ha + 2Ha'), 3.80 (s, 2Ha), 3.75 (s, 2Ha'), 3.40 – 3.31 (m, 
1Ha), 3.29 – 3.20 (m, 1Ha'), 2.74 (s, 2Ha), 2.68 (t, J = 6.8 
Hz, 2Ha), 2.62 (t, J = 7.2 Hz, 2Ha'), 2.59 (s, 2Ha'), 2.47 (s, 6Ha + 6Ha'), 2.43 – 2.35 (m, 
2Ha + 2Ha'), 2.32 (s, 3Ha + 3 Ha'), 2.17 – 2.08 (m, 2Ha + 2Ha'), 2.06 (t, J = 5.3 Hz, 
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2Ha), 1.85 (t, J = 7.1 Hz, 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 167.9, 159.9, 159.8, 
157.4, 155.0, 154.9, 133.5, 133.4, 130.7, 130.5, 118.2, 118.2, 66.7, 66.1, 53.4, 53.4, 
53.2, 51.6, 51.6, 41.4, 41.3, 41.1, 40.7, 39.0, 34.1, 33.3, 24.3, 23.1. HRMS (ESI) for 
C20H27N4OS [M+H]+: calculated: 371.1905, found: 371.1902. 
N-(5-((2-(2-methoxy-6-methylpyridin-4-yl)-6-azaspiro[3.4]octan-6-
yl)methyl)thiazol-2-yl)acetamide 
 Purified by RP HPLC (Stationary phase: C18 XBridge 30 x 
100 mm 5 um), Mobile phase: Gradient from 81% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 19% CH3CN to 
64% 0.1% NH4CO3H/NH4OH pH 9 solution in Water, 36% 
CH3CN), yielded the two diastereoisomers separatelly 
146a (2.5% yield) and 146a’ (2.5% yield) both as sticky 
oils.  
 
1H NMR (CDCl3, 400 MHz) δ 11.80 (s, 1Ha), 7.23 (s, 1Ha), 
6.52 (s, 1Ha), 6.32 (s, 1Ha), 3.89 (s, 3Ha), 3.81 (s, 2Ha), 
3.24 (p, J = 9.0 Hz, 1Ha), 2.74 (s, 2Ha), 2.63 (t, J = 7.2 Hz, 
2Ha), 2.40 (s, 3Ha), 2.40 – 2.36 (m, 2Ha), 2.31 (s, 3Ha), 
2.09 (td, J = 9.6, 2.6 Hz, 2Ha), 1.85 (t, J = 7.2 Hz, 2Ha). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 167.9, 164.0, 159.7, 157.6, 
155.9, 133.6, 130.5, 114.3, 104.4, 66.0, 53.2, 53.2, 51.5, 
41.2, 41.0, 38.9, 34.1, 24.1, 23.1. HRMS (ESI) for 
C20H27N4O2S [M+H]+: calculated: 387.1854, found: 387.1853. 
1H NMR (CDCl3, 400 MHz) δ 11.99 (s, 1Ha'), 7.20 (s, 1Ha'), 
6.52 (s, 1Ha'), 6.31 (s, 1Ha'), 3.89 (s, 3H), 3.75 (s, J = 5.4 
Hz, 2H), 3.34 (p, J = 9.0 Hz, 1H), 2.68 (t, J = 6.8 Hz, 2H), 
2.59 (s, 2H), 2.40 (s, 3H), 2.36 – 2.31 (m, 2H), 2.30 (s, 4H), 
2.12 (td, J = 9.5, 2.6 Hz, 2H), 2.06 (t, J = 6.8 Hz, 2H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 167.9, 164.0, 159.7, 157.5, 
155.9, 133.6, 130.4, 114.3, 104.4, 66.7, 53.4, 53.2, 51.6, 
41.3, 40.7, 38.9, 33.3, 24.1, 23.1. HRMS (ESI) for 
C20H27N4O2S [M+H]+: calculated: 387.1854  found: 
387.1853. 
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2-Benzyl-7-((2,6-dimethylpyridin-4-yl)methyl)-2-azaspiro[4.4]nonane 
Flash column chromatography (MeOH in DCM 0/100 to 5/95) 
yielded 147 (57% yield) as a colourless oil as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 7.29 (m, 
5Ha + 5Ha'), 6.74 (s, 2Ha + 2Ha'), 3.60 (s, 2Ha + 2Ha'), 2.62 (m, 
4Ha), 2.47 (m, 6Ha + 10Ha'), 2.35 (m, 2Ha), 2.20 (m, 1Ha), 2.09 
(m, 1Ha'), 1.97 – 1.75 (m, 2Ha + 2Ha'), 1.74 – 1.70 (m, 2Ha'), 1.70 
– 1.61 (m, 2Ha + 2Ha'), 1.59 – 1.49 (m, 2Ha), 1.36 – 1.08 (m, 2Ha 
+ 2Ha'), 0.83 (m, 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 157.3, 
151.3, 128.7, 128.7, 128.1, 126.8, 126.8, 120.7, 82.8, 67.4, 66.9, 
60.7, 60.6, 54.1, 54.0, 49.0, 48.9, 47.1, 46.7, 41.9, 41.8, 40.0, 39.7, 39.6, 39.6, 39.0, 
31.5, 31.4. HRMS (ESI) for C23H31N2 [M+H]+: calculated: 335.2482, found: 335.2481. 
7-((2,6-dimethylpyridin-4-yl)methyl)-2-azaspiro[4.4]nonane 
Purification by RP HPLC (Stationary phase: C18 XBridge 30 x 100 
mm 5 um), Mobile phase: Gradient from 81% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 19% CH3CN to 64% 
0.1% NH4CO3H/NH4OH pH 9 solution in Water, 36% CH3CN) 
yielded 148 (72% yield) as a colourless oil as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 6.72 (s, 
2Ha + 2Ha'), 3.31 – 3.16 (m, 2Ha + 2Ha'), 3.01 (dd, J = 23.4, 11.2 
Hz, 2Ha), 2.91 (s, 2Ha'), 2.51(m, 2Ha + 2Ha'), 2.46 (s, 6Ha + 6Ha'), 
2.19 (m, 1Ha + 1Ha'), 1.85 (m, 2Ha + 2Ha'), 1.79 (m, 2Ha + 2Ha'), 1.75 (2Ha), 1.65 (m, 
2Ha'), 1.55 (dt, J = 13.1, 8.4 Hz, 1H), 1.27 (m, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 
MHz) δ 169.5, 157.5, 120.6, 55.2, 49.5, 49.4, 43.9, 43.2, 42.9, 41.2, 40.2, 40.1, 38.0, 
37.9, 36.2, 35.8, 31.6, 31.4, 24.3. HRMS (ESI) for C16H25N2 [M+H]+: calculated: 
245.2012, found: 245.2015. 
N-(5-((7-((2,6-dimethylpyridin-4-yl)methyl)-2-azaspiro[4.4]nonan-2-
yl)methyl)thiazol-2-yl)acetamide 
Purification by RP HPLC (Stationary phase: C18 XBridge 30 x 
100 mm 5 um), Mobile phase: Gradient from 74% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 26% CH3CN to 
58% 0.1% NH4CO3H/NH4OH pH 9 solution in Water, 42% 
CH3CN) yielded the two diastereoisomers separatelly 149a 
(24% yield) and 149a’ (26%) both as sticky colorless oils 
(relative configuration not determined). A low amount was 
sent to SFC chiral separation to get the pure enantiomers, 
which were analyzed in the biological assays. 
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1H NMR (CDCl3, 400 MHz) δ 7.16 (s, 1Ha), 6.69 (s, 2Ha), 3.74 
(s, 2Ha), 2.64 (dtd, J = 16.2, 9.2, 7.1 Hz, 2Ha), 2.50 (dd, J = 
28.1, 9.0 Hz, 2Ha), 2.44 (dd, J = 7.5, 2.6 Hz, 2Ha), 2.42 (s, 
6Ha), 2.24 (s, 3Ha), 2.18 – 2.10 (m, 1Ha), 1.75 – 1.65 (m, 
2Ha), 1.65 – 1.60 (m, 3Ha), 1.49 (dt, J = 12.8, 7.6 Hz, 1Ha), 
1.22 – 1.14 (m, 2Ha). 13C {1H} NMR (CDCl3, 100 MHz) δ 
167.9, 159.7, 157.3, 151.3, 133.9, 120.8, 66.1, 53.3, 51.4, 
49.0, 46.3, 41.7, 39.7, 39.3, 31.5, 24.2, 23.1. HRMS (ESI) for 
C22H31N4OS [M+H]+: calculated: 399.2213, found: 399.2220. 
1H NMR (CDCl3, 400 MHz) δ 7.25 (s, 1H), 6.76 (s, 2H), 3.87 
(d, J = 2.5 Hz, 2H), 2.79 (td, J = 7.1, 3.0 Hz, 2H), 2.54 (dd, J = 
13.8, 6.0 Hz, 4H), 2.49 (s, 5H), 2.29 (s, 3H), 2.18 – 2.07 (m, 
1H), 1.86 – 1.77 (m, 3H), 1.73 (dt, J = 13.0, 7.1 Hz, 1H), 1.67 
– 1.61 (m, 2H), 1.34 – 1.26 (m, 1H), 1.22 (dd, J = 12.8, 9.7 
Hz, 1H).13C {1H} NMR (CDCl3, 100 MHz) δ 168.1, 167.1, 
160.0, 157.1, 151.7, 134.8, 121.0, 65.8, 52.9, 50.9, 49.1, 
46.3, 41.7, 40.0, 38.9, 38.6, 31.4, 23.8, 23.0. HRMS (ESI) for 
C22H31N4OS [M+H]+: calculated: 399.2213, found: 399.2220. 
(2-Benzyl-2-azaspiro[4.4]nonan-7-yl)methanol 
Flash column chromatography (EtOAc in Heptane 0/100 to 66/44 
to 100/0) yielded 150 (97% yield) as a white solid as a mixture of 
diastereoisomers 1:1 (a:a’).1H NMR (CDCl3, 400 MHz) δ 7.35 – 
7.28 (m, 4Ha + 4Ha'), 7.26 – 7.19 (m, 1Ha + 1Ha'), 3.60 (s, 2Ha), 
3.60 (s, 2Ha'), 3.47 (d, J = 6.9 Hz, 2Ha), 3.45 (d, J = 6.9 Hz, 2Ha'), 
2.61 (m, 3Ha + 3Ha'), 2.47 (q, J = 9.2 Hz, 2Ha), 2.40 (d, J = 2.0 Hz, 
2Ha'), 2.19 (m, 1Ha), 2.09 (m, 1Ha'), 1.89 – 1.81 (m, 1Ha'), 1.78 
(m, 2Ha + 2Ha'), 1.73 – 1.67 (m, 2Ha + 1Ha'), 1.67 – 1.53 (m, 2Ha + 2Ha'), 1.39 – 1.27 
(m, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 139.1, 139.0, 128.7, 128.6, 128.0, 
126.7, 67.2, 67.1, 66.8, 66.3, 60.7, 60.6, 54.0, 53.9, 49.1, 49.0, 43.3, 43.1, 41.0, 40.8, 
39.3, 38.8, 38.2, 27.9, 27.8. HRMS (ESI) for C16H24NO [M+H]+: calculated: 246.1852, 
found: 246.1857. 
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2-Benzyl-7-(((2,6-dimethylpyridin-4-yl)oxy)methyl)-2-azaspiro[4.4]nonane 
Flash column chromatography (EtOAc in Heptane 0/100 to 
100/0) yielded 151 (79% yield) as brown oil as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 7.34 
– 7.27 (m, 4Ha + 4Ha'), 7.25 – 7.20 (m, 1Ha + 1Ha'), 6.46 (s, 
2Ha), 6.44 (s, 2Ha'), 3.82 (m, 2Ha + 2Ha'), 3.61 (s, 2Ha), 3.60 
(s, 2Ha'), 2.67 – 2.59 (m, 2Ha + 2Ha'), 2.53 – 2.46 (m, 2Ha + 
2Ha'), 2.45 (s, 6Ha + 6Ha'), 2.42 – 2.30 (m, 2Ha + 2Ha'), 1.98 
– 1.81 (m, 1Ha + 1iHa'), 1.79 (t, J = 7.0 Hz, 2Ha), 1.73 (t, J = 
7.0 Hz, 2Ha'), 1.70 – 1.65 (m, 2Ha), 1.61 (m, 2Ha'), 1.49 – 1.32 
(m, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 165.9, 
159.0, 139.3, 128.6, 128.1, 126.7, 120.8, 106.6, 71.8, 71.8, 66.7, 66.3, 60.6, 60.5, 
54.0, 53.9, 49.3, 49.2, 43.4, 43.2, 39.3, 39.2, 38.8, 38.2, 37.9, 37.6, 28.2, 28.2, 24.5. 
HRMS (ESI) for C23H31N2O [M+H]+: calculated: 351.2431, found: 351.2454. 
N-(5-((7-(((2,6-dimethylpyridin-4-yl)oxy)methyl)-2-azaspiro[4.4]nonan-2-
yl)methyl)thiazol-2-yl)acetamide 
Flash column chromatography (MeOH in DCM 0/100 to 
6/94) yielded 152 (49% yield) as a colourless oil as a mixture 
of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 
12.64 (s, 1Ha + 1Ha'), 7.19 (s, 1Ha + 1Ha'), 6.46 (s, 2Ha), 6.44 
(s, 2Ha'), 3.85 – 3.79 (m, 2Ha + 2Ha'), 3.75 (s, 2Ha + 2Ha'), 
2.65 (m, 2Ha + 2Ha'), 2.51 (d, J = 3.1 Hz, 2Ha), 2.44 (s, 6Ha 
+ 2Ha'), 2.43 (s, 6Ha'), 2.36 (m, 2Ha + 2Ha'), 2.30 (s, 3Ha), 
2.29 (s, 3Ha'), 1.92 (m, 1Ha), 1.84 (m, 1Ha'), 1.78 (t, J = 7.0 
Hz, 2Ha), 1.71 (t, J = 7.0 Hz, 2Ha'), 1.68 – 1.54 (m, 2Ha + 
2Ha'), 1.50 – 1.30 (m, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 
MHz) δ 168.0, 165.8, 159.9, 158.9, 133.2, 130.8, 106.6, 71.7, 66.2, 65.8, 53.5, 53.4, 
51.6, 51.6, 49.3, 49.2, 43.1, 43.0, 39.1, 39.0, 38.6, 38.1, 37.8, 37.6, 28.1, 24.4, 23.0. 
HRMS (ESI) for C22H31N4O2S [M+H]+: calculated: 415.2162, found: 415.2166. 
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Tert-butyl 7-(2,6-dimethylpyridin-4-yl)-7-hydroxy-2-azaspiro[4.4]nonane-2-
carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 30/70) 
yielded 154 (53% yield) as a white solid as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 7.02 (s, 
2Ha + 2Ha'), 3.50 – 3.29 (m, 4Ha + 4Ha'), 2.52 (s, 6Ha + 6Ha'), 2.20 
– 2.07 (m, 2Ha + 2Ha'), 2.06 – 1.94 (m, 4Ha + 4Ha'), 1.90 – 1.69 
(m, 4Ha + 4Ha'), 1.46 (s, 9Ha + 9Ha'). 13C {1H} NMR (CDCl3, 100 
MHz) δ 157.9, 156.2, 155.8, 154.7, 116.6, 116.5, 79.1, 59.2, 58.5, 
58.0, 52.5, 52.5, 52.0, 51.9, 48.0, 45.6, 45.2, 45.2, 44.8, 41.5, 41.3, 
41.3, 39.7, 39.2, 39.1, 38.5, 36.2, 36.0, 35.9, 35.9, 28.5, 24.5. 
HRMS (ESI) for C20H31N2O3 [M+H]+: calculated: 347.2334, found: 
347.2335. 
Tert-butyl 7-(2,6-dimethylpyridin-4-yl)-2-azaspiro[4.4]nonane-2-carboxylate 
After filtration and evaporation yielded 155 (91% yield) as a 
colourless oil as a mixture of diastereoisomers 1:1 (a:a’). 1H NMR 
(CDCl3, 400 MHz) δ 6.85 (s, 2Ha + 2Ha'), 3.39 (m, 2Ha + 2Ha'), 3.23 
(m, 2Ha + 2Ha'), 3.08 ( broad m, 1Ha + 1Ha'), 2.53 (s, 6Ha + 6Ha'), 
2.12 (m, 2Ha), 2.03 (m, 2Ha'), 1.80 (m, 4Ha + 4Ha'), 1.67 (m, 2Ha + 
2Ha'), 1.46 (s, 9Ha + 9Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 157.2, 
154.6, 119.3, 79.1, 58.1, 57.9, 57.4, 49.5, 49.3, 48.7, 48.5, 45.4, 
45.0, 44.7, 44.1, 44.1, 38.4, 38.3, 37.7, 36.9, 36.3, 36.0, 33.1, 32.8, 
32.7, 32.5, 28.5, 23.9. HRMS (ESI) for C20H31N2O2 [M+H]+: 
calculated: 331.2380, found: 331.2390. 
N-(5-((7-(2,6-dimethylpyridin-4-yl)-2-azaspiro[4.4]nonan-2-yl)methyl)thiazol-2-
yl)acetamide 
 Purificatiion by RP HPLC (Stationary phase: XBridge C18 50 
x 100 mm, 5 μm), Mobile phase: Gradient from 73% 
NH4HCO3 0.25% solution in Water, 27% CH3CN to 56% 
NH4HCO3 0.25% solution in Water, 44% CH3CN), yielded 
156 (63% yield) as a colourless oil as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 
12.80 (s, 1Ha + 1Ha'), 7.18 (s, 1Ha + 1Ha'), 6.76 (s, 2Ha + 
2Ha'), 3.76 (s, 2Ha + 2Ha'), 3.00 (m, 1Ha), 2.90 (m, 1Ha'), 
2.67 (m, 2Ha + 2Ha'), 2.53 (m, 2Ha), 2.47 (m, 2Ha'), 2.44 (s, 
6Ha + 6Ha'), 2.29 (s, 3Ha + 3Ha'), 2.05 (m, 2Ha + 2Ha'), 1.88 
– 1.79 (m, 2Ha + 2Ha'), 1.79 – 1.72 (m, 2Ha + 2Ha'), 1.68 (m, 2Ha), 1.64 (m, 2Ha'), 
1.60 (m, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 167.9, 159.9, 159.9, 157.3, 
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155.5, 155.4, 133.1, 133.1, 130.8, 130.7, 118.9, 66.7, 66.2, 53.4, 53.2, 51.6, 51.5, 
49.3, 49.2, 47.6, 47.3, 43.9, 43.5, 39.8, 39.6, 39.4, 38.5, 32.5, 32.5, 24.2, 22.9. HRMS 
(ESI) for C21H29N4OS [M+H]+: calculated: 385.2062, found: 385.2061. 
Tert-butyl 2-((2,6-dimethylpyridin-4-yl)methyl)-6-azaspiro[3.5]nonane-6-
carboxylate 
Flash column chromatography (MeOH in DCM 0/100 to 
5/95) yielded 157 (50% yield) as a colourless oil as a 
mixture of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 
400 MHz) δ 6.67 (s, 2Ha + 2Ha'), 3.24 (m, 4Ha + 4Ha'), 
2.56 (m, 2Ha + 2Ha'), 2.45 (m, 1Ha), 2.41 (s, 6Ha + 6Ha'), 
2.38 – 2.30 (m, 1Ha'), 1.87 (t, J = 9.2 Hz, 2Ha), 1.76 (t, J = 
9.9 Hz, 2Ha'), 1.54 – 1.46 (m, 2Ha + 2Ha'), 1.40 (s, 9Ha + 
2Ha), 1.38 (s, 9Ha' + 2Ha’), 1.33 – 1.25 (m, 2Ha), 1.20 (m, 2Ha'). 13C {1H} NMR (CDCl3, 
100 MHz) δ 157.3, 154.9, 150.2, 120.4, 118.2, 79.1, 38.5, 36.3, 36.1, 29.4, 28.4, 28.4, 
28.3, 24.3, 22.0, 14.0. HRMS (ESI) for C21H33N2O2 [M+H]+: calculated: 345.2542, 
found: 345.2546. 
N-(5-((2-((2,6-dimethylpyridin-4-yl)methyl)-6-azaspiro[3.5]nonan-6-
yl)methyl)thiazol-2-yl)acetamide 
Flash column chromatography (MeOH in 
DCM 0/100 to 6/94) yielded 158 (67% yield) 
as a colourless oil as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 
400 MHz) δ 12.80 (s, 1Ha + 1Ha'), 7.16 (s, 
1Ha), 7.15 (s, 1Ha'), 6.68 (s, 2Ha + 2Ha'), 3.61 
(s, 2Ha + 2Ha'), 2.56 (d, J = 7.6 Hz, 2Ha), 2.53 
(d, J = 7.6 Hz, 2Ha'), 2.43 (s, 6Ha + 6Ha'), 2.40 
– 2.34 (m, 1Ha + 1Ha'), 2.32 (broad m, 3Ha), 2.29 (broad m, 4Ha + 4Ha'), 2.22 (broad 
s, 3Ha'), 1.95 (m, 2Ha), 1.89 – 1.79 (m, 2Ha'), 1.55 – 1.28 (m, 6Ha + 6Ha'). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 167.9, 160.1, 157.2, 157.2, 150.5, 133.6, 133.3, 130.6, 
130.0, 120.3, 120.3, 103.6, 65.4, 62.8, 54.6, 54.6, 53.5, 53.4, 42.8, 38.3, 37.5, 37.3, 
35.1, 35.0, 34.8, 29.9, 29.4, 24.1, 23.0, 22.3, 22.2. HRMS (ESI) for C22H29N4OS [M-H]-
: calculated: 397.2062, found: 397.2057. 
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Tert-butyl 2-((2-methoxy-6-methylpyridin-4-yl)methyl)-6-azaspiro[3.5]nonane-6-
carboxylate 
Flash column chromatography (MeOH in DCM 0/100 to 
5/95) yielded 159 (71% yield) as a colourless oil as a 
mixture of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 
400 MHz) δ 6.46 (s, 1Ha + 1Ha'), 6.28 (s, 1Ha + 1Ha'), 
3.85 (s, 3Ha + 3Ha'), 3.34 – 3.10 (m, 4Ha + 4Ha'), 2.64 – 
2.52 (m, 2Ha + 2Ha'), 2.42 (m, 1Ha + 1Ha'), 2.39 – 2.31 
(s, 3Ha + 3Ha'), 1.84 (m, 2Ha + 2Ha'), 1.41 (broad s, 9Ha 
+ 9Ha’), 1.20 (broad s, 6Ha + 6Ha'). 13C {1H} NMR (CDCl3, 
100 MHz) δ 163.8, 163.8, 155.6, 152.6, 116.4, 116.3, 106.5, 106.4, 82.7, 79.0, 53.0, 
42.6, 38.5, 38.5, 36.2, 31.7, 29.2, 28.9, 28.3, 28.3, 24.7, 24.7, 23.9, 22.5, 21.9, 14.0. 
HRMS (ESI) for C21H33N2O3 [M+H]+: calculated: 361.2491, found: 361.2491. 
N-(5-((2-((2-methoxy-6-methylpyridin-4-yl)methyl)-6-azaspiro[3.5]nonan-6-
yl)methyl)thiazol-2-yl)acetamide 
Flash column chromatography (MeOH in 
DCM 0/100 to 6/94) yielded 160 (68% yield) 
as a colourless oil as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 
400 MHz) δ 12.80 (s, 1Ha + 1Ha'), 7.17 (s, 
1Ha), 7.16 (s, 1Ha'), 6.47 (s, 2Ha), 6.26 (s, 
2Ha'), 3.86 (s, 3Ha + 3Ha'), 3.62 (s, 2Ha + 
2Ha'), 2.55 (m, 2Ha + 2Ha'), 2.46 – 2.39 (m, 
1Ha + 1Ha'), 2.37 (s, 3Ha + 3Ha'), 2.33 – 2.30 
(borad s, 3Ha + 2Ha + 3Ha' + 2Ha'), 2.01 – 1.89 (m, 2Ha), 1.89 – 1.81 (m, 2Ha'), 1.58- 
1.38 (m, 6Ha +6Ha'), 1.19 (s, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 167.9, 
163.8, 163.8, 160.2, 155.6, 152.9, 133.6, 133.3, 130.6, 130.0, 116.4, 106.4, 106.3, 
82.7, 65.5, 62.8, 54.6, 54.6, 53.6, 53.5, 53.1, 42.8, 42.8, 38.3, 37.6, 37.3, 35.1, 35.0, 
34.8, 29.8, 29.4, 24.7, 24.7, 23.9, 23.0, 22.4, 22.2. HRMS (ESI) for C22H31N4O2S 
[M+H]+: calculated: 415.21677, found: 415.2169. 
Tert-butyl 2-(hydroxymethyl)-6-azaspiro[3.5]nonane-6-carboxylate 
 Flash column chromatography (EtOAc in Heptane 0/100 to 
66/44 to 100/0) yielded 161 (97% yield) as a transparent oil as 
a mixture of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 
MHz) δ 3.59 (m, 2Ha + 2Ha'), 3.32 (s, 2Ha), 3.28 (d, J = 3.8 Hz, 
2Ha + 2Ha'), 3.22 (s, 2Ha'), 2.41 (m, 1Ha + 1Ha'), 1.86 (t, J = 11.4 
Hz, 2Ha), 1.81 – 1.72 (t, J = 11.4 Hz, 2Ha'), 1.59 (dd, J = 7.3, 4.2 
Hz, 1H), 1.50 – 1.46 (m, 1H), 1.45 (s, 2H), 1.44 (s, 9Ha), 1.44 (s, 
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9Ha'), 1.32 – 1.19 (m, 1H). 13C {1H} NMR (CDCl3, 100 MHz) δ 155.1, 79.2, 67.7, 55.3, 
53.5, 44.4, 43.4, 38.1, 32.6, 32.4, 31.8, 30.5, 30.0, 28.4, 22.6, 14.1. HRMS (ESI) for 
C14H25NNaO3 [M+H]+: calculated: 278.17321, found: 278.1731. 
Tert-butyl 2-(((2,6-dimethylpyridin-4-yl)oxy)methyl)-6-azaspiro[3.5]nonane-6-
carboxylate 
Flash column chromatography (EtOAc in Heptane 
0/100 to 100/0) yielded 162 (31% yield) as a colourless 
oil as a mixture of diastereoisomers 1:1 (a:a’). 1H NMR 
(CDCl3, 400 MHz) δ 6.46 (s, 2Ha), 6.45 (s, 2Ha'), 3.92 
(d, J = 6.4 Hz, 2Ha), 3.89 (d, J = 5.9 Hz, 2Ha'), 3.33 (s, 
2Ha), 3.28 (broad s, 2Ha + 2Ha'), 3.24 (s, 2Ha'), 2.64 
(m, 1Ha + 1Ha'), 2.43 (s, 6Ha + 6Ha'), 1.94 (m, 2Ha), 
1.84 (m, 2Ha'), 1.67 (m, 2Ha), 1.60 (m, 2Ha'), 1.55 – 
1.48 (m, 4Ha + 4Ha'), 1.44 (s, 9Ha), 1.42 (s,9Ha').13C 
{1H} NMR (CDCl3, 100 MHz) δ 165.8, 159.0, 106.6, 
106.6, 106.5, 79.1, 79.1, 71.6, 55.0, 54.3, 53.2, 52.2, 44.3, 43.4, 37.9, 32.7, 28.3, 28.3, 
27.6, 27.2, 24.5, 22.0. HRMS (ESI) for C21H33N2O3 [M+H]+: calculated: 361.2486, 
found: 361.2487. 
N-(5-((2-(((2,6-dimethylpyridin-4-yl)oxy)methyl)-6-azaspiro[3.5]nonan-6-
yl)methyl)thiazol-2-yl)acetamide 
Purification by RP HPLC (Stationary phase: 
C18 XBridge 30 x 100 mm 5 um), Mobile 
phase: Gradient from 67% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 
33% CH3CN to 50% 0.1% NH4CO3H/NH4OH 
pH 9 solution in Water, 50% CH3CN) 
,yielded 163 (48% yield) as brown sticky 
oil as a mixture of diastereoisomers 1:1 
(a:a’). 1H NMR (CDCl3, 400 MHz) δ 12.68 
(s, 1Ha + 1Ha'), 7.18 (s, 1Ha), 7.17 (s, 
1Ha'), 6.45 (s, 2Ha), 6.39 (s, 2Ha'), 3.88 (d, J = 6.4 Hz, 2Ha), 3.85 (d, J = 6.3 Hz, 2Ha'), 
3.64 (s, 2Ha), 3.61 (s, 2Ha'), 2.64 (m, 1Ha), 2.55 (m, 1Ha'), 2.43 (s, 6Ha), 2.40 (s, 6Ha'), 
2.34 (broad s, 4Ha + 4Ha'), 2.31 (s, 3Ha), 2.27 (s, 3Ha'), 1.98 (m, 2Ha), 1.89 (m, 2Ha'), 
1.62 (m, 2Ha), 1.52 (m, 4Ha + 4Ha'), 1.39 (m, 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) 
δ 167.9, 167.8, 165.9, 165.8, 160.1, 160.1, 158.9, 158.9, 133.4, 130.7, 130.4, 106.6, 
106.6, 72.1, 72.0, 64.7, 63.0, 54.7, 54.6, 53.6, 37.8, 35.6, 35.3, 35.0, 34.0, 33.8, 27.8, 
24.4, 24.4, 23.0, 23.0, 22.3, 22.1. HRMS (ESI) for C22H31N4O2S [M+H]+: calculated: 
415.21677, found: 415.2168. 
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Tert-butyl 2-(azidomethyl)-6-azaspiro[3.5]nonane-6-carboxylate 
 Flash column chromatography (EtOAc in Heptane 0/100 to 
15/85) yielded 164 (75% yield) as a colourless oil as a mixture 
of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 
3.32 (s, 2Ha), 3.28 (m, 4Ha + 4Ha'), 3.23 (s, 2Ha'), 2.51 (m, 1Ha 
+ 1Ha'), 1.94 (m, 2Ha), 1.85 (m, 2Ha'), 1.59 (m, 2Ha + 2Ha'), 
1.51 – 1.47 (m, 2Ha + 2Ha'), 1.44 (s, 9Ha + 9Ha'), 1.42 (m, 2Ha 
+ 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 155.0, 79.3, 56.9, 
56.8, 55.2, 54.6, 53.1, 52.1, 44.2, 43.3, 38.2, 35.0, 33.9, 28.4, 
27.9, 22.0, 21.9. HRMS (ESI) for C14H24N4NaO2 [M+H]+: 
calculated: 303.1796, found: 303.1795. 
Tert-butyl 2-(aminomethyl)-6-azaspiro[3.5]nonane-6-carboxylate 
After evaporation yielded 165 (82% yield) as a transparent oil as 
a mixture of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 
MHz) δ 3.29 (s, 1H), 3.21 (s, 2Ha), 3.17 (d, J = 4.8 Hz, 2Ha + 2Ha'), 
3.10 (s, 2Ha'), 2.60 (m, 2Ha + 2Ha'), 2.52 (s, 2Ha + 2Ha'), 2.17 (m, 
1Ha + 1Ha'), 1.81 (m, 2Ha), 1.73 – 1.66 (m, 2Ha'), 1.48 (m, 2Ha), 
1.40 – 1.35 (m, 2Ha + 2Ha'), 1.34 (s, 9Ha), 1.34 (s, 9Ha'), 1.27 (m, 
2Ha + 2Ha'), 1.22 – 1.14 (m, 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) 
δ 154.9, 78.9, 57.3, 55.3, 54.2, 53.2, 49.5, 48.1, 44.1, 43.1, 38.1, 
35.8, 35.1, 33.6, 33.4, 30.9, 28.1, 21.8, 21.7. HRMS (ESI) for 
C14H27N2O2 [M+H]+: calculated: 255.2072 found: 255.2072. 
Tert-butyl 2-((bis(2,6-dimethylpyridin-4-yl)amino)methyl)-6-azaspiro[3.5]nonane-
6-carboxylate  
Flash column chromatography ((NH3 7N in MeOH) in 
DCM 0/100 to 5/95) yielded 166 (50% yield) as a 
colourless oil as a mixture of diastereoisomers 1:1 (a:a’). 
1H NMR (CDCl3, 400 MHz) δ 6.52 (s, 4Ha + 4Ha'), 3.71 (m, 
2Ha + 2Ha'), 3.25 (s, 2Ha + 2Ha'), 3.23 – 3.20 (m, 2Ha), 
3.17 (m, 2Ha'), 2.60 (m, 1Ha + 1Ha'), 2.43 (s, 12Ha + 
12Ha'), 1.84 (m, 2Ha), 1.76 (m, 2Ha'), 1.53 (m, 2Ha), 1.42 
(broad s, 2Ha + 2Ha'), 1.40 (s, 9Ha + 9Ha'), 1.30 (s, 2Ha'), 
1.22 (m, 2Ha + 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 
158.8, 154.9, 153.6, 112.0, 79.2, 79.2, 57.2, 57.1, 57.0, 
55.7, 54.6, 52.8, 51.9, 44.4, 43.5, 38.4, 35.3, 35.0, 34.8, 
28.4, 28.4, 28.0, 24.5, 22.0, 21.9. HRMS (ESI) for 
C28H41N4O2 [M+H]+: calculated: 465.3229, found: 465.3227. 
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N-(5-((2-((bis(2,6-dimethylpyridin-4-yl)amino)methyl)-6-azaspiro[3.5]nonan-6-
yl)methyl)thiazol-2-yl)acetamide 
 Purification by RP HPLC (Stationary phase: 
C18 XBridge 30 x 100 mm 5 um), Mobile 
phase: Gradient from 81% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 
19% CH3CN to 64% 0.1% NH4CO3H/NH4OH 
pH 9 solution in Water, 36% CH3CN) yielded 
the two diastereoisomers separately 167a 
(22% yield) and 167a’ (29%) both as clear 
transparent oils. 
 
1H NMR (CDCl3, 400 MHz) δ 12.02 (s, 1Ha), 
7.16 (s, 1Ha), 6.53 (s, 4Ha), 3.67 (d, J = 7.0 Hz, 
2Ha), 3.65 – 3.61 (s, 2Ha), 2.58 (m, 1Ha), 2.44 
(s, 12Ha), 2.33 (m, 2Ha), 2.30 (s, 3Ha), 2.18 
(broad s, 2Ha), 1.83 (m, 2Ha), 1.54 (m, 2Ha), 
1.40 (m, 4Ha). 13C {1H} NMR (CDCl3, 100 
MHz) δ 167.7, 159.7, 158.8, 153.6, 133.9, 
130.1, 112.0, 65.3, 57.1, 54.6, 53.4, 36.3, 
35.2, 34.7, 28.1, 24.6, 23.1, 22.4. HRMS (ESI) 
for C29H39N6OS[M+H]+: calculated: 519.2906, 
found: 519.2914. 
1H NMR (CDCl3, 400 MHz) δ 12.37 (s, 1Ha'), 
7.15 (s, 1Ha'), 6.53 (s, 4Ha'), (d, J = 7.0 Hz, 
2Ha'), 3.62 (s, 2Ha'), 2.53 (m, 1Ha'), 2.44 (s, 
12Ha'), 2.32 (broad s, 2Ha'), 2.29 (s, 3Ha'), 
2.24 (broad s, 2Ha'), 1.94 (m, 2Ha'), 1.46 (m, 
2Ha'), 1.32 ( m, 4Ha'). 13C {1H} NMR (CDCl3, 
100 MHz) δ 167.8, 160.0, 158.8, 153.6, 
133.6, 130.6, 112.0, 62.5, 57.2, 54.7, 53.4, 
38.3, 35.9, 35.5, 27.9, 24.5, 23.1, 22.1. HRMS 
(ESI) for C29H39N6OS[M+H]+: calculated: 
519.2906, found: 519.2914. 
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Tert-butyl 3-((2,6-dimethylpyridin-4-yl)oxy)-1-oxa-7-azaspiro[4.4]nonane-7-
carboxylate 
Flash column chromatography (MeOH in DCM 0/100 to 5/95) 
and repurified by RP HPLC (Stationary phase: C18 XBridge 30 x 
100 mm 5 um), Mobile phase: Gradient from 67% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 33% CH3CN to 50% 
0.1% NH4CO3H/NH4OH pH 9 solution in Water, 50% CH3CN), 
yielding 168 (70% yield) as a colourless oil. 1H NMR (CDCl3, 400 
MHz) δ 6.42 (s, 2Ha + 2Ha'), 4.96 (d, J = 4.9 Hz, 1Ha + 1Ha'), 4.21 
– 4.08 (m, 1Ha + 1Ha'), 4.06 – 3.97 (m, 1Ha + 1Ha'), 3.52 (m, 1Ha 
+ 1Ha'), 3.44 (broad s, 2Ha + 2Ha'), 3.26 (m, 1Ha + 1Ha'), 2.45 (s, 
6Ha + 6Ha'), 2.37 – 2.20 (m, 2Ha), 2.20 – 2.08 (m, 2Ha'), 2.05 – 1.93 (m, 2Ha), 1.86 
(m, 2Ha'), 1.43 (s, 9Ha + 9Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 164.0, 162.5, 159.4, 
159.3, 154.4, 107.3, 107.2, 106.2, 88.3, 88.15, 87.4, 87.4, 79.3, 79.2, 72.2, 72.1, 72.0, 
56.2, 55.8, 55.6, 55.3, 45.2, 44.8, 44.7, 44.3, 40.1, 39.9, 39.7, 39.6, 37.0, 36.5, 36.4, 
36.3, 35.9, 31.4, 28.4, 24.6. HRMS (ESI) for C19H29N2O4 [M+H]+: calculated: 349.2127, 
found: 349.2127. 
N-(5-((3-((2,6-dimethylpyridin-4-yl)oxy)-1-oxa-7-azaspiro[4.4]nonan-7-
yl)methyl)thiazol-2-yl)acetamide 
Purified by by RP HPLC (Stationary phase: XBridge C18 50 x 
100 mm, 5 μm), Mobile phase: Gradient from 73% 
NH4HCO3 0.25 solution in Water, 27% CH3CN to 56% 
NH4HCO3 0.25% solution in Water, 44% CH3CN), yielded 
the two diastereoisomers separated. 169a (26.6% yield) 
and 169a’ (25.1%) as a transparent oil. 
1H NMR (CDCl3, 400 MHz) δ 12.52 (s, 1H), 7.20 (s, 1H), 6.39 
(s, 2H), 4.92 (m, 1H), 4.13 (dd, J = 10.4, 5.0 Hz, 1H), 3.92 
(dd, J = 10.4, 1.9 Hz, 1H), 3.79 (s, 2H), 2.76 (s, 2H), 2.71 – 
2.64 (m, 2H), 2.43 (s, 6H), 2.29 (s, 3H), 2.24 (d, J = 1.9 Hz, 
1H), 2.23 (d, J = 5.8 Hz, 1H), 2.09 (m, 1H), 1.92 (m, 1H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 168.1, 166.6, 164.7, 160.1, 
158.8, 134.4, 128.5, 107.8, 88.6, 72.0, 63.6, 52.8, 51.1, 
50.5, 42.3, 37.8, 23.7, 23.0. HRMS (ESI) for C20H27N4O3S 
[M+H]+: calculated: 403.1804, found: 403.1808. 
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1H NMR (CDCl3, 400 MHz) δ 12.41 (broad s, 1H), 7.21 (s, 
1H), 6.41 (s, 2H), 4.91 (m, 1H), 4.14 – 4.05 (m, 1H), 3.96 (dd, 
J = 10.4, 1.9 Hz, 1H), 3.80 (s, 2H), 2.80 – 2.74 (m, 2H), 2.71 
– 2.64 (m, 2H), 2.45 (s, 6H), 2.30 (s, 3H), 2.29 – 2.24 (m, 
1H), 2.18 – 2.10 (m, 2H), 2.01 – 1.91 (m, 1H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 168.1, 166.8, 164.5, 160.0, 158.9, 
134.2, 128.9, 107.6, 88.6, 72.0, 64.3, 52.1, 51.0, 50.3, 42.7, 
37.6, 23.9, 23.1. HRMS (ESI) for C20H27N4O3S [M+H]+: 
calculated: 403.1804, found: 403.1808. 
Tert-butyl 3-((2,6-dimethylpyrimidin-4-yl)oxy)-1-oxa-7-azaspiro[4.4]nonane-7-
carboxylate 
 Flash column chromatography (MeOH in DCM 0/100 to 10/90) 
yielded 170 (98% yield) as a colorless oil as mixture of 
diastereoisomers. 1H NMR (CDCl3, 400 MHz) δ 6.37 (s, 1H + 
1Ha’), 5.69 – 5.55 (m, 1Ha + 1Ha’), 4.23 – 4.10 (m, 1Ha + 1Ha’), 
3.97 (dd, J = 13.2, 12.5 Hz, 1Ha + 1Ha’), 3.54 (m, 1Ha + 1Ha’), 
3.45 (m, 2Ha + 2Ha’), 3.30 (m, 1Ha + 1Ha’), 2.55 (s, 3Ha + 3Ha’), 
2.39 (s, 3Ha + 3Ha’), 2.22 (m, 2Ha + 2Ha’), 1.92 (m, 2Ha + 2Ha’), 
1.45 (s, 9Ha + 9Ha’). 13C {1H} NMR (CDCl3, 100 MHz) δ 168.6, 
167.4, 154.5, 118.0, 117.3, 104.3, 104.0, 103.6, 88.1, 87.2, 79.2, 
72.6, 72.3, 56.2, 55.8, 55.7, 55.3, 45.5, 45.2, 44.8, 44.7, 44.4, 40.9, 40.1, 40.0, 39.8, 
39.6, 37.0, 36.5, 36.3, 35.9, 28.4, 25.9, 23.8. HRMS (ESI) for C18H27N3NaO4 [M+Na]+: 
calculated: 372.1899, found: 372.1903. 
N-(5-((3-((2,6-dimethylpyrimidin-4-yl)oxy)-1-oxa-7-azaspiro[4.4]nonan-7-
yl)methyl)thiazol-2-yl)acetamide 
 Flash column chromatography (MeOH in DCM 0/100 to 
10/90) yielded 171 as mixture of diastereoisomers (28% 
yield) as a transparent oil as mixture of diastereoisomers. 
1H NMR (CDCl3, 400 MHz) δ 12.22 (s, 1Ha + 1Ha'), 7.22 (s, 
1Ha + 1Ha'), 6.36 (s, 1Ha), 6.34 (s, 1Ha'), 5.57 (m, 1Ha + 
1Ha'), 4.16 (dd, J = 10.6, 5.1 Hz, 1Ha), 4.12 (dd, J = 10.6, 5.2 
Hz, 1Ha'), 3.88 (dd, J = 10.7, 2.3 Hz, 1Ha + 1Ha'), 3.82 (s, 
2Ha + 2Ha'), 2.83 – 2.79 (m, 2Ha + 2Ha'), 2.74 – 2.65 (m, 
2Ha + 2Ha'), 2.54 (s, 3Ha + 3Ha'), 2.38 (s, 3Ha), 2.37 (s, 3Ha'), 2.35-2.27 (m, 2Ha), 
2.30 (s, 3Ha + 3Ha'), 2.23 (m, 2Ha'), 2.15- 2.09 (m, 2Ha), 2.01-1.93 (m, 2Ha'). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 168.8, 168.7, 167.8, 167.8, 167.3, 159.7, 159.6, 133.8, 
130.1, 104.0, 88.6, 77.2, 76.4, 76.3, 72.4, 72.3, 64.8, 64.4, 52.9, 52.4, 51.5, 51.3, 43.1, 
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42.8, 38.1, 37.8, 29.7, 25.9, 23.8, 23.1. HRMS (ESI) for C19H24N5O3S [M-H]-: 
calculated: 402.1599 found: 402.1602. 
Tert-butyl 3-iodo-1-oxa-7-azaspiro[4.4]nonane-7-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 15/85) 
yielded 172 (78% yield) as a colourless oil. 1H NMR (CDCl3, 400 
MHz) δ 4.32 – 4.19 (m, 1Ha + 1Ha'), 4.13 (dd, J = 15.9, 7.7 Hz, 2Ha), 
4.00 (dd, J = 9.8, 6.2 Hz, 2Ha'), 3.56 – 3.34 (m, 3Ha + 3Ha'), 3.21 (s, 
1Ha), 3.18 (s, 1Ha'), 2.60 (dt, J = 15.3, 7.8 Hz, 1Ha + 1Ha'), 2.34 (d, 
J = 6.3 Hz, 1Ha), 2.31 (d, J = 6.4 Hz, 1Ha'), 2.25 (m, 1Ha + 1Ha'), 2.02 
– 1.84 (m, 1Ha + 1Ha'), 1.43 (s, 9Ha + 9Ha'). 13C {1H} NMR (CDCl3, 
100 MHz) δ 154.4, 154.3, 88.4, 87.5, 79.3, 56.5, 55.9, 45.9, 45.7, 
45.1, 44.7, 37.3, 36.6, 28.5, 16.7, 16.2. HRMS (ESI) for C24H41I2N2O6 [MM+H]+: 
calculated: 707.1054, found: 707.1053. 
Tert-butyl 3-(2,6-dimethylpyridin-4-yl)-1-oxa-7-azaspiro[4.4]nonane-7-
carboxylate 
Flash column chromatography (MeOH in DCM 0/100 to 10/85) 
yielded 173 (19% yield) as a colourless oil. 1H NMR (CDCl3, 400 
MHz) δ 6.82 (s, 2Ha + 2Ha'), 4.20 (m, 1Ha + 1Ha'), 3.78 (m, 2Ha), 
3.55 (m, 2Ha'), 3.31 (m, 2Ha + 2Ha'), 2.49 (s, 6Ha +6Ha'), 2.34 (m, 
1Ha + 1Ha'), 2.15 – 2.00 (m, 3Ha + 3Ha'), 1.45 (s, 9Ha + 9Ha'), 1.24 
(m, 2Ha), 1.20 (m, 2Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 158.5, 
158.0, 146.8, 119.0, 119.0, 118.1, 88.8, 88.0, 79.4, 75.0, 72.8, 
56.5, 56.2, 55.8, 45.2, 45.0, 44.7, 44.1, 41.5, 41.1, 40.8, 37.2, 36.9, 
36.4, 28.5, 24.8, 24.5, 24.4. HRMS (ESI) for C19H29N2O3 [M+H]+: 
calculated: 333.2178, found: 333.2182. 
N-(5-((3-(2,6-dimethylpyridin-4-yl)-1-oxa-7-azaspiro[4.4]nonan-7-
yl)methyl)thiazol-2-yl)acetamide  
 Flash column chromatography (MeOH in DCM 0/100 to 
10/85) yielded 174 (54% yield) as a colourless oil. 1H NMR 
(CDCl3, 400 MHz) δ 12.50 (s, 1Ha + 1Ha'), 7.23 (s, 1Ha + 
1Ha'), 6.80 (s, 2Ha), 6.80 (s, 2Ha’), 4.13 (m, 1Ha + 1Ha'), 
3.82 (s, 2Ha + 2Ha'), 3.77 – 3.66 (m, 1Ha + 1Ha'), 3.37 (m, 
1Ha), 3.28 (m, 1Ha'), 2.89 (d, J = 10.1 Hz, 1Ha), 2.86 – 2.77 
(m, 2Ha), 2.75 (dd, J = 9.9, 4.3 Hz, 1Ha + 1Ha'), 2.69 (m, 
2Ha'), 2.65 (d, J = 9.6 Hz, 1Ha'), 2.48 (s, 6Ha), 2.47 (s, 6Ha'), 
2.42 (dd, J = 12.6, 7.8 Hz, 1Ha), 2.33 (dd, J = 9.9, 5.1 Hz, 
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1Ha'), 2.31 (s, 3Ha), 2.30 (s, 3Ha'), 2.21 – 2.10 (m, 1Ha), 2.10 – 1.94 (m, 2Ha + 2Ha'), 
1.87 (m, 1Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 167.88, 167.85, 164.11, 159.72, 
156.44, 153.87, 153.80, 133.84, 130.18, 130.13, 114.95, 114.92, 105.57, 103.80, 
103.76, 103.69, 89.40, 89.37, 72.69, 72.60, 65.62, 64.83, 52.91, 52.77, 51.53, 51.49, 
44.92, 44.41, 44.31, 44.13, 38.94, 38.27, 24.15, 23.18. HRMS (ESI) for C20H27N4O2S 
[M+H]+: calculated: 387.1854, found: 387.1877. 
N-(5-((3-(2-methoxy-6-methylpyridin-4-yl)-1-oxa-7-azaspiro[4.4]nonan-7-
yl)methyl)thiazol-2-yl)acetamide 
Purified by RP HPLC (Stationary phase: C18 XBridge 30 x 100 
mm 5 um), Mobile phase: Gradient from 81% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 19% CH3CN to 
64% 0.1% NH4CO3H/NH4OH pH 9 solution in Water, 36% 
CH3CN) yielded 175 (5% yield) as a sticky solid. 1H NMR 
(CDCl3, 400 MHz) δ 12.10 (s, 1Ha + 1Ha'), 7.22 (s, 1Ha 
+1Ha'), 6.58 (s, 1Ha), 6.57 (s, 1Ha'), 6.38 (s, 1Ha), 6.37 (s, 
1Ha'), 4.22 – 4.05 (m, 1Ha + 1Ha'), 3.89 (s, 3Ha), 3.89 (s, 
3Ha'), 3.81 (m, 2Ha + 2Ha'), 3.78 – 3.67 (m, 1Ha + 1Ha'), 
3.37 (m, 1Ha), 3.27 (m, 1Ha'), 2.88 (d, J = 10.0 Hz, 1Ha), 2.83 
(m, 1Ha), 2.77 (m, 1Ha'), 2.72 (m, 2Ha + 2Ha'), 2.64 (d, J = 9.5 Hz, 1Ha'), 2.41 (s, 3Ha), 
2.41 (s, 3Ha'), 2.31 (s, 3Ha), 2.31 (s, 3Ha'), 2.15 (m, 1Ha), 2.11 – 1.95 (m, 2Ha + 2Ha'), 
1.87 (m, 1Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 167.85, 164.11, 159.71, 156.43, 
153.87, 153.79, 133.84, 130.13, 114.95, 114.92, 105.56, 103.78, 89.40, 89.37, 72.69, 
72.60, 65.62, 64.83, 53.31, 52.91, 52.77, 51.53, 44.92, 44.41, 44.31, 44.13, 38.94, 
38.27, 24.15, 23.18. HRMS (ESI) for C20H27N4O3S [M+H]+: calculated: 403.1803, 
found: 403.1806. 
Tert-butyl 3-((2,6-dimethylpyridin-4-yl)oxy)-1-oxa-8-azaspiro[4.5]decane-8-
carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 
100/0) yielded 176 (71% yield) as a colourless oil as a mixture 
of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 6.40 
(s, 2Ha + 2Ha'), 4.93 (m, 1Ha + 1Ha'), 4.11 (dd, J = 10.5, 4.7 Hz, 
2Ha), 4.02 (dd, J = 10.5, 1.7 Hz, 2Ha'), 3.65 (m, 2Ha + 2Ha'), 3.29 
(m, 2Ha + 2Ha'), 2.45 (s, 6Ha + 6Ha'), 2.04 (m, 2Ha + 2Ha'), 1.86 
(m, 2Ha), 1.57 (m, 2Ha + 4Ha'), 1.43 (s, 9Ha + 9Ha'). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 164.1, 159.3, 154.7, 107.2, 80.6, 79.4, 
71.2, 43.4, 36.4, 36.1, 31.3, 28.3, 24.5. HRMS (ESI) for 
C20H31N2O4 [M+H]+: calculated: 363.2283, found: 363.2282. 
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N-(5-((3-((2,6-dimethylpyridin-4-yl)oxy)-1-oxa-8-azaspiro[4.5]decan-8-
yl)methyl)thiazol-2-yl)acetamide 
Purification by RP HPLC (Stationary phase: C18 XBridge 30 x 
100 mm 5 um), Mobile phase: Gradient from 81% 0.1% 
NH4CO3H/NH4OH pH 9 solution in Water, 19% CH3CN to 64% 
0.1% NH4CO3H/NH4OH pH 9 solution in Water, 36% 
CH3CN)yielded 177 (63% yield) as a colourless oil as a mixture 
of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 
12.79 (s, 1Ha + 1Ha'), 7.15 (s, 1Ha + 1Ha'), 6.38 (s, 2Ha + 2Ha'), 
4.88 (broad s, 1Ha + 1Ha'), 4.06 (dd, J = 10.3, 4.4 Hz, 2Ha), 
3.96 (m, 2Ha'), 3.64 (s, 2Ha + 2Ha'), 2.53 (broad s, 4Ha + 4Ha'), 
2.41 (s, 6Ha + 6Ha'), 2.27 (s, 3Ha + 3Ha'), 2.14 – 1.78 (m, 4Ha 
+ 2Ha'), 1.75 – 1.61 (m, 2Ha + 4Ha'). 13C {1H} NMR (CDCl3, 100 
MHz) δ 167.9, 164.0, 159.9, 159.0, 133.7, 129.8, 107.1, 80.3, 77.5, 70.8, 54.0, 53.3, 
50.0, 43.1, 36.1, 24.3, 22.9. HRMS (ESI) for C21H29N4O3S [M+H]+: calculated: 
417.19604, found: 417.1963. 
Tert-butyl 3-oxo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 50/50) 
yielded 178 (84% yield) as a transparent oil. 1H NMR (CDCl3, 400 MHz) 
δ 4.01 (s, 2H), 3.64 (m, 2H), 3.37 (m, 2H), 2.35 (s, 2H), 1.78 (m, 2H), 1.65 
(m, 2H), 1.45 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) δ 214.6, 154.6, 79.6, 
79.5, 69.4, 48.0, 40.2, 35.2, 28.40. HRMS (ESI) for C13H22NO4 [M+H]+: 
calculated: 254.1392, found: 254.1393. 
 
Tert-butyl 3-(2,6-dimethylpyridin-4-yl)-3-hydroxy-1-oxa-8-azaspiro[4.5]decane-8-
carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 
40/60) yielded 179 (61% yield) as a transparent oil as a mixture 
of diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 7.03 
(s, 2Ha + 2Ha'), 3.96 (s, 2Ha + 2Ha'), 3.61 (s, 2Ha + 2Ha'), 3.36 (m, 
2Ha + 2Ha'), 2.71 (broad s, 1Ha + 1Ha'), 2.51 (s, 6Ha + 6Ha'), 2.19 
(d, J = 13.8 Hz, 2Ha), 2.12 (d, J = 13.7 Hz, 2Ha'), 1.97 (m, 2Ha), 
1.80 – 1.69 (m, 2Ha + 2Ha'), 1.63 (m, 2Ha'), 1.45 (s, 9Ha + 9Ha'). 
13C {1H} NMR (CDCl3, 100 MHz) δ 158.07, 154.78, 151.89, 116.72, 
81.86, 81.31, 79.57, 78.48, 60.38, 53.35, 40.93, 37.48, 36.26, 
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28.42, 24.54, 21.01, 14.16. HRMS (ESI) for C20H31N2O4 [M+H]+: calculated: 
363.22838, found: 363.2279. 
N-(5-((3-(2,6-dimethylpyridin-4-yl)-3-fluoro-1-oxa-8-azaspiro[4.5]decan-8-
yl)methyl)thiazol-2-yl)acetamide 
 Purification by RP HPLC (Stationary phase: XBridge C18 50 x 
100 mm, 5 μm), Mobile phase: Gradient from 73% NH4HCO3 
0.25% solution in Water, 27% CH3CN to 56% NH4HCO3 0.25% 
solution in Water, 44% CH3CN), yielded 180 (36% yield) as a 
colourless oil as a mixture of diastereoisomers 1:1 (a:a’). 1H 
NMR (CDCl3, 400 MHz) δ 12.72 (s, 1Ha + 1Ha'), 7.18 (s, 1Ha + 
1Ha'), 6.92 (s, 2Ha + 2Ha'), 4.19 (ddd, J = 20.2, 10.9, 1.2 Hz, 
2Ha), 3.95 (dd, J = 32.3, 11.0 Hz, 2Ha'), 3.68 (s, 2Ha + 2Ha'), 
2.72 – 2.51 (m, 4Ha + 4Ha'), 2.50 (s, 6Ha + 6Ha'), 2.46 – 2.33 
(m, 2Ha + 2Ha'), 2.29 (s, 3Ha + 3Ha'), 2.17 – 2.01 (m, 2Ha), 
1.85 – 1.67 (m, 2Ha + 4Ha'). 13C {1H} NMR (CDCl3, 100 MHz) 
δ 167.9, 160.1, 158.1, 158.1, 158.0, 148.5, 148.3, 140.1, 136.4, 133.7, 131.5, 130.0, 
129.9, 116.7, 115.7, 115.6, 104.1, 102.3, 88.0, 81.6, 73.0, 54.3, 54.1, 51.4, 51.2, 50.1, 
49.9, 49.8, 36.6, 36.3, 35.8, 24.4, 24.3, 23.0. HRMS (ESI) for C21H28FN4O2S [M+H]+: 
calculated: 419.1917, found: 419.1921. 
8-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-3-(2,6-dimethylpyridin-4-yl)-3-
fluoro-1-oxa-8-azaspiro[4.5]decane 
Double purification was needed: First: by flash column 
chromatography (MeOH in DCM 0/100 to 10/90) the desired 
fractons were collected and evaporated in vacuo. Second: the 
collected and evaporated fractions were purified by RP HPLC 
(Stationary phase: C18 XBridge 30 x 100 mm 5 um), Mobile 
phase: Gradient from 67% 0.1% NH4CO3H/NH4OH pH 9 solution 
in Water, 33% CH3CN to 50% 0.1% NH4CO3H/NH4OH pH 9 
solution in Water, 50% CH3CN) yielded 181 (17% yield) as a 
colourless oil as a mixture of diastereoisomers 1:1 (a:a’). 1H 
NMR (CDCl3, 400 MHz) δ 6.93 (s, 2Ha + 2Ha'), 6.83 (m, 1Ha + 
1Ha'), 6.79 – 6.75 (m, 2Ha + 2Ha'), 4.23 (s, 4Ha + 4Ha'), 4.22 – 
4.14 (m, 2Ha), 3.95 (m, 2Ha'), 3.37 (m, 1Ha + 1Ha'), 2.52 (s, 6Ha + 6Ha'), 2.39 (m, 
4Ha + 2Ha'), 2.20 (m, 2Ha'), 2.04 (m, 2Ha + 2Ha'), 1.77 (m, 4Ha + 4Ha'), 1.33 (d, J = 
6.7 Hz, 3Ha + 3Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 158.1, 158.1, 158.1, 148.8, 
148.5, 143.1, 142.2, 140.3, 137.0, 136.3, 131.7, 120.5, 120.5, 120.5, 116.7, 116.7, 
116.2, 116.2, 115.8, 115.7, 104.2, 102.3, 88.6, 82.2, 73.0, 64.3, 64.2, 63.9, 63.7, 51.3, 
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51.1, 47.7, 47.6, 47.4, 47.3, 47.2, 47.2, 37.1, 36.7, 36.3, 36.2, 24.5, 24.4, 19.3. HRMS 
(ESI) for C25H32FN2O3 [M+H]+: calculated: 427.2397, found: 427.2392. 
Tert-butyl 3-(2,6-dimethylpyridin-4-yl)-1-oxa-8-azaspiro[4.5]decane-8-
carboxylate 
Flash column chromatography (EtOAc in Heptane 0/100 to 40/60) 
yielded 182 (84% yield) as a colorless oil as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 6.88 (s, 
2Ha + 2Ha'), 4.20 (m, 2Ha), 3.79 (m, 2Ha'), 3.64 (broad s, 2Ha + 
2Ha'), 3.44 (m, 1Ha + 1Ha'), 3.40 – 3.26 (m, 2Ha + 2Ha'), 2.55 (s, 
6Ha + 6Ha'), 2.25 (m, 2Ha), 1.83 – 1.65 (m, 4Ha + 4Ha'), 1.57 (m, 
2Ha'), 1.47 (s, 9Ha + 9Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 157.3, 
154.7, 152.6, 119.6, 81.0, 79.4, 72.1, 44.7, 44.0, 41.0, 36.8, 36.1, 
28.4, 23.5. HRMS (ESI) for C20H31N2O3 [M+H]+: calculated: 
347.23347, found: 347.2339. 
 
N-(5-((3-(2,6-dimethylpyridin-4-yl)-1-oxa-8-azaspiro[4.5]decan-8-
yl)methyl)thiazol-2-yl)acetamide 
Flash column chromatography (MeOH in DCM 0/100 to 5/95) 
yielded 183 (32% yield) as a colourless oil as a mixture of 
diastereoisomers 1:1 (a:a’). 1H NMR (CDCl3, 400 MHz) δ 12.68 
(s, 1Ha + 1Ha'), 7.18 (s, 1Ha + 1Ha'), 6.79 (s, 2Ha + 2Ha'), 4.14 
(m, 2Ha), 3.72 (m, 2Ha'), 3.67 (s, 2Ha + 2Ha'), 3.35 (m, 1Ha + 
1Ha'), 2.52 (broad s, 4Ha + 4Ha'), 2.46 (s, 6Ha + 6Ha'), 2.29 (s, 
3Ha + 3Ha'), 2.19 (m, 2Ha), 1.80 – 1.59 (m, 4Ha + 6Ha'). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 167.9, 160.0, 157.8, 151.3, 
133.8, 130.0, 119.0, 80.7, 72.0, 54.2, 50.4, 50.1, 44.5, 43.8, 
37.0, 36.4, 24.3, 23.0. HRMS (ESI) for C21H29N4O2S [M+H]+: 
calculated: 401.2011, found: 401.2041. 
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8-(1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-3-(2,6-dimethylpyridin-4-yl)-1-
oxa-8-azaspiro[4.5]decane 
Double purification was needed: First: by flash column 
chromatography (MeOH in DCM 0/100 to 10/90) the desired 
fractons were collected and evaporated in vacuo. Second: the 
collected and evaporated fractions were purified by RP HPLC 
(Stationary phase: C18 XBridge 30 x 100 mm 5 um), Mobile 
phase: Gradient from 67% 0.1% NH4CO3H/NH4OH pH 9 solution 
in Water, 33% CH3CN to 50% 0.1% NH4CO3H/NH4OH pH 9 
solution in Water, 50% CH3CN) yielded 184 (15% yield) as a 
colourless oil as a mixture of diastereoisomers 1:1 (a:a’). 1H 
NMR (CDCl3, 400 MHz) δ 6.81 (s, 1Ha + 1Ha'), 6.79 (s, 2Ha + 
2Ha'), 6.77 (s, 1Ha + 1Ha'), 6.75 (m, 1Ha + 1Ha'), 4.23 (s, 4Ha + 
4Ha'), 4.13 (m, 1Ha + 1Ha'), 3.72 (m, 1Ha + 1Ha'), 3.34 (m, 2Ha 
+ 2Ha'), 2.53 (broad s, 4Ha + 2Ha'), 2.47 (s, 6Ha + 6Ha'), 2.42 (broad s, 2Ha'), 2.18 
(dd, J = 12.5, 8.3 Hz, 2Ha), 1.74 (m, 4Ha + Ha'), 1.62 (m, 2Ha'), 1.33 (d, J = 6.7 Hz, 3Ha 
+ 3Ha'). 13C {1H} NMR (CDCl3, 100 MHz) δ 157.8, 151.5, 143.1, 142.3, 136.8, 120.5, 
119.0, 116.7, 116.2, 81.1, 72.0, 64.3, 64.2, 63.9, 63.9, 47.9, 47.7, 47.5, 44.4, 43.9, 
37.4, 36.7, 24.3, 19.3, 19.2. HRMS (ESI) for C25H33N2O3 [M+H]+: calculated: 
409.24912, found: 409.2488. 
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8.5. Experimental procedures and spectral data of Chapter 6 
8.5.1 General procedure for the protection of amines with sulphonyl 
chloride derivatives[14] 
N,N-diisopropyletilamina (DIPEA, 2 equiv, 20 mmol) and the arenesulphonyl 
chloride derivative (1 equiv, 10 mmol) were added to a solution of methyl 
piperidine-4-carboxylate (1 equiv, 10 mmol) in dry dichlorometane (0.14 M) at room 
temperature. The mixture was stirred for 4-16 h until complete consumption of the 
corresponding arenesulphonyl chloride. The organic phase was washed with 10% of 
NaHCO3. The aqueous phase was extracted with ethyl acetate. The organic extracts 
were combined, washed with H2O and NaCl sat. solution, dried (MgSO4), filtered and 
the volatiles removed in vacuo. The crude product was purified by flash column 
chromatography. 
8.5.2 General procedure for the alkylation reaction with different alkyl 
bromides[3, 15] 
To a 0 °C solution of iPr2NH (2.0 mL, 1.5 equiv, 15 mmol) in THF (15 mL), was added 
a hexane solution of nBuLi 2 M (4.4 mL, 1.1 equiv, 11 mmol) dropwise. The reaction 
mixture was stirred for 20 min. and then cooled to -78 °C. The corresponding ester 
(1.0 equiv, 10 mmol) was added dropwise and the reaction mixture was stirred for 
1 h at -78 °C. The corresponding alkyl halide (1.5 equiv, 15 mmol, for n=1, allyl 
bromide; n=2, 4-bromobut-1-ene) was then added dropwise into the reaction 
mixture. The reaction mixture was then warmed naturally to room temperature and 
stirred until consumption of the starting sulphonamide. The reaction mixture was 
quenched by addition of NH4Cl sat. and extracted with Et2O three times. The 
combined organic layers were then dried (MgSO4) filtered and concentrated in 
vacuo. The crude product was purified by flash column chromatography. 
8.5.3 General procedure for the reduction of the ester to alcohols[4] 
To a slurry of LiAlH4 (1.5 equiv, 6 mmol) in anhydrous Et2O (0.9 M) was added a 
solution of the methyl ester (1 equiv, 4 mmol) in Et2O (1 M) dropwise at       0 °C. The 
mixture was stirred for 2 h (or until consumption of the substrate). Reaction was 
then quenched by addition of EtOH dropwise after no observation of bubbles. Then, 
water was added and the mixture was stirred until a white solid was formed. The 
mixture was then filtered and extracted with EtOAc. The organic layers were 
separated, dried (MgSO4), filtered and concentrated under reduced pressure to 
obtain the alcohol without need of further purification for the next reaction step. 
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8.5.4 General procedure for the oxidation of primary alcohols to 
aldehydes[8] 
To a solution of the cyclic alkenyl alcohol (2 mmol, 1 equiv) in DCM (2 mL) was added 
DMP (5 mmol, 2 equiv) and stirred at room temperature for 16 h. Then NaHCO3 sat. 
solution was added and extracted few times with DCM. The organic layer was 
separated, dried (MgSO4), filtered and the solvent removed in vacuo. The crude was 
purified by flash column chromatography. 
8.5.5 General procedure for the borylative cyclization catalyzed by 
copper (I) complex[17] 
Copper chloride (5 mol%, 0.025 mmol), bis(pinacolato)diboron (1.2 equiv, 0.6 mmol) 
and Xantphos (5 mol%, 0.025 mmol) were placed in an oven-dried resalable Teflon 
screw-cap Schlenk reaction tube. The Schlenk tube was connected to a 
vacuum/nitrogen manifold evacuated and backfilled with nitrogen. Then THF (0.48 
ml, 1 M). KOtBu (1.2 equiv, 0.6 mmol) in THF (0.24 ml, 1 M) were added in the vial 
through the rubber septum. Then alkenyl aldehyde (1 equiv, 0.5 mmol) in THF (0.48 
ml, 1 M) was added dropwise at 30 °C. After the reaction was complete, the reaction 
mixture was filtered over celite. The organic extracts were then concentrated in 
vacuo. The crude product was purified by flash chromatography. 
8.5.6 General procedure for the oxidation of the spiroboronates 
products[7] 
The oxidation was performed in a reaction vial, NaBO3·H2O (199.6 mg, 10 
equiv, 2 mmol) was dissolved in THF/H2O (3:2, 0.2 M) and the boronate (83.8 
mg, 1 equiv, 0.2 mmol) was then added at room temperature. After stirred 
for 1.5 h, the reaction mixture was extracted three times with EtOAc, dried 
(MgSO4), filtered and concentrated in vacuo. The crude mixture was further 
purified by flash column chromatography. 
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8.5.7 Spectral data of Chapter 6 
Methyl 1-tosylpiperidine-4-carboxylate 
Flash column chromatography (pentane: EtOAc 100:0 to 60:40) yielded 
185 (60% yield) as white solid. 1H NMR (CDCl3, 400 MHz) δ 7.62 (d, J = 7.9 
Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 3.64 (s, 3H), 3.61 (m, 2H), 2.43 (td, J = 
11.4, 2.9 Hz, 2H), 2.42 (s, 3H), 2.24 (tt, J = 10.7, 4.0 Hz, 1H), 1.95 (m, 2H), 
1.79 (m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 174.2, 143.5, 132.9, 129.6, 
127.6, 51.8, 45.3, 39.8, 27.3, 21.4. HRMS (ESI) for C28H38N2NaO8S2 [2M + 
Na]+: calculated: 617.1968, found: 617.1985. 
 
 
Methyl 4-allyl-1-tosylpiperidine-4-carboxylate 
Flash column chromatography (pentane: EtOAc 100:0 to 60:40) 
yielded 187 (62% yield) as white solid. 1H NMR (CDCl3, 400 MHz) δ 
7.59 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 5.58 (ddt, J = 14.9, 
10.1, 7.5 Hz, 1H), 5.06 – 4.90 (m, 2H), 3.60 – 3.50 (m, 3H), 3.55 (s, 
3H), 2.40 (s, 3H), 2.37 (dd, J = 12.0, 2.1 Hz, 2H), 2.19 (d, J = 7.5 Hz, 
2H), 2.15 (m, 2H), 1.54 (m, 2H). 13C {1H} NMR (CDCl3, 100 MHz) δ 
174.8, 143.3, 133.3, 132.1, 129.5, 127.5, 118.6, 51.7, 45.2, 44.2, 
43.6, 32.4, 21.4. HRMS (ESI) for C17H24NO4S [M + H]+: 
calculated:338.1421, found: 338.1425. 
 
4-Allyltetrahydro-2H-pyran-4-carbaldehyde 
Flash column chromatography (pentane: Et2O 100:0 to 60:40) yielded 
188 (52% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ 9.50 (s, 1H), 
5.66 (m, 1H), 5.10 (m, 2H), 3.81 (dt, J = 12.0, 4.3 Hz, 2H), 3.43 (m, 2H), 
2.25 (d, J = 7.5 Hz, 2H), 1.93 (dt, J = 13.7, 3.9 Hz, 2H), 1.60 (m, 3H). 13C 
{1H} NMR (CDCl3, 100 MHz) δ 204.6, 131.2, 118.5, 64.0, 46.9, 40.4, 
30.2. HRMS (ESI) for C9H15O2 [M + H]+: calculated:155.1067, found: 
155.1053. 
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4-(But-3-en-1-yl)tetrahydro-2H-pyran-4-carbaldehyde 
 Flash column chromatography (pentane: Et2O 100:0 to 60:40) 
yielded 189 (76% yield) as a clear oil.1H NMR (CDCl3, 400 MHz) δ 
9.42 (s, 1H), 5.67 (ddt, J = 16.8, 10.1, 6.5 Hz, 1H), 4.92 (m, 2H), 
3.76 (dt, J = 11.8, 4.0 Hz, 2H), 3.36 (td, J = 11.5, 2.6 Hz, 2H), 1.94 – 
1.81 (m, 4H), 1.59 – 1.45 (m, 4H). 13C {1H} NMR (CDCl3, 100 MHz) 
δ 205.3, 137.4, 115.1, 64.5, 47.3, 35.9, 30.9, 27.3. HRMS (ESI) for 
C10H17O2 [M + H]+: calculated: 169.1223, found:169.1221. 
4-Allyl-1-tosylpiperidine-4-carbaldehyde 
Flash column chromatography (pentane: EtOAc 100:0 to 60:40) 
yielded 190 (77% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ 9.32 
(s, 1H), 7.57 (d, J = 7.9 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 5.56 (m, 1H), 
5.05 (m, 2H), 3.54 (dt, J = 11.8, 3.2 Hz, 2H), 2.40 (s, 3H), 2.33 (td, J = 
12.1, 2.8 Hz, 2H), 2.16 (d, J = 7.5 Hz, 2H), 2.05 (m, 2H), 1.64 (m, 2H). 
13C {1H} NMR (CDCl3, 100 MHz) δ 204.7, 143.6, 132.8, 130.9, 129.6, 
127.4, 119.5, 47.6, 43.2, 40.6, 29.6, 21.4. HRMS (ESI) for C16H22NO3S 
[M + H]+: calculated: 308.1315, found: 308.1315. 
 
Tert-butyl 3-allyl-3-formylpiperidine-1-carboxylate 
Flash column chromatography (pentane: EtOAc 100:0 to 60:40) 
yielded 191 (93% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) 
δ 9.49 (s, 1H), 5.61 (m, 1H), 5.03 (m, 2H), 3.97 (m, 1H), 3.61 
(broad s, 1H), 2.99 (broad s, 2H), 2.16 (m, 2H), 1.93 (broad s, 
1H), 1.49 (m, 2H), 1.39 (s, 9H). 13C {1H} NMR (CDCl3, 100 MHz) 
δ 204.7, 154.6, 131.5, 119.1, 79.8, 60.3, 49.7, 48.1, 44.1, 43.5, 
38.3, 37.8, 29.0, 28.3, 21.7, 20.9, 14.1. HRMS (ESI) for 
C14H23NNaO3 [M + Na]+: calculated: 276.1570, found: 276.1573. 
1-Allylcyclohexane-1-carbaldehyde 
Flash column chromatography (pentane: DCM 80:20) yielded 192 
(82% yield) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 9.38 (s, 1H), 
5.69 – 5.48 (m, 1H), 4.97 (m, 2H), 2.11 (d, J = 7.5 Hz, 2H), 1.86 – 1.76 
(m, 2H), 1.56 – 1.43 (m, 3H), 1.31 – 1.16 (m, 5H). 13C {1H} NMR (CDCl3, 
100 MHz) δ 206.8, 132.6, 118.2, 49.6, 40.7, 30.7, 29.6, 25.6, 22.4. 
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Anti-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-7-
oxaspiro[3.5]nonan-1-ol 
Flash column chromatography (pentane: EtOAc 100:0 to 60:40) 
yielded 193 (71% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ 
3.87 (dt, J = 10.8, 4.4 Hz, 1H), 3.72 (dt, J = 10.9, 4.4 Hz, 1H), 3.59 (m, 
1H), 3.46 (d, J = 8 Hz, 1H), 3.43 (dd, J = 11.5, 2.3 Hz, 1H), 2.14 (m, 1H), 
1.93 (m, 2H), 1.76 (ddd, J = 13.3, 9.6, 3.9 Hz, 1H), 1.49 (m, 1H), 1.39 
(m, 1H), 1.25 (s, 12H), 1.09 (dd, J = 16.4, 5.1 Hz, 1H), 0.95 (t, J = 10.2 
Hz, 1H), 0.86 (dd, J = 16.4, 10.6 Hz, 1H). 13C {1H} NMR (CDCl3, 100 
MHz) δ 83.3, 80.9, 64.9, 64.7, 39.4, 38.8, 36.3, 33.6, 30.5, 24.7, 24.7. 
11B NMR (129 MHz, CDCl3) δ 33.8. HRMS (ESI) for C15H26BO3 [M - H20 
+ H]+: calculated: 265.1975, found: 265.1964. 
Anti-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-7-tosyl-7-
azaspiro[3.5]nonan-1-ol 
Flash column chromatography (pentane: EtOAc 100:0 to 60:40) 
yielded 194 (67% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ 
7.63 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 3.43 (d, J = 7.8 Hz, 
1H), 3.38 (m, 1H), 3.21 (m, 1H), 2.84 (s, 1H), 2.79 (m, 1H), 2.66 (m, 
1H), 2.42 (s, 3H), 2.07 (m, 1H), 1.95 (m, 1H), 1.77 (m, 1H), 1.73 (t, J = 
10.2 Hz, 1H), 1.63 (m, 1H), 1.52 (m, 1H), 1.22 (s, 12H), 1.04 (dd, J = 
16.7, 4.9 Hz, 1H), 0.81 (t, J = 10.2 Hz, 1H), 0.76 (m, 1H). 13C {1H} NMR 
(CDCl3, 100 MHz) δ 143.1, 133.5, 129.4, 127.5, 83.4, 80.4, 43.4, 43.2, 
39.4, 37.5, 36.2, 29.4, 24.7, 21.4. 11B NMR (129 MHz, CDCl3) δ 33.0. 
HRMS (ESI) for C22H35BNO5S [M - H20 + H]+: calculated: 436.2329, 
found: 436.2330. 
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Anti-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-7-tosyl-7-
azaspiro[3.5]nonan-1-ol 
Flash column chromatography (pentane: EtOAc 100:0 to 60:40) 
yielded 195 (25% yield) as a clear oil. 1H NMR (Toluene-D8, 95°C, 400 
MHz) δ 3.49 (dd, J = 42.6, 13.8 Hz, 2H), 3.35 (broad s, 1H), 3.34 (d, J 
= 7.2 Hz, 1H), 3.15 (m, 1H), 2.23 (m, 1H), 1.83 (t, J = 10.1 Hz, 1H), 1.50 
(m, 1H), 1.40 (s, 9H), 1.25 (m, 3H), 1.04 (s, 12H), 0.96 (d, J = 7.5 Hz, 
2H), 0.72 (t, J = 10.1 Hz, 1H). 13C {1H} NMR (CDCl3, 60°C, 100 MHz) δ 
155.2, 83.1, 80.9, 79.2, 48.2, 44.4, 42.1, 37.3, 37.2, 31.9, 28.4, 24.7, 
24.6, 22.8, 22.6. 11B NMR (129 MHz, CDCl3) δ 33.7. HRMS (ESI) for 
C20H37BNO5 [M + H]+: calculated: 382.2759, found: 382.2763. 
Anti-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[3.5]nonan-1-ol 
Flash column chromatography (pentane: Et2O 60:40) yielded 196 
(49% yield) as a colourless oil. 1H NMR (CDCl3, 400 MHz) δ 3.33 (d, 
J = 7.6 Hz, 1H), 2.09 – 1.95 (m, 1H), 1.84 – 1.76 (m, 1H), 1.64 – 1.24 
(m, 10H), 1.18 (s, 12H), 0.99 (dd, J = 16.4, 5.6 Hz, 1H), 0.83 – 0.79 
(m, 1H), 0.77 (d, J = 10.5 Hz, 1H. 13C {1H} NMR (CDCl3, 100 MHz) δ 
83.35, 81.80, 42.12, 39.41, 36.64, 34.07, 29.93, 26.40, 24.84, 23.32, 
23.09, 22.55. 11B NMR (129 MHz, CDCl3) δ 34.0. HRMS (ESI) for 
C16H33BNO3 [M + NH4]+: calculated: 298.2557, found: 298.2553. 
Anti-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-7-
oxaspiro[3.5]nonan-1-ol 
Flash column chromatography (pentane: EtOAc 100:0 to 50:50) 
yielded 197 (45% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) 
δ 3.82 (m, 2H), 3.49 (m, 2H), 3.12 (d, J = 8.3 Hz, 1H), 1.84 (m, 
4H), 1.72 (m, 1H), 1.40 (m, 2H), 1.24 (s, 12H), 1.13 (m, 2H), 1.06 
– 0.93 (m, 2H).13C {1H} NMR (CDCl3, 100 MHz) δ 87.0, 83.3, 65.3, 
64.5, 42.2, 40.6, 36.9, 31.9, 30.2, 29.3, 24.7. 11B NMR (129 MHz, 
CDCl3) δ 33.8. HRMS (ESI) for C16H30BO4 [M + H]+: calculated: 
297.2237, found: 297.2238. 
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Anti-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-7-
oxaspiro[3.5]nonan-1-ol 
Flash column chromatography (pentane: EtOAc 100:0 to 50:50) yielded 
198 (75% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ 3.85 (m, 2H), 
3.51 (m, 2H), 3.09 (d, J = 8.5 Hz, 1H), 1.81 (m, 5H), 1.45 (m, 1H), 1.15 (m, 3H), 
1.07 (d, J = 6.3 Hz, 3H).13C {1H} NMR (CDCl3, 100 MHz) δ 87.2, 65.5, 64.4, 
42.0, 39.0, 36.8, 31.7, 30.1, 27.9, 18.4. HRMS (ESI) for C10H19O2 [M + H]+: 
calculated: 171.1380, found: 171.1382. 
 
Anti-2-(hydroxymethyl)-7-oxaspiro[3.5]nonan-1-ol 
Flash column chromatography (pentane: EtOAc 100:0 to 0:100) yielded 
199 (61% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ 3.89 (dt, J = 
11.3, 4.1 Hz, 1H), 3.73 (m, 1H + 2H CH2-OH), 3.59 (m, 1H + 1H CH-OH), 
3.43 (td, J = 11.1, 2.6 Hz, 1H), 2.33 (m, 1H), 1.88 (m, 2H), 1.77 (m, 1H), 
1.50 (apparent d, 1H), 1.40 (m, 1H), 1.09 (t, J = 10.1 Hz, 1H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 77.2, 76.6, 64.9, 64.5, 42.6, 40.1, 38.1, 30.4, 
29.6, 27.2. HRMS (ESI) for C9H17O3 [M + H]+: calculated:173.1172, 
found:173.1185. 
Anti-2-(hydroxymethyl)-7-tosyl-7-azaspiro[3.5]nonan-1-ol 
Flash column chromatography (pentane: EtOAc 100:0 to 0:100) 
yielded 200 (75% yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ 7.63 
(d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 3.72 (d, J = 7.5 Hz, 1H), 3.67 
(dd, J = 10.9, 5.3 Hz, 1H), 3.59 (dd, J = 10.9, 5.3 Hz, 1H), 3.49 (m, 1H), 
3.32 (m, 1H), 2.67 (td, J = 11.4, 3.0 Hz, 1H), 2.53 (td, J = 11.4, 3.0 Hz, 
1H), 2.43 (s, 3H), 2.27 (m, 1H), 1.90 (m, 1H), 1.78 (m, 1H), 1.64 (m, 1H), 
1.59 (t, J = 10.8 Hz, 1H), 1.51 (m, 1H), 0.97 (t, J = 10.8 Hz, 1H). 13C {1H} 
NMR (CDCl3, 100 MHz) δ 143.3, 133.3, 129.6, 127.6, 75.6, 64.4, 43.3, 
42.9, 42.4, 40.1, 36.7, 29.2, 26.5, 21.5. HRMS (ESI) for C16H24NO4S [M 
+ H]+: calculated: 326.1421, found:326.1427. 
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Anti-2-(hydroxymethyl)spiro[3.5]nonan-1-ol2-(hydroxymethyl)spiro[3.5]nonan-
1-ol 
Flash column chromatography (pentane: EtOAc 100:0 to 0:100) 
yielded 201 (90% yield) as colourless oil. 1H NMR (CDCl3, 400 MHz) δ 
3.63 (dd, J = 10.9, 5.1 Hz, 1H), 3.53 – 3.44 (m, 2H), 3.37 (s, 1H), 2.28 – 
2.14 (m, 1H), 1.65 (t, J = 10.3 Hz, 1H), 1.62 – 1.24 (m, 8H), 1.24 – 1.09 
(m, 2H), 0.85 (t, J = 10.2 Hz, 1H). 13C {1H} NMR (CDCl3, 100 MHz) δ 78.0, 
65.7, 42.7, 42.6, 38.7, 29.8, 27.4, 26.3, 23.1, 22.3. HRMS (ESI) for 
C10H18O2 [M]+:calculated: 170.1307, found: 170.1309.  
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9.1. Summary of the thesis 
The interest of the scientific community on organoborane chemistry has grown 
steadily over the last decades. Reported methods for the intramolecular cyclization 
through boron reagents have demonstrated high value to provide useful building 
blocks with high synthetic potential for further functionalization. In this thesis, we 
aimed to contribute on the development of new methodologies for the 
intramolecular cyclization through activation of organoborane reagents, both in 
metal-catalyzed[1] and transition metal-free[2] contexts. 
Chapter 3 deals with the direct insertion of diazo compounds into σ-bonds in a 
transition metal-free context, as it represents an efficient process that guarantees 
access to complex molecular entities. Based on previous work from our group in the 
insertion of diazo compounds into unsymmetrical diboron reagent pinB-Bdan,[3] we 
proposed in the first project of the thesis to study the insertion of commercially 
available [CH(N2)(SiMe3)] (7) into pinB-SPh (6a) and pinB-STol (6b) reagents. This 
studies resulted in a straightforward methodology to access multisubstituted sp3 
carbons (Si, B, S, H). The selective functionalization of the formed gem-
polymetalloids following a selective base-mediated strategy, gave access to 
structurally diverse molecules of synthetic application (Scheme 9.1). 
 
Scheme 9.1 Strategic trimethylsilyldiazomethane insertion into pinB-SR σ-bonds, followed by 
selective functionalizations. 
The insertion of 7 into the B-S σ-bond was examined with pinB-SPh (6a) and pinB-
STol (6b) providing access to tri-substituted methanes [CH(Bpin)(SiMe3)(SR)] in 
quantitative yields, even to a gram scale. 
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Remarkably, the functionalization of the gem-polymetaloids was controlled by the 
base and exhibited not dependency on the electrophile nature. Up to twelve 
different electrophiles were submitted to alkylation conditions with different bases. 
Alkylation of the boryl fragment was facilitated by the use of sodium tert-butoxide 
providing the alkyl deborylated products. Alkyl tetra-substituted methanes with 
retention of the boron group were also obtained by alkylation of a carbanion formed 
by deprotonation with bulky lithium amide base such as LTMP. This carbanion is 
highly stabilized due to the three metalloid substituents in α-position. 
Going one step further, if 1,n-lineal dihaloalkanes are used in the deproto-alkylation 
procedure, an intermediate containing both, a geminal silyl, boryl, sulfide carbon 
and a distal halogen is obtained. Such intermediate can be further cyclized 
intramolecularly with concomitant deborylation or desilylation as a function of the 
employed base.  
In Chapters 4 and 5 we became interested in the formation spiro-bicyclic 
compounds through intramolecular borylative cyclization processes and their 
corresponding application in Medicinal Chemistry projects. For this purpose 
synthetized a variety of well-designed substrates containing a haloalkene chain 
which under borylative cyclization conditions, mediated by copper (I), can afforded 
spiro-bicyclic products with a pendant methyl boryl unit (Scheme 9.2). 
 
Scheme 9.2 Copper (I) mediated borylative cyclization. 
The substrates selected proved a high functional group tolerance for the spiro-
cyclization reaction, as cyclic substrates containing oxygen or nitrogen heteroatoms 
and diverse functional groups underwent the transformation. Moreover, the boryl 
moiety installed through regioselective borylcupration step, could be selectively 
derivatized into different functional groups. 
Additionally, this method was suitable to prepare dispiro-tricyclic structures (108) 
which are high valuable scaffolds in medicinal chemistry and agrochemicals 
research[4] (Figure 9.1). 
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Figure 9.1 ORTEP of the X-Ray diffraction analysis for dispiro-heterocycle 108. 
Furthermore, a mechanistic proposal supported by DFT calculations was carried out 
in collaboration with Prof. Maseras and Mr. Ni from ICIQ. With this studies it was 
possible to identify transition states that justify the reactivity observed with the 
different ring size spiro-bicyclic compounds, as well as, the important role of the 
leaving group ability of the halide in the transformation. 
Next we started a collaboration with the Janssen-Cilag Medicinal Chemistry team in 
Toledo to study the applicability of our spiro-bicyclic cores on programs directed 
towards the identification of therapies to treat Alzheimer’s disease. These 
collaborative efforts focused on intercepting, though small-molecule O-GlcNAcase 
(OGA) inhibition, the progression of the characteristic tauophaty observed in AD 
brains.[5] 
For this purpose, five central spiro-bicyclic cores were prepared in large scale (up to 
3-4 grams) and then were selectively derivatized. The exploration focused on 
investigating the effect of introducing different linkers, heteroaromatic 
replacements, and ring-size of the spiro-bicycles on the OGA inhibitory activity of 
this series. In this sense, we were able to synthesize 20 different final targets, which 
were evaluated in OGA enzymatic and cellular assays. Interestingly, compound 167a 
showed high remarkable activity as OGA inhibitor with single-digit nanomolar 
activities in both biochemical and cellular assays (Figure 9.2). 
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Figure 9.2 Compound 167a. 
Finally, we wanted to develop a new methodology to cover a gap in the spiro-bicyclic 
library.[6] To achieve this goal, we prepared a series of heterocyclic alkenyl aldehydes 
and submitted them to the borylative cyclization reaction conditions that were 
optimized in Chapter 4. Gladly, the corresponding hydroxy-functionalized spiro-
bicycles were obtained with total chemo- and diastereoselectivity (Scheme 9.3). 
 
Scheme 9.3 Copper (I) mediated borylative cyclization of alkenyl aldehydes. 
Moreover, this transformation showed a good group tolerance as well as easy 
functionalization under mild oxidative conditions rendering the formation of spiro-
bicyclic diols with potential for further derivatization. The oxidized product (200) 
was crystallized and fully characterized by X-Ray diffraction, confirming the anti-
diastereoselective transformation through the borylative cyclization of alkenyl 
aldehydes (Figure 9.3). 
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Figure 9.3 X-Ray diffraction of anti-2-(hydroxymethyl)-7-(phenylsulfonyl)spiro[3.5]nonan-1-ol (200). 
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